PDL Biopharma (PDLI) 10-Q 13 Nov 20 2020 Q3 Quarterly report Financial data

COVER PAGE

COVER PAGE - shares	9 Months Ended
	Sep. 30, 2020	Oct. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	000-19756
Entity Registrant Name	PDL BIOPHARMA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3023969
Entity Address, Address Line One	932 Southwood Boulevard
Entity Address, City or Town	Incline Village,
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89451
City Area Code	775
Local Phone Number	832-8500
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	PDLI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		114,226,566
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000882104
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENT OF NET ASSETS $ in Thousands	Sep. 30, 2020USD ($)
Current assets:
Cash and cash equivalents	$ 125,736
Proforma, Cash and Cash Equivalents	83,035
Accounts receivable, net	8,323
Proforma, Accounts Receivable, Excluding Asset Sale, Net	5,894
Receivables from asset sales	39,389
Proforma, Accounts Receivable From Asset Sales, Net	39,389
Notes receivable	53,070
Proforma, Notes Receivable, Net	52,081
Inventory	13,685
Proforma, Inventory, Net, Current	0
Royalty assets	227,738
Proforma, Royalty Assets, Current	227,738
Income tax receivable	88,778
Proforma, Income Tax Receivable, Current	76,949
Property and equipment, net	783
Proforma, Property, Plant and Equipment, Net	0
Equipment under lease	3,033
Proforma, Leased Equipment, Current	0
Intangible assets, net	42,113
Proforma, Intangible Assets, Current	0
Other assets	12,462
Proforma, Other Assets, Current	7,599
Total assets	615,110
Proforma, Assets, Current	492,685
Current liabilities:
Accounts payable	3,639
Proforma, Accounts Payable, Current	1,290
Liquidity Basis of Accounting, Accrued Liabilities	7,678
Proforma, Accrued Liabilities	0
Liquidity Basis of Accounting, Uncertain Tax Postions	34,942
Proforma, Uncertain Tax Positions	34,942
Liquidation Basis of Accounting, Deferred Compensation Liability	21,219
Proforma, Deferred Compensation Liability	21,219
Liquidation Basis of Accounting, Lease Obligations	10,700
Proforma, Lease Obligations	10,700
Liquidation Basis Of Accounting, Other Liabilities, Current	5,007
Proforma, Other Liabilities, Current	5,007
Liquidation Basis Of Accounting, Accrued Liquidation Costs, Current	14,770
Proforma, Accrued Liquidation Costs, Current	14,770
Proforma, Convertible Debt	15,238
Liquidation Basis of Accounting, Convertible Debt	15,238
Total liabilities	113,193
Proforma, Liabilities, Current	103,166
Net assets in liquidation	501,917
Proforma, Net Assets (Liabilities)	$ 389,519

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN NET ASSETS $ in Thousands	1 Months Ended
	Sep. 30, 2020USD ($)
Liquidation Basis Of Accounting, Change In Net Assets [Roll Forward]
Net assets in liquidation, at September 1, 2020	$ 446,553
Changes in assets and liabilities in liquidation:
Decrease in liquidation value of royalty assets	(3,944)
Decrease in receivables from asset sales	9,078
Increase (Decrease) in Notes Receivables	7,460
Other assets	1,768
Increase (Decrease) in Income Taxes Receivable	53,106
Increase (Decrease) In Disposal Cost	3,048
Increase (Decrease) in Prepaid Taxes	4,414
Increase (Decrease) in Accounts Payable	(413)
Increase (Decrease) in Other Operating Liabilities	(997)
Increase (Decrease) in Other Operating Assets and Liabilities, Net	55,364
Net assets in liquidation, at September 30, 2020	$ 501,917

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2019
Revenues
Revenues	$ 4,115	$ 8,031	$ 15,321	$ 22,185
Operating expenses
Cost of Revenue	1,127	4,765	6,626	13,494
Amortization of intangible assets	204	321	841	983
Business Exit Costs	2,400	0	24,713	0
General and administrative	7,224	10,062	29,695	27,067
Selling and Marketing Expense	835	1,545	3,322	4,980
Research and Development Expense	1,053	4,310	4,374	6,106
Gain (Loss) on Investments	(5,576)	0	(5,576)	0
Gain on sale of intangible assets	0	3,476	0	3,476
Costs and Expenses	12,843	21,003	69,571	52,630
Operating loss from continuing operations	(8,728)	(12,972)	(54,250)	(30,445)
Non-operating expense, net
Interest and other income, net	26	1,460	608	4,984
Interest expense	(210)	(3,011)	(996)	(8,950)
Loss on extinguishment of convertible notes	0	(3,900)	(606)	(3,900)
Total non-operating expense, net	(5,760)	(1,975)	(6,570)	(4,390)
Loss from continuing operations before income taxes	(14,488)	(14,947)	(60,820)	(34,835)
Income tax benefit from continuing operations	(3,636)	(3,136)	(17,780)	(6,558)
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	(10,852)	(11,811)	(43,040)	(28,277)
Total non-operating income (expense), net	191	(4,962)	(57,921)	18,555
Discontinued Operation, Tax Effect of Discontinued Operation	(15,045)	1,193	(23,006)	6,141
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax	15,236	(6,155)	(34,915)	12,414
Net (loss) income	4,384	(17,966)	(77,955)	(15,863)
Net Income (Loss) Attributable to Noncontrolling Interest	(14)	(182)	(659)	(340)
Net loss from continuing operations	$ 4,398	$ (17,784)	$ (77,296)	$ (15,523)
Net income per share
Income (Loss) from Continuing Operations, Per Basic Share	$ (0.10)	$ (0.10)	$ (0.36)	$ (0.23)
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share	0.14	(0.06)	(0.30)	0.10
Basic (in Dollars per Share)	0.04	(0.16)	(0.66)	(0.13)
Income (Loss) from Continuing Operations, Per Diluted Share	(0.10)	(0.10)	(0.36)	(0.23)
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share	0.14	(0.06)	(0.30)	0.10
Net income per diluted share (in Dollars per Share)	$ 0.04	$ (0.16)	$ (0.66)	$ (0.13)
Weighted average shares outstanding
Basic (in Shares)	113,889	112,986	118,001	119,966
Diluted (in Shares)	113,889	112,986	118,001	119,966
Product Revenue [Member]
Revenues
Revenue from Contract with Customer, Including Assessed Tax	$ 2,831	$ 5,856	$ 10,946	$ 15,860
Lease Revenue
Revenues
Revenue from Contract with Customer, Including Assessed Tax	703	1,322	2,139	3,854
Service
Revenues
Revenue from Contract with Customer, Including Assessed Tax	544	898	2,126	2,510
Queen et al. patents [Member]
Revenues
Revenues	0	0	0	9
License and other [Member]
Revenues
Revenues	$ 37	$ (45)	$ 110	$ (48)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2019
Net (loss) income	$ 4,384	$ (17,966)	$ (77,955)	$ (15,863)
Other comprehensive income (loss), net of tax
Other Comprehensive Income (Loss), Net of Tax	0	0	0	0
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	4,384	(17,966)	(77,955)	(15,863)
Net Income (Loss) Attributable to Noncontrolling Interest	(14)	(182)	(659)	(340)
Comprehensive income (loss) attributable to PDL’s shareholders	$ 4,398	$ (17,784)	$ (77,296)	$ (15,523)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS $ in Thousands	Dec. 31, 2019USD ($)
Current assets:
Cash and cash equivalents	$ 168,982
Accounts receivable, net	6,559
Notes receivable	52,583
Inventory	8,061
Assets held for sale (Note 3)	70,366
Prepaid and other current assets	7,344
Total current assets	313,895
Property and equipment, net	2,560
Notes receivable, long-term	827
Intangible assets, net	13,186
Long-term assets held for sale (Note 3)	377,491
Other assets	9,247
Total assets	717,206
Current liabilities:
Accounts payable	2,675
Accrued liabilities	11,923
Liabilities held for sale (Note 3)	31,095
Total current liabilities	45,693
Convertible notes payable	27,250
Liabilities held for sale, long-term (Note 3)	120
Other long-term liabilities	50,865
Total liabilities	123,928
Commitments and contingencies (Note 14)
Stockholders' deficit:
Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding	0
Common stock, par value $0.01 per share, 350,000 shares authorized;124,303 shares issued and outstanding at December 31, 2019	1,243
Additional paid-in capital	(78,875)
Retained earnings	670,832
Total PDL’s stockholders’ equity	593,200
Noncontrolling interests	78
Total stockholders’ equity	593,278
Total liabilities and stockholders’ equity	$ 717,206

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) shares in Thousands	Dec. 31, 2019$ / sharesshares
Preferred stock par value (in Dollars per Share) | $ / shares	$ 0.01
Preferred stock, shares authorized (in Shares)	10,000
Preferred stock, shares issued (in Shares)	0
Preferred stock, shares outstanding (in Shares)	0
Common stock par value (in Dollars per Share) | $ / shares	$ 0.01
Common stock, shares authorized (in Shares)	350,000
Common stock, shares issued (in Shares)	124,303
Common stock, shares outstanding (in Shares)	124,303

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	1 Months Ended	2 Months Ended	3 Months Ended			8 Months Ended	9 Months Ended
	Sep. 30, 2020	Aug. 31, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Aug. 31, 2020	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net (loss) income		$ 4,384	$ (32,011)	$ (17,966)	$ 6,617	$ (77,955)		$ (15,863)
Less: (Loss) income from discontinued operations		15,236		(6,155)		(34,915)		12,414
Net loss from continuing operations		(10,852)		(11,811)		(43,040)		(28,277)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of convertible notes conversion option and debt issuance costs						622		5,776
Accreted interest on convertible note principal						44		79
Amortization of intangible assets		204		321		841		983
Amortization of right-of-use assets						497		544
Loss on investment						5,576		0
Change in fair value of derivative assets						110		(48)
Gain on sale of intangible assets		0		(3,476)		0		(3,476)
Loss on extinguishment of convertible notes		0	3,900	3,900		606		3,900
Other amortization and depreciation						1,017		2,124
Loss on disposal of property and equipment						331		0
Stock-based compensation expense						18,802		5,192
Deferred income taxes						(18,723)		8,936
Changes in assets and liabilities:
Accounts receivable	$ 9,078					3,344		1,462
Prepaid and other current assets						(29,875)		1,706
Inventory						(8,062)		(3,079)
Other assets	1,768					306		337
Accounts payable						371		6,502
Accrued liabilities						5,762		3,518
Other long-term liabilities						1,030		493
Net cash (used in) provided by operating activities - continuing operations						(60,441)		6,672
Net cash provided by (used in) operating activities - discontinued operations						28,318		(19,971)
Cash flows from investing activities
Settlement agreement cash received							$ 7,500	0
Proceeds from the sale of intangible assets							0	5,000
Purchase of intangible assets						0		(1,700)
Property and equipment, net purchases						(221)		(504)
Net cash provided by investing activities - continuing operations						7,279		2,796
Net cash provided by (used in) investing activities - discontinued operations						38,966		(1,710)
Cash flows from financing activities
Proceeds from the exercise of stock options						461		0
Repurchase of convertible notes			(97,900)			(18,845)		0
Repayments of Convertible Debt							0	(7,451)
Net receipts (payments) for capped call transactions						801		(3,694)
Payment of contingent consideration						0		(1,071)
Repurchase of Company common stock						(39,373)		(75,891)
Net settlement of stock-based compensation awards						(3,462)		0
Net cash used in financing activities - continuing operations						(60,418)		(88,107)
Net cash used in financing activities - discontinued operations						(359)		0
Net decrease in cash and cash equivalents						(46,655)		(100,320)
Cash and cash equivalents at beginning of the period	$ 146,796		$ 193,451		$ 394,590	193,451	$ 193,451	394,590
Cash and cash equivalents at end of the period		146,796		294,270		146,796		294,270
Less: Cash and cash equivalents of discontinued operations		25,060		16,982		25,060		16,982
Cash and cash equivalents of continuing operations at end of period		$ 121,736		$ 277,288		121,736		277,288
Supplemental cash flow information
Cash refunded for income taxes						(4)		(2,685)
Cash paid for interest						298		2,063
Supplemental schedule of non-cash investing and financing activities
Noncash liquidating distribution						$ 64,400		$ 0

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Non-controlling Interest
Shares, Issued at Dec. 31, 2018		136,512,522
Stockholders' Equity Attributable to Parent at Dec. 31, 2018	$ 729,779	$ 1,365	$ (2,103)	$ (98,030)	$ 828,547
Other Noncontrolling Interests at Dec. 31, 2018						$ 0
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		764,785
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0	$ (8)		(8)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	1,169			1,169
Stock Repurchased During Period, Shares		(13,460,164)
Treasury Stock, Retired, Par Value Method, Amount		$ (135)
Treasury Stock, Value, Acquired, Cost Method			613
Treasury Stock, Retired, Cost Method, Amount					(44,831)
Noncontrolling Interest, Period Increase (Decrease)	572					572
Stock Repurchased and Retired During Period, Value	(44,353)
Net Income (Loss) Attributable to Parent					6,680
Net Income (Loss) Attributable to Noncontrolling Interest						(63)
Net (loss) income	6,617
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	6,617
Shares, Issued at Mar. 31, 2019		123,817,143
Stockholders' Equity Attributable to Parent at Mar. 31, 2019	693,784	$ 1,238	(1,490)	(96,869)	790,396
Other Noncontrolling Interests at Mar. 31, 2019						509
Shares, Issued at Dec. 31, 2018		136,512,522
Stockholders' Equity Attributable to Parent at Dec. 31, 2018	729,779	$ 1,365	(2,103)	(98,030)	828,547
Other Noncontrolling Interests at Dec. 31, 2018						0
Noncash liquidating distribution (0.11591985 shares of Evofem Biosciences, Inc. common stock distributed per share of the Company’s common stock )	0
Net Income (Loss) Attributable to Parent	(15,523)
Net Income (Loss) Attributable to Noncontrolling Interest	(340)
Net (loss) income	(15,863)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(15,863)
Shares, Issued at Sep. 30, 2019		114,184,610
Stockholders' Equity Attributable to Parent at Sep. 30, 2019		$ 1,142	0	(100,419)	736,695
Other Noncontrolling Interests at Sep. 30, 2019						16
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Sep. 30, 2019	637,434
Shares, Issued at Mar. 31, 2019		123,817,143
Stockholders' Equity Attributable to Parent at Mar. 31, 2019	693,784	$ 1,238	(1,490)	(96,869)	790,396
Other Noncontrolling Interests at Mar. 31, 2019						509
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		37,996
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	2,175			2,175
Stock Repurchased During Period, Shares		(8,185,970)
Treasury Stock, Retired, Par Value Method, Amount		$ (81)
Treasury Stock, Value, Acquired, Cost Method			944
Treasury Stock, Retired, Cost Method, Amount					(26,897)
Noncontrolling Interest, Period Increase (Decrease)	13			229		(216)
Stock Repurchased and Retired During Period, Value	(26,034)
Net Income (Loss) Attributable to Parent					(4,419)
Net Income (Loss) Attributable to Noncontrolling Interest						(95)
Net (loss) income	(4,514)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(4,514)
Shares, Issued at Jun. 30, 2019		115,669,169
Stockholders' Equity Attributable to Parent at Jun. 30, 2019		$ 1,157	(546)	(94,465)	759,080
Other Noncontrolling Interests at Jun. 30, 2019						198
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Jun. 30, 2019	665,424
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		(18,061)
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	(8)				(8)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	2,059			2,059
Stock Repurchased During Period, Shares		(1,466,498)
Treasury Stock, Retired, Par Value Method, Amount		$ (15)
Treasury Stock, Value, Acquired, Cost Method			546
Treasury Stock, Retired, Cost Method, Amount					(4,609)
Stock Repurchased and Retired During Period, Value	(4,078)
Exchange of debt	(8,013)			(8,013)
Net Income (Loss) Attributable to Parent	(17,784)				(17,784)
Net Income (Loss) Attributable to Noncontrolling Interest	(182)					(182)
Net (loss) income	(17,966)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(17,966)
Shares, Issued at Sep. 30, 2019		114,184,610
Stockholders' Equity Attributable to Parent at Sep. 30, 2019		$ 1,142	0	(100,419)	736,695
Other Noncontrolling Interests at Sep. 30, 2019						16
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Sep. 30, 2019	637,434
Shares, Issued at Dec. 31, 2019		124,302,616
Stockholders' Equity Attributable to Parent at Dec. 31, 2019	593,200	$ 1,243	0	(78,875)	670,832
Other Noncontrolling Interests at Dec. 31, 2019	78					78
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2019	593,278
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		1,781,197
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0	$ (18)		(18)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	14,453			14,453
Stock Repurchased During Period, Shares		(5,564,841)
Treasury Stock, Retired, Par Value Method, Amount		$ (56)
Treasury Stock, Value, Acquired, Cost Method			(2,244)		(17,978)
Noncontrolling Interest, Period Increase (Decrease)						100
Stock Repurchased and Retired During Period, Value	(20,278)
Adjustments to Additional Paid in Capital, Other				683
Noncontrolling Interest, Increase from Subsidiary Equity Issuance	783
Write off of Deferred Debt Issuance Cost	(3,911)			(3,911)
Call option unwind	801			801
Net Income (Loss) Attributable to Parent					(31,723)
Net Income (Loss) Attributable to Noncontrolling Interest						(288)
Net (loss) income	(32,011)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(32,011)
Shares, Issued at Mar. 31, 2020		120,518,972
Stockholders' Equity Attributable to Parent at Mar. 31, 2020		$ 1,205	(2,244)	(66,867)	621,131
Other Noncontrolling Interests at Mar. 31, 2020						(110)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Mar. 31, 2020	553,115
Shares, Issued at Dec. 31, 2019		124,302,616
Stockholders' Equity Attributable to Parent at Dec. 31, 2019	593,200	$ 1,243	0	(78,875)	670,832
Other Noncontrolling Interests at Dec. 31, 2019	78					78
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2019	593,278
Noncash liquidating distribution (0.11591985 shares of Evofem Biosciences, Inc. common stock distributed per share of the Company’s common stock )	(64,400)
Net Income (Loss) Attributable to Parent	(77,296)
Net Income (Loss) Attributable to Noncontrolling Interest	(659)
Net (loss) income	(77,955)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(77,955)
Shares, Issued at Aug. 31, 2020		114,111,358
Stockholders' Equity Attributable to Parent at Aug. 31, 2020	425,214	$ 1,141	0	(65,337)	489,891
Other Noncontrolling Interests at Aug. 31, 2020						(481)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Aug. 31, 2020	425,214
Shares, Issued at Mar. 31, 2020		120,518,972
Stockholders' Equity Attributable to Parent at Mar. 31, 2020		$ 1,205	(2,244)	(66,867)	621,131
Other Noncontrolling Interests at Mar. 31, 2020						(110)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Mar. 31, 2020	553,115
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		183,903
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	460	$ (2)		458
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	245			245
Stock Repurchased During Period, Shares		(6,758,147)
Treasury Stock, Retired, Par Value Method, Amount		$ (68)
Treasury Stock, Value, Acquired, Cost Method			2,244
Treasury Stock, Retired, Cost Method, Amount					(21,267)
Stock Repurchased and Retired During Period, Value	(19,091)
Noncash liquidating distribution (0.11591985 shares of Evofem Biosciences, Inc. common stock distributed per share of the Company’s common stock )	(64,400)				(64,400)
Net Income (Loss) Attributable to Parent					(49,971)
Net Income (Loss) Attributable to Noncontrolling Interest						(357)
Net (loss) income	(50,328)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(50,328)
Shares, Issued at Jun. 30, 2020		113,944,728
Stockholders' Equity Attributable to Parent at Jun. 30, 2020		$ 1,139	0	(66,164)	485,493
Other Noncontrolling Interests at Jun. 30, 2020						(467)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Jun. 30, 2020	420,001
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		166,630
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0	$ (2)		(2)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	829			829
Net Income (Loss) Attributable to Parent	4,398				4,398
Net Income (Loss) Attributable to Noncontrolling Interest	(14)					(14)
Net (loss) income	4,384
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	4,384
Shares, Issued at Aug. 31, 2020		114,111,358
Stockholders' Equity Attributable to Parent at Aug. 31, 2020	425,214	$ 1,141	$ 0	$ (65,337)	$ 489,891
Other Noncontrolling Interests at Aug. 31, 2020						$ (481)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Aug. 31, 2020	$ 425,214

CONDENSED CONSOLIDATED STATEM_7

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Parenthetical) - USD ($) $ in Thousands	2 Months Ended	8 Months Ended
	Aug. 31, 2020	Aug. 31, 2020
Income Statement [Abstract]
Discontinued Operation, Held-For-Sale, Income (Loss) From Discontinued Operation, Before Income Tax	$ 0	$ 28,904

CONDENSED CONSOLIDATED STATEM_8

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)	3 Months Ended
	Jun. 30, 2020shares
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract]
Share conversion rate	0.11591985

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Basis of Presentation Throughout its history, the mission of PDL BioPharma, Inc. and its subsidiaries (collectively, the “Company” or “PDL”) has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies. PDL was founded in 1986 as Protein Design Labs, Inc. when it pioneered the humanization of monoclonal antibodies, enabling the discovery of a new generation of targeted treatments that have had a profound impact on patients living with different cancers as well as a variety of other debilitating diseases. In 2006, the Company changed its name to PDL BioPharma, Inc. Historically, the Company generated a substantial portion of its revenues through license agreements related to patents covering the humanization of antibodies, which it refers to as the Queen et al. patents. In 2012, the Company began providing alternative sources of capital through royalty monetizations and debt facilities, and, in 2016, the Company began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products first with its acquisition of branded prescription pharmaceutical drugs from Novartis AG, Novartis Pharma AG and Speedel Holding AG (collectively, “Novartis”) in 2016 and, in 2017, with the acquisition of LENSAR, Inc. (“LENSAR”), a medical device ophthalmology equipment manufacturing company. In 2019, it entered into a securities purchase agreement with Evofem Biosciences, Inc. (“Evofem”), pursuant to which it invested $60.0 million in a private placement of securities structured in two tranches. Evofem is a publicly-traded commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. Evofem is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-R™) platform for PhexxiTM (L-lactic acid, citric acid and potassium bitartrate) for hormone-free birth control. Based on the composition of its investment portfolio, the Company historically structured its operations in four segments designated as Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets. Following is a summary of the Company’s segments including those that have been classified as discontinued operations: • The Company’s Medical Devices segment consists of revenue derived from the LENSAR ® Laser System sales made by the Company’s subsidiary, LENSAR which may include equipment, Patient Interface Devices (“PIDs” or “consumables”), procedure licenses, training, installation, warranty and maintenance agreements. • The Company’s Strategic Positions segment consisted of an investment in Evofem, which included shares of common stock and warrants to purchase shares of common stock. • The Company’s Pharmaceutical segment consisted of revenue derived from branded prescription medicine products sold under the name Tekturna ® and Tekturna HCT ® in the United States and Rasilez ® and Rasilez HCT ® in the rest of the world and an authorized generic form of Tekturna sold in the United States (collectively, the “Noden Products”). The branded prescription Noden Products were acquired from Novartis in July 2016 (the “Noden Transaction”) by the Company’s wholly-owned subsidiary, Noden Pharma DAC (“Noden DAC”). • The Company’s Income Generating Assets segment consists of revenue derived from (i) notes and other long-term receivables, (ii) equity investments and (iii) royalties from issued patents in the United States and elsewhere covering the humanization of antibodies (“Queen et al. patents”). In September 2019, the Company engaged financial and legal advisors and initiated a review of its strategy. This review was completed in December 2019 at which time the Company announced that it decided to halt the execution of its growth strategy, cease additional strategic transactions and investments and instead pursue a formal process to unlock value by monetizing its assets and returning net proceeds to stockholders (the “monetization strategy”). Pursuant to the Company’s monetization strategy, the Company does not expect to enter into any additional strategic investments. The Company further announced in December 2019 that it would explore a variety of potential transactions in connection with the monetization strategy, including a whole Company sale, divestiture of assets, spin-offs of operating entities, merger opportunities or a combination thereof. Over the subsequent months, the Company’s Board of Directors (the “Board”) and management analyzed, together with outside financial and legal advisors, how to best capture value pursuant to the monetization strategy and best return the value of the assets in its portfolio to its stockholders. During the first quarter of 2020, the Board approved a plan of complete liquidation (the “Plan of Liquidation”) and passed a resolution to seek stockholder approval to dissolve the Company as permitted by the General Corporation Law of the State of Delaware (the “DGCL”). The proposal was approved by stockholders on August 19, 2020 at the Company’s 2020 Annual Meeting of Stockholders. On November 5, 2020, our Board approved filing a Certificate of Dissolution with the Secretary of State of Delaware on January 4, 2021 (the “Final Record Date”) and proceeding to complete the dissolution process for the Company in accordance with the Delaware General Corporate Law. The liquidation and dissolution process will take a minimum of three years. However, the timing may be extended due to circumstances such as pending litigation or other factors that may affect the ability of the Company to wind down its business. Upon filing the Certificate of Dissolution on January 4, 2021 (the Final Record Date), we will close our stock transfer books. After such time, we will not record any further transfers of our common stock, except pursuant to the provisions of a deceased stockholder’s will, intestate succession, or by operation of law and we will not issue any new stock certificates, other than replacement certificates. In addition, after the Final Record Date, we will not issue any shares of our common stock upon exercise of outstanding stock options. As a result of the closing of our transfer books, it is anticipated that distributions, if any, made in connection with the dissolution will be made pro rata to the same stockholders of record as the stockholders of record as of the Final Record Date, and it is anticipated that no further trading of our common stock will occur after the Final Record Date. In accordance with our dissolution plan, we intend to begin the voluntary delisting process from the Nasdaq Stock Market exchange so that such delisting will occur at market close on December 31, 2020 and we do not anticipate transferring into OTC trading. Pursuant to the Company’s monetization strategy, the Company explored a variety of potential transactions, including a whole Company sale, divestiture of assets, spin-offs of operating entities, merger opportunities or a combination. During the quarter ended March 31, 2020, the Company’s Pharmaceutical segment and the royalty right assets within the Income Generating Assets segment met the criteria to be classified as held for sale. Those investments are reported as discontinued operations on the Condensed Consolidated Statements of Operations for the two and eight months ended August 31, 2020 and for the three and nine months ended September 30, 2019, and as Assets and Liabilities held for sale on the Condensed Consolidated Balance Sheet as of December 31, 2019. During the quarter ended June 30, 2020, the Evofem common stock held within the Strategic Positions segment was distributed to the Company’s stockholders and, as a result, the Strategic Positions segment and all investments included in the segment met the criteria to be classified as discontinued operations. Therefore, the Strategic Positions segment is also presented as discontinued operations on the Condensed Consolidated Statements of Operations. The Company continues to hold warrants to purchase shares of Evofem’s common stock. In September 2020, the Company sold the Noden business, including its Noden Pharma USA, Inc. subsidiary (“Noden USA” and, together with Noden DAC, “Noden”) to a third party. Separately, the Company also sold three royalty right assets in August 2020 to a third party. As a result of the approval of the Company’s stockholders to pursue dissolution of the Company pursuant to a plan of dissolution, the Company’s basis of accounting transitioned, effective September 1, 2020, from the going concern basis of accounting (“Going Concern Basis”) to the liquidation basis of accounting (“Liquidation Basis”) in accordance with Generally Accepted Accounting Principles (“GAAP”) of the United States. Under the Liquidation Basis, all assets are valued at the estimated amount of cash or other consideration that the Company expects to collect. Liabilities with specified, contractual amounts are measured in accordance with applicable GAAP and all other liabilities are stated at their estimated settlement amounts over the remaining estimated liquidation period. The assets and liabilities of LENSAR included in the Statement of Net Assets reflect the expected distribution value. LENSAR was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information. The accompanying unaudited Condensed Consolidated Financial Statements of PDL have been prepared in accordance with GAAP for interim financial information. The financial statements include all adjustments that management of the Company believes are necessary for a fair statement of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year. The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited Consolidated Financial Statements and the related notes thereto for the fiscal year ended December 31, 2019, included in its Current Report on Form 8-K, filed with the Securities and Exchange Commission (“SEC”) on June 29, 2020, which re-casts certain historical financial information from our 2019 Annual Report on Form 10-K to present the Pharmaceutical segment and the royalty right assets within the Income Generating Assets segment as discontinued operations for all periods presented. The Condensed Consolidated Balance Sheet at December 31, 2019, included herein, has been derived from the audited Consolidated Financial Statements at that date, as adjusted to conform with the financial statement presentation as of and for the two and eight months ended August 31, 2020 as discussed in Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , but does not include all disclosures required by GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying Notes to the Condensed Consolidated Financial Statements. The accounting estimates that require management’s most significant, difficult and subjective judgments include the estimated sales proceeds of our assets in liquidation and estimated settlement amounts of our liabilities as well as the estimated revenue and operating expenses during dissolution that are projected under the Liquidation Basis. Significant estimates include, the valuation of royalty rights, product revenue recognition and allowances for customer rebates, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, the recognition and measurement of current and deferred income tax assets and liabilities, including amounts recoverable under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, and the valuation of warrants to acquire shares of common stock. Furthermore, the impact on accounting estimates and judgments on the Company’s financial condition and results of operations due to COVID-19 has introduced additional uncertainties. Actual results may differ materially from those estimates. The Condensed Consolidated Financial Statements included herein include the accounts of the Company and its wholly-owned subsidiaries (up to the date of sale) and majority-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have, and, as a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict. If the financial markets or the overall economy are impacted for an extended period, the Company’s liquidity, revenues and assets may be adversely affected. Significant Accounting Policies Liquidation Basis of Accounting Under the Liquidation Basis, the values of the Company's assets and liabilities include management's estimate of income to be generated from the remaining assets until the anticipated date of sale, estimated sales proceeds, estimates for operating expenses and expected amounts required to settle liabilities. The estimated liquidation values for assets derived from future revenue streams and asset sales and the settlement of estimated liabilities are reflected on the Condensed Consolidated Statement of Net Assets in Liquidation. The actual amounts realized could differ materially from the estimated amounts. Assets Held for Sale Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale. The assets and liabilities held for sale as of December 31, 2019 are recorded on the Company’s Condensed Consolidated Balance Sheet as Assets held for sale and Liabilities held for sale, respectively. Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period, represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes and represent a strategic shift that has or will have a major effect on the Company’s operations and financial results. The profits and losses are presented on the Condensed Consolidated Statements of Operations as discontinued operations. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. Severance and retention After the Company announced its monetization strategy, it recognized that its ability to execute on its plan and optimize returns to its stockholders depended to a large extent on its ability to retain the necessary expertise to effectively transact with respect to its assets. On December 21, 2019, the Compensation Committee of the Board adopted a Wind Down Retention Plan in which the Company’s executive officers and other employees who are participants in the Company’s Severance Plan are eligible to participate. Under the Wind Down Retention Plan, participants are eligible to earn a retention benefit in consideration for their continued employment with the Company. The Wind Down Retention benefits are equivalent to previously disclosed compensation payments contemplated in connection with a change in control under the Company’s existing Severance Plan. Under the Wind Down Retention Plan, the Company is currently obligated to pay a retention benefit to each participant upon termination of the participant’s employment with the Company either by the Company without cause or by the participant for good reason. The retention benefit, if paid, would be in lieu of (and not in addition to) any other severance compensation that could become payable to the participant under the Company’s Severance Plan. In connection with the adoption of the Wind Down Retention Plan, a severance liability was being recorded over the remaining service period for the participating employees under the Going Concern Basis. Upon the adoption of the Liquidation Basis on September 1, 2020, all remaining estimated severance and retention costs were accrued. As of September 30, 2020, the Company has recorded a severance liability of $10.9 million, which is reported as Compensation and benefit costs on the Company’s Condensed Consolidated Statement of Net Assets. Expenses associated with severance payments and accruals are reflected in Severance and retention on the Company’s Condensed Consolidated Statements of Operations for the two and eight months ended August 31, 2020. The Wind Down Retention Plan also provides that, consistent with the existing terms of the Company’s Amended and Restated 2005 Equity Incentive Plan (the “Equity Plan”), the vesting of all outstanding equity awards held by participants as of the date the Wind Down Retention Plan was adopted will be accelerated upon the earlier of: (i) a termination of the participant’s employment with the Company either by the Company without cause or by the participant for good reason or (ii) the consummation of a change in control (as defined in the Equity Plan) of the Company. In addition, the post-termination exercise period for all outstanding stock options will be extended until their expiration date. In connection with the Board adopting the Plan of Liquidation in the first quarter of 2020, all of the outstanding and unvested stock options and restricted stock granted to the Company’s employees and executive officers, with the exception of certain outstanding awards under the 2016/20 Long-Term Incentive Plan, accelerated and vested under the change in control definition in the Equity Plan. The expense associated with the accelerated vesting, totaling $15.7 million is reported as Severance and retention on the Company’s Condensed Consolidated Statements of Operations for the two and eight months ended August 31, 2020. For a discussion of other accounting policies, refer to the Company’s Current Report on Form 8-K for the fiscal year ended December 31, 2019. Summarized below are the accounting pronouncements and policies adopted subsequent to December 31, 2019 in addition to those described above. Adopted Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments . The guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. The Company adopted ASU No. 2016-13 on January 1, 2020 using a modified retrospective approach. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. As a consequence of adopting ASU 2016-13, the Company’s accounts receivable accounting policy has been updated, as follows: Accounts and Notes Receivable The Company makes estimates of the collectability of accounts receivable. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for credit losses. Amounts are charged off against the allowance for credit losses when the Company determines that recovery is unlikely and the Company ceases collection efforts. The Company applies the practical expedient for its collateral-dependent notes receivable. Estimated credit losses are based on the fair value of the collateral (less costs to sell, as applicable). In April 2020, the FASB issued a staff question-and-answer document, “Topic 842 and Topic 840: Accounting for Lease Concessions Related to the Effects of the COVID-19 Pandemic” (the “COVID-19 Q&A”), to address certain frequently-asked questions pertaining to lease concessions arising from the effects of the COVID-19 pandemic. Existing lease guidance requires entities to determine if a lease concession was a result of a new arrangement reached with the lessee (which would be addressed under the lease modification accounting framework) or if a lease concession was under the enforceable rights and obligations within the existing lease agreement (which would not fall under the lease modification framework). The COVID-19 Q&A clarifies that entities may elect to not evaluate whether lease-related relief granted in light of the effects of COVID-19 is a lease or obligations of the lease. This election is available for concessions that result in the total payments required by the modified contract being substantially the same or less than the total payments required by the original contract. As a result of the COVID-19 pandemic, LENSAR entered into agreements with 23 customers through which LENSAR agreed to waive monthly rental and minimum monthly license fees ranging from one In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement . The new guidance modifies disclosure requirements related to fair value measurement. The Company adopted ASU No. 2018-13 on January 1, 2020. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required. In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software . The new guidance reduces complexity for the accounting for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The Company adopted ASU No. 2018-15 on January 1, 2020 using the prospective transition option. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. For public companies, the amendments in ASU No. 2019-12 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its Consolidated Financial Statements.

Net Assets in Liquidation

Net Assets in Liquidation	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Assets in Liquidation	Net Assets in LiquidationUpon adoption of the Liquidation Basis on September 1, 2020, the Company has estimated the net assets in liquidation, which represents the expected future cash flows related to the remaining assets and estimated liabilities and operating costs through dissolution. The actual cash inflows and outflows may differ from the estimated amounts. (in thousands) Consolidated Net Equity, as of August 31, 2020 $ 425,214 Effect of adopting the liquidation basis of accounting: Change in the estimated value of royalty rights (1) 13,770 Change in the receivable from the sale of Noden (2) 9,056 Increase in intangible assets (3) 28,702 Change in the estimated value of other assets (4) (4,813) Estimated liquidation and future operating costs (5) (25,376) Total effect of adopting the liquidation basis of accounting 21,339 Net assets in liquidation, as of September 1, 2020 $ 446,553 (1) The royalty assets, consisting of Assertio and University of Michigan (“U-M”), are valued using undiscounted estimated cash receipts until the estimated date of sale plus a discounted value of the remaining estimated cash flows to determine the expected cash consideration from such sale. Previously, under the going concern basis of accounting, royalty assets were valued using discounted cash flow models, see Note 7, Fair Value Measurements . (in thousands) August 31, 2020 September 1, 2020 Change (Going Concern Basis) (Liquidation Basis) Assertio $ 200,463 $ 211,626 $ 11,163 U-M 17,450 20,057 2,607 Total $ 217,913 $ 231,683 $ 13,770 (2) Adjustments reflect Liquidation Basis which does not discount future estimated cash receipts. Previously, under the going concern basis of accounting we had estimated the fair value of Noden, as an asset held for sale, using a discounted cash flow model, see Note 7, Fair Value Measurements . (3) The increase in intangible assets represents the difference between the existing assets and liabilities of LENSAR upon adoption of liquidation basis of accounting and its enterprise value that will be distributed to PDL shareholders in the spin-off. The enterprise value was determined through an analysis of comparable public companies combined with cash flow forecasts. Also see Note 10, Intangible Assets and Note 21, Subsequent Events. (4) Adjustments to other assets include a liquidity discount for the Evofem warrants and the write-off of certain assets that will not be converted to cash such as prepaid expenses, fixed assets and right of use assets. (5) Represents estimated future expenses related to operating the business through dissolution and settlement of future liabilities including estimated costs to dispose of our assets. Some of the estimated costs to dispose of our assets had already been accrued under the Going Concern Basis and were presented net with our assets held for sale.

Discontinued Operations Classif

Discontinued Operations Classified as Assets Held for Sale	9 Months Ended
	Sep. 30, 2020
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations Classified as Assets Held for Sale	Discontinued Operations Classified as Assets and Liabilities Held for Sale under Going Concern BasisAs a result of the above-described monetization strategy and subsequent efforts to monetize the Company’s key assets, representing a strategic shift in the operations of the Company, the assets held for sale and discontinued operations criteria were met for the Company’s royalty assets (included in the Income Generating Assets segment) and its Noden subsidiaries (Pharmaceutical segment) during the first quarter of 2020. The discontinued operations criteria were met for the Company’s investment in Evofem (Strategic Positions segment) during the second quarter of 2020 after the Company distributed all of its shares of common stock of Evofem to the Company’s stockholders. The historical financial results of the investment in Evofem, royalty assets and Noden are reflected in the Company’s consolidated financial statements as discontinued operations for all Going Concern Basis periods presented herein, and assets and liabilities were retrospectively reclassified as assets and liabilities held for sale. On July 30, 2020, the Company signed a definitive agreement for the sale of the Company’s interest in Noden DAC and Noden USA to CAT Capital Bidco Limited (“Stanley Capital”). In accordance with the terms of the agreement, the Company will receive consideration of up to $52.8 million. Stanley Capital made an initial cash payment to the Company of $12.2 million on the September 9, 2020 closing date. The Company is also entitled to recover $0.5 million related to value-added tax (“VAT”) for inventory purchases from Novartis. The agreement provides for an additional $33.0 million to be paid to the Company in twelve equal quarterly installments from January 2021 to October 2023. An additional $3.9 million will be paid in four equal quarterly installments from January 2023 to October 2023. The agreement also provides for the potential for additional contingent payments to the Company. The Company is entitled to receive $2.5 million upon Stanley Capital or any of its affiliates entering into a binding agreement for a specified transaction within one year of the closing date. The Company is also entitled to 50% of a license fee from a third party distributor within 10 days of receipt by Noden. Upon closing, the Company recorded a gain of $0.2 million. In connection with the closing of the transaction, the guaranty agreement between Novartis and the Company which guaranteed certain payments owed to Novartis by Noden was terminated. On August 31, 2020, the Company announced the signing and closing of a definitive agreement for the sale of its royalty interests for Kybella ® , Zalviso ® , and Coflex ® to SWK Funding, LLC, a wholly owned subsidiary of SWK Holdings Corporation, for $4.35 million in cash. Components of amounts reflected in Income (loss) from discontinued operations on the Company’s Condensed Consolidated Statement of Operations are as follows: Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Revenues Product revenue, net $ 6,281 $ 12,269 $ 29,479 $ 42,644 Royalty rights - change in fair value (1,893) 23,865 (8,804) (4,277) Total revenues 4,388 36,134 20,675 38,367 Operating expenses Cost of product revenue (excluding intangible asset amortization) 3,894 10,268 17,576 26,697 Amortization of intangible assets — 1,253 389 3,760 General and administrative 1,540 2,029 6,105 5,969 Sales and marketing 59 168 257 1,536 Research and development — — — (41) Total operating expenses 5,493 13,718 24,327 37,921 Operating (loss) income from discontinued operations (1,105) 22,416 (3,652) 446 Non-operating income (expense), net Equity affiliate - change in fair value 1,296 (27,378) (25,365) 18,109 Loss on classification as held for sale — — (28,904) — Total non-operating income (expense), net 1,296 (27,378) (54,269) 18,109 Income (loss) from discontinued operations before income taxes 191 (4,962) (57,921) 18,555 Income tax (benefit) expense from discontinued operations (15,045) 1,193 (23,006) 6,141 Income (loss) from discontinued operations $ 15,236 $ (6,155) $ (34,915) $ 12,414 The carrying amounts of the major classes of assets reported as “Assets held for sale” on the Company’s Condensed Consolidated Balance Sheet consisted of the following: (in thousands) December 31, 2019 Cash and cash equivalents (1) $ 24,469 Accounts receivable, net 6,993 Inventory 31,712 Prepaid and other current assets 7,192 Property and equipment, net 2,960 Royalty rights - at fair value 266,196 Investment in equity affiliate 82,267 Intangible assets, net 10,112 Other assets 15,956 Total assets held for sale $ 447,857 ________________ (1) Cash and cash equivalents represent balances maintained by Noden as of December 31, 2019, which were retained by the buyer upon the sale of the Noden business and used to settle the commitment with Novartis as further described in Note 14, Commitments and Contingencies . The carrying amounts of the major classes of liabilities reported as “Liabilities held for sale” on the Company’s Condensed Consolidated Balance Sheet consisted of the following: (in thousands) December 31, 2019 Accounts payable $ 14,695 Accrued liabilities 16,400 Other long-term liabilities 120 Total liabilities held for sale $ 31,215

Investment in Evofem Bioscience

Investment in Evofem Biosciences, Inc.	9 Months Ended
	Sep. 30, 2020
Investments, Equity Securities [Abstract]
Investment in Evofem Biosciences, Inc.	4. Investment in Evofem Biosciences, Inc. On April 10, 2019, the Company entered into a securities purchase agreement with Evofem and two other purchasers pursuant to which the Company purchased $60.0 million of Evofem securities in a private placement. The transaction was structured in two tranches. The first tranche closed on April 11, 2019, pursuant to which the Company invested $30.0 million to purchase 6,666,667 shares of Evofem common stock at $4.50 per share and was also issued warrants to purchase up to 1,666,667 shares of Evofem common stock. The warrants are exercisable beginning six months after the issuance date for a period of seven years from the issuance date at an exercise price of $6.38 per share. The second tranche closed on June 10, 2019, pursuant to which the Company invested an additional $30.0 million to purchase 6,666,667 additional shares of Evofem common stock at $4.50 per share and was also issued warrants to purchase up to an additional 1,666,667 shares of Evofem common stock with the same terms as the warrants issued in the first tranche. On May 21, 2020, the Company announced that it had completed the distribution of all of the Company’s 13,333,334 shares of common stock of Evofem to the Company’s stockholders, which represented approximately 26.7% of the outstanding shares of Evofem common stock as of the close of business on May 15, 2020. The distribution was recorded as a noncash distribution of $64.4 million, reducing retained earnings. Following the distribution, the Company continues to hold warrants to purchase up to 3,333,334 shares of Evofem common stock. As of September 30, 2020, the Evofem warrants were valued under the Liquidation Basis at $2.5 million and are classified as “Other assets” on the Company’s Condensed Consolidated Statement of Net Assets. The Evofem common stock and the Evofem warrants are included in “Long- term assets held for sale” o n the Company’s December 31, 2019 Condensed Consolidated Balance She et. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. For the eight months ended August 31, 2020, the Company recorded a loss of $17.9 million in Income (loss) from discontinued operations before income taxes on the Company’s Condensed, Consolidated Statement of Operations for the change in fair value of the Evofem common stock. For the two and eight months ended August 31, 2020, the Company recorded an unrealized gain of $1.3 million and an unrealized loss of $7.5 million, respectively, for the change in fair value of the Evofem warrants. These amounts are included in Income (loss) from discontinued operations before income taxes on the Company’s Condensed, Consolidated Statements of Operations.

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2020
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	5. Cash and Cash Equivalents As of September 30, 2020 and December 31, 2019, the Company had invested its excess cash balances primarily in cash and money market funds. The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. The following table summarizes the Company’s cash and cash equivalents by significant investment category reported as cash and cash equivalents on the Condensed Consolidated Statement of Net Assets and the Condensed Consolidated Balance Sheet as of September 30, 2020 and December 31, 2019, respectively: (in thousands) September 30, 2020 December 31, 2019 (Liquidation Basis) (Going Concern Basis) Cash (1) (2) $ 74,580 $ 37,718 Money market funds 51,156 131,264 Total $ 125,736 $ 168,982 ________________ (1) The December 31, 2019 cash amount excludes $24.5 million of cash at Noden classified as held for sale. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. (2) The table above includes amounts held by LENSAR which was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2020
Inventory [Abstract]
Inventories	6. Inventories Inventories consisted of the following: (in thousands) September 30, 2020 December 31, 2019 (Liquidation Basis) (Going Concern Basis) Raw materials $ 3,840 $ 3,739 Work in process 2,039 1,170 Finished goods 7,806 3,152 Total inventory (1) (2) $ 13,685 $ 8,061 ____________ (1) The December 31, 2019 amounts presented above exclude $31.7 million of inventory in aggregate at Noden classified as held for sale. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The fair value of the Company’s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or pay to transfer a liability (exit price) in an orderly transaction between market participants at the measurement date. The assets and liabilities are categorized and disclosed in one of the following three categories: Level 1 – based on quoted market prices in active markets for identical assets and liabilities; Level 2 – based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable. Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The following table presents the fair value of the Company’s financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy under the Going Concern Basis: December 31, 2019 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Money market funds $ 131,264 $ — $ — $ 131,264 Corporate securities (1) 82,267 — — 82,267 Warrants (2) — 14,152 — 14,152 Royalty rights - at fair value (3) — — 266,196 266,196 Total $ 213,531 $ 14,152 $ 266,196 $ 493,879 ___________________ (1) Corporate securities are classified as “Long-term assets held for sale” on the December 31, 2019 Condensed Consolidated Balance Sheet. (2) Warrants consist of Evofem warrants, which are classified as “Long-term assets held for sale” and CareView Communications, Inc. (“CareView”) warrants, classified as “Other assets” on the Condensed Consolidated Balance Sheet as of December 31, 2019. (3) Royalty rights are classified as “Long-term assets held for sale” on the Condensed Consolidated Balance Sheet as of December 31, 2019. Money Market Funds - The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. Corporate Securities - Corporate securities consisted of common stock shares of Evofem, a commercial-stage biopharmaceutical company listed on Nasdaq (EVFM). For additional information, see Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , and Note 4, Investment in Evofem Biosciences, Inc. Warrants - Warrants consist of rights to purchase shares of common stock in Evofem and CareView, see Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis, Note 4, Investment in Evofem Biosciences, Inc. and Note 8, Notes and Other Long-Term Receivables. The fair value of the warrants is based upon recently quoted market prices of the underlying equity security and the Black-Scholes option pricing model and adjusted by an estimated discount to sell. Royalty Rights - At Fair Value During the quarter ended March 31, 2020, it was determined that the Company’s royalty assets met the criteria as an asset held for sale, see Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis . Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sale under the Going Concern Basis. The Company historically accounted for such royalty rights assets at fair value, which, as discussed below, primarily reflected the expected future cash to be received but did not consider the expected costs to sell the assets. The Company’s royalty assets are comprised of several separate and distinct royalty rights. Assertio (Depomed) Royalty Agreement On October 18, 2013, the Company entered into the Royalty Purchase and Sale Agreement (the “Assertio Royalty Agreement”) with Assertio Therapeutics, Inc. (formerly known as Depomed, Inc.), and Depo DR Sub, LLC (together, “Assertio”), whereby the Company acquired the rights to receive royalties and milestones payable on sales of five Type 2 diabetes products licensed by Assertio in exchange for a $240.5 million cash payment. Total consideration was $241.3 million, which was comprised of the $240.5 million cash payment to Assertio and $0.8 million in transaction costs. The rights acquired include Assertio’s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus, Inc., which was subsequently acquired by Salix Pharmaceuticals, Inc., which itself was acquired by Valeant Pharmaceuticals International, Inc. (“Valeant”), which, in July 2018, changed its name to Bausch Health Companies Inc. (“Bausch Health”) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck & Co., Inc. with respect to sales of Janumet ® XR (sitagliptin and metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica N.V. with respect to potential future development milestones and sales of its approved fixed-dose combination of Invokana ® (canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor) and extended-release metformin tablets, marketed as Invokamet XR ® ; (d) from Boehringer Ingelheim and Eli Lilly (“Lilly”) and Company with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Assertio’s license agreement with Boehringer Ingelheim, including its approved products, Jentadueto XR ® and Synjardy XR ® ; and (e) from LG Chem, Ltd. and Bausch Health for sales of extended-release metformin tablets in Korea and Canada, respectively. In February 2013, a generic equivalent to Glumetza was approved by the U.S. Food and Drug Administration (“FDA”) and in August 2016, two additional generic equivalents to Glumetza were approved by the FDA. In February 2016, Lupin Pharmaceuticals, Inc., in August 2017, Teva Pharmaceutical Industries Ltd., and in July 2018, Sun Pharmaceutical, Inc. (“Sun”) each launched a generic equivalent approved product. In May 2017, the Company received notification that a subsidiary of Valeant had launched an authorized generic equivalent product in February 2017, and the Company received royalties on such authorized generic equivalent product under the same terms as the branded Glumetza product, retroactive to February 2017. The Company continues to monitor whether the generic competition further affects sales of Glumetza and thus royalties on such sales paid to the Company, and the impact of the launched authorized generic equivalent. Due to the uncertainty around Bausch Health’s marketing and pricing strategy, as well as Sun’s generic product and limited historical demand data after generic market entrance, the Company may need to further evaluate future cash flows in the event of more rapid reduction or increase in market share of Glumetza and its authorized generic equivalent product and/or a further erosion in net pricing. The Company determined that its royalty purchase interest in Depo DR Sub, LLC represented a variable interest in a variable interest entity. However, the Company did not have the power to direct the activities of Depo DR Sub, LLC that most significantly impact Depo DR Sub, LLC’s economic performance and was not the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC was not subject to consolidation by the Company. On August 2, 2018, PDL Investment Holding, LLC (“PDLIH”), a wholly-owned subsidiary of the Company and assignee from the Company under the Assertio Royalty Agreement, entered into an amendment to the Assertio Royalty Agreement with Assertio. Pursuant to the amendment, PDLIH purchased all of Assertio’s remaining interests in royalty and milestone payments payable on sales of Type 2 diabetes products licensed by Assertio for $20.0 million. Prior to the amendment, the Assertio Royalty Agreement provided that the Company would have received all royalty and milestone payments due under license agreements between Assertio and its licensees until the Company received payments equal to two times the cash payment it made to Assertio, or approximately $481.0 million, after which all net payments received by Assertio would have been shared equally between the Company and Assertio. Following the amendment, the Assertio Royalty Agreement provides that the Company will receive all royalty and milestone payments due under the license agreements between Assertio and its licensees. After the amendment, the Company elected to continue to follow the fair value option and carry the financial asset at fair value. The Assertio Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms. As of December 31, 2018, in conjunction with the amendment described above, the Company was provided the power to direct the activities of Depo DR Sub, LLC and is the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC is subject to consolidation by the Company. As of December 31, 2019 and the current periods, Depo DR Sub, LLC did not have any assets or liabilities of value for consolidation with the Company. The financial asset acquired represents a single unit of accounting. Under Going Concern Basis, this financial asset is classified as a Level 3 asset as of December 31, 2019 within the fair value hierarchy, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by regulatory agencies outside of the United States. The estimated fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected amount and timing future cash flows to be generated by each licensed product. The discounted cash flows are based upon expected royalties from sales of licensed products over approximately an eight-year period. Significant judgment is required in selecting appropriate discount rates. The discount rates utilized range from 10% to 24%. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated value of the asset. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Refer to Note 2, Net Assets in Liquidation , for a discussion of the valuation of Assertio under the Liquidation Basis of accounting. Viscogliosi Brothers Royalty Agreement On June 26, 2014, the Company entered into a Royalty Purchase and Sale Agreement (the “VB Royalty Agreement”) with Viscogliosi Brothers, LLC (“VB”), whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that received pre-market approval from the FDA held by VB and commercialized by Paradigm Spine, LLC (“Paradigm Spine”) in exchange for a $15.5 million cash payment, less fees. Paradigm Spine was acquired in March 2019 by RTI Surgical Holdings, Inc. The royalty rights acquired include royalties accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company was eligible to receive all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company received payments equal to 2.3 times the cash payment made to VB, after which all rights to receive royalties would be returned to VB. VB’s ability to repurchase the royalty right for a specified amount expired on June 26, 2018. In August 2020, the Company sold the royalty rights to a third-party for $4.2 million. No gain or loss was recognized on the date of sale due to an adjustment to the royalty rights fair value in the prior quarter that was informed by bids received. University of Michigan Royalty Agreement On November 6, 2014, the Company acquired a portion of all royalty payments of the Regents of the University of Michigan’s (“U-M”) worldwide royalty interest in Cerdelga ® (eliglustat) for $65.6 million pursuant to the Royalty Purchase and Sale Agreement with U-M (the “U-M Royalty Agreement”). Under the terms of the U-M Royalty Agreement, the Company receives 75% of all royalty payments due under the U-M license agreement with Genzyme Corporation, a Sanofi company (“Genzyme”) until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States in August 2014, in the European Union (“EU”) in January 2015, and in Japan in March 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities. While marketing applications have been approved in the United States, the EU and Japan, national pricing and reimbursement decisions are delayed in some countries. The estimated fair value of the royalty right at December 31, 2019 was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. Under Going Concern Basis, this asset was classified as a Level 3 asset as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The estimated fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected amount and timing of future cash flows. The discounted cash flow was based upon expected royalties from sales of licensed product over approximately a two-year period. Significant judgment is required in selecting the appropriate discount rate. The discount rate utilized was approximately 12.8%. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates is performed in each reporting period. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. Refer to Note 2, Net Assets in Liquidation , for a discussion of the valuation of the U-M Royalty Agreement under the Liquidation Basis of accounting. AcelRx Royalty Agreement On September 18, 2015, the Company entered into a royalty interest assignment agreement (the “AcelRx Royalty Agreement”) with ARPI LLC, a wholly-owned subsidiary of AcelRx Pharmaceuticals, Inc. (“AcelRx”), whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso ® (sufentanil sublingual tablet system) in the EU, Switzerland and Australia by AcelRx’s commercial partner, Grünenthal, in exchange for a $65.0 million cash payment. Under the terms of the AcelRx Royalty Agreement, the Company was eligible to receive 75% of all royalty payments and 80% of the first four commercial milestone payments due under AcelRx’s license agreement with Grünenthal until the earlier to occur of (i) receipt by the Company of payments equal to three times the cash payments made to AcelRx and (ii) the expiration of the licensed patents. Zalviso received marketing approval by the European Commission in September 2015. Grünenthal launched Zalviso in the second quarter of 2016 and the Company started to receive royalties in the third quarter of 2016. On May 15, 2020, AcelRx received notice that the product marketer of Zalviso, Grünenthal GmbH, would exercise its right to terminate the license agreement with AcelRx, effective as of 180 days from the date of the notice. AcelRx is obligated to use commercially reasonable efforts to find a new license agreement under the terms no less favorable than those in the license with Grünenthal. In August 2020, the Company sold the asset to a third-party for zero consideration. No gain or loss was recognized on the date of sale, due to an adjustment to the royalty rights fair value in the prior quarter that resulted from the notification that the license agreement was terminated by the marketer of the product. Kybella Royalty Agreement On July 8, 2016, the Company entered into a royalty purchase and sales agreement with an individual, whereby the Company acquired that individual’s rights to receive certain royalties on sales of KYBELLA ® by Allergan plc in exchange for a $9.5 million cash payment and up to $1.0 million in future milestone payments based upon product sales targets. The Company started to receive royalty payments during the third quarter of 2016. In August 2020, the Company sold the asset to a third-party for $0.2 million. No gain or loss was recognized on the date of sale, due to an adjustment to the royalty rights fair value in the prior quarter that was informed by bids received. The following tables summarize the changes in Level 3 Royalty Right Assets and the gains and losses included in earnings for the eight months ended August 31, 2020 under the Going Concern Basis: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Right Assets (in thousands) Royalty Rights - Fair value as of December 31, 2019 $ 266,196 Total net change in fair value for the period Change in fair value of royalty rights - at fair value (8,804) Cash received from royalty rights (35,129) Total net change in fair value for the period (43,933) Sale of royalty rights (4,350) Fair value as of August 31, 2020 $ 217,913 The table above does not include the aggregate remaining estimated cost to sell the royalty right assets of $4.6 million. Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Right Assets Fair Value as of Sale of Royalty Rights - Fair Value as of (in thousands) December 31, 2019 Royalty Rights (1) Change in Fair Value August 31, 2020 (2) Assertio $ 218,672 $ — $ (18,209) $ 200,463 VB 13,590 (4,182) (9,408) — U-M 20,398 — (2,948) 17,450 AcelRx 12,952 — (12,952) — KYBELLA 584 (168) (416) — $ 266,196 $ (4,350) $ (43,933) $ 217,913 ________________ (1) In August 2020 the Company sold the royalty rights to VB, AcelRx, and KYBELLA to a third party. (2) Excludes the aggregate remaining estimated costs to sell of $4.6 million. Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of long-lived assets, including property and equipment and intangible assets and the shares of AEON BioPharma, Inc. (“AEON”) and Alphaeon 1, LLC, (formerly collectively referred to as “Alphaeon” and currently and collectively referred to as “AEON”), common stock, received in connection with the loans made to LENSAR by the Company prior to its acquisition of LENSAR. The Company’s carrying values of the 1.7 million shares of AEON common stock as of December 31, 2019 under Going Concern Basis was $6.6 million based on an estimated per share value of $3.84, which was established by a valuation performed when the shares were acquired. The value of the Company’s investment in AEON is not readily determinable as AEON’s shares are not publicly traded. Under the Going Concern Basis, the Company evaluated the fair value of this investment by performing a qualitative assessment each reporting period. If the results of this qualitative assessment indicate that the fair value was less than the carrying value, the investment is written down to its fair value. Based on additional financial information received from AEON, the Company performed an analysis on August 31, 2020 and concluded the investment was impaired and wrote it down to $1.0 million. The loss is reported as Loss on investment on the Company’s Condensed Consolidated Statement of Operations. This investment is included in Other Assets on the Company’s Condensed Consolidated Statement of Net Assets as of September 30, 2020 and as Other long-term assets on the December 31, 2019 Condensed Consolidated Balance Sheet. For additional information on the AEON investment, see Note 8, Notes and Other Long-Term Receivables . During the quarter ended March 31, 2020, it was determined that Noden met the criteria as an asset held for sale. As a result of the Company’s analysis of the fair value of Noden, the Company recorded a loss on classification as held for sale of $6.7 million during the quarter ended March 31, 2020 of which $1.8 million related to the estimated costs to sell Noden and $4.9 million related to the difference in carrying value versus fair value. The fair value calculation was made using a discounted cash flow model, utilizing a discount rate of approximately 19%, and included level 3 inputs. During the quarter ended June 30, 2020, the Company recorded an additional loss of $16.8 million related primarily to the difference in carrying value and fair value. The reduction in fair value reflected lower estimated sales proceeds as informed by the Company’s sales process. At June 30, 2020, the fair value calculation was made using a discounted cash flow model, utilizing a discount rate of approximately 17%, and included level 3 inputs. For information on the sale of the business in September 2020, see Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis . Assets/Liabilities Not Subject to Fair Value Recognition The Company has two notes receivable assets with an aggregate carrying value of $52.1 million as of December 31, 2019 under the Going Concern Basis. The estimated fair value of these notes receivable of $57.3 million exceeded the carrying value as of December 31, 2019. The notes receivable were classified under the Going Concern Basis as Level 3 in the fair value hierarchy as the Company’s valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values, required yield and the value of underlying collateral. The Company engages third-party valuation experts when deemed necessary to assist in evaluating its investments and the related inputs needed to estimate the fair value of certain investments. As of December 31, 2019 under the Going Concern Basis, the estimated fair value of the CareView note receivable was determined using a liquidation analysis. A liquidation analysis considers the asset side of the balance sheet and adjusts the value in accordance with the relative risk associated with the asset and the probable liquidation value. The asset recovery rates varied by asset. As of December 31, 2019 under the Going Concern Basis, the estimated fair value of the Wellstat Diagnostics note receivable was determined by using an asset approach and discounted cash flow model related to the underlying collateral and adjusted to consider estimated costs to sell the asset. The Company’s liabilities not subject to fair value recognition under the Going Concern Basis consist of its 2021 and 2024 convertible notes. The fair values of the Company’s convertible senior notes were determined using quoted market pricing and were classified as Level 2 in the fair value hierarchy. The aggregate carrying value of the convertible notes was $27.3 million as of December 31, 2019. The aggregate fair values of the convertible notes was $33.9 million as of December 31, 2019. The following table represents significant unobservable inputs used in determining the estimated fair value of the Wellstat Diagnostics note receivable investment under the Going Concern Basis: Asset Valuation Unobservable December 31, 2019 Wellstat Diagnostics Wellstat Guarantors intellectual property Income Approach Discount rate 12% Undiscounted royalty amount $21 million Settlement Amount Income Approach Discount rate 15% Undiscounted settlement amount $28 million Real Estate Property Market Approach Annual appreciation rate —% Estimated realtor fee 6% Undiscounted market value $16 million

Notes Receivable and Other Long

Notes Receivable and Other Long-term Receivables	9 Months Ended
	Sep. 30, 2020
Receivables [Abstract]
Notes and Other Long-term Receivables	. Notes and Other Long-Term Receivables Notes and other long-term receivables included the following significant agreements: Wellstat Diagnostics Note Receivable and Credit Agreement and Related Litigation On November 2, 2012, the Company and Wellstat Diagnostics entered into a $40.0 million credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, the Company was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics’ products, if any, commencing upon the commercialization of its products. A portion of the proceeds of the $40.0 million credit agreement were used to repay certain notes receivable which Wellstat Diagnostics entered into in March 2012. In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. The Company sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, the Company exercised one of its available remedies and transferred approximately $8.1 million of available cash from a bank account of Wellstat Diagnostics to the Company and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby the Company agreed to refrain from exercising additional remedies for 120 days. During such forbearance period, the Company provided approximately $1.3 million to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately $8.7 million was advanced pursuant to the forbearance agreement. On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement. Except as otherwise described herein, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, the Company was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately $44.1 million, which was comprised of approximately $33.7 million original loan principal and interest, $1.3 million term loan principal and interest and $9.1 million forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics’ obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below). In June 2014, the Company received information from Wellstat Diagnostics showing that it was generally unable to pay its debts as they became due, constituting an event of default under the amended and restated credit agreement. On August 5, 2014, the Company delivered a notice of default to Wellstat Diagnostics, which accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately $53.9 million, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations. On August 7, 2014, the Company delivered a notice to each of the guarantors of Wellstat Diagnostics’ obligations to the Company (collectively, the “Wellstat Diagnostics Guarantors”) under the credit agreement, which included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics’ stockholders. On September 24, 2014, the Company filed an ex-parte petition for appointment of receiver with the Circuit Court of Montgomery County, Maryland, which was granted on the same day. Wellstat Diagnostics remained in operation during the period of the receivership with incremental additional funding from the Company. On May 24, 2017, Wellstat Diagnostics transferred substantially all of its assets to the Company pursuant to a credit bid. The credit bid reduced the outstanding balance of the loan by an immaterial amount. On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against certain of the Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, the Company filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantor defendants’ assets. Although the court denied the Company’s request for a temporary restraining order at a hearing on September 24, 2015, it ordered that assets of the Wellstat Diagnostics Guarantor defendants should be held in status quo ante and only used in the normal course of business. On July 29, 2016, the Supreme Court of New York granted the Company’s motion for summary judgment and held that the Wellstat Diagnostics Guarantor defendants are liable for all “Obligations” owed by Wellstat Diagnostics to the Company. After appeal by the Wellstat Diagnostics Guarantor defendants on February 14, 2017, the Appellate Division of the Supreme Court of New York reversed on procedural grounds a portion of the Memorandum of Decision granting the Company summary judgment in lieu of complaint, but affirmed the portion of the Memorandum of Decision denying the Wellstat Diagnostics Guarantor defendants’ motion for summary judgment in which they sought a determination that the guarantees had been released. As a result, the litigation has been remanded to the Supreme Court of New York to proceed on the Company’s claims as a plenary action. On June 21, 2017, the Supreme Court of New York ordered the Company to file a Complaint, which was filed by the Company on July 20, 2017. The Wellstat Diagnostics Guarantors filed their answer on August 9, 2017, including counterclaims against the Company alleging breach of contract, breach of fiduciary duty, and tortious interference with prospective economic advantage. On October 14, 2016, the Company sent a notice of default and reference to foreclosure proceedings to certain of the Wellstat Diagnostics Guarantors which are not defendants in the New York action, but which are owners of real estate assets over which a deed of trust in favor of the Company securing the guarantee of the loan to Wellstat Diagnostics had been executed. On March 2, 2017, the Company sent a second notice to foreclose on the real estate assets, and noticed the sale for March 29, 2017. The sale was taken off the calendar by the trustee under the deed of trust and has not been re-scheduled yet. On March 6, 2017, the Company sent a letter to the Wellstat Diagnostics Guarantors seeking information in preparation for a UCC Article 9 sale of some or all of the intellectual property-related collateral of the Wellstat Diagnostics Guarantors. The Wellstat Diagnostics Guarantors did not respond to the Company’s letter, but on March 17, 2017, filed an order to show cause with the Supreme Court of New York to enjoin the Company’s sale of the real estate or enforcing its security interests in the Wellstat Diagnostics Guarantors’ intellectual property during the pendency of any action involving the guarantees at issue. On February 6, 2018, the Supreme Court of New York issued an order from the bench which enjoins the Wellstat Diagnostics Guarantors from selling, encumbering, removing, transferring or altering the collateral pending the outcome of the proceedings before it. The Supreme Court of New York also issued an order precluding the Company from foreclosing on certain of the Wellstat Diagnostics Guarantors’ collateral pending the outcome of the proceedings before it. In September of 2018, discovery in the New York action was completed. Summary judgment motions were filed by Wellstat Diagnostics and the Company in 2018 and a hearing was held on May 22, 2019. On September 11, 2019, the Supreme Court of New York granted the Company’s summary judgment motion, the court holding that the guarantees executed by the Wellstat Diagnostics Guarantors are valid and enforceable, and that the Wellstat Diagnostics Guarantors are liable for the amount owed under the loan agreement. The court ordered a damages inquest before a special referee to calculate the amount owed under the loan agreement between Wellstat Diagnostics and the Company. On September 12, 2019, the Wellstat Diagnostics Guarantors filed a notice of appeal in relation to the court’s decision. On September 17, 2019, the Wellstat Diagnostics Guarantors requested a stay of the enforcement of the New York Supreme Court’s decision pending their appeal of the decision, which was denied on November 21, 2019. A damages hearing was scheduled to begin before a judicial hearing officer on December 17, 2019. At the request of the judicial hearing officer, the parties agreed to mediate their dispute prior to the commencement of the damages hearing. As a result, no decision has been made by the hearing officer with respect to the amount of damages owed to the Company. In an unrelated litigation, Wellstat Therapeutics filed a lawsuit against BTG International, Inc. for breach of contract (the “BTG Litigation”). In September 2017, the Delaware Chancery Court found in favor of Wellstat Therapeutics and awarded a judgment of $55.8 million in damages, plus interest. In October 2017, the Company filed a motion with the Supreme Court of New York requesting a pre-judgement attachment of the award. In June 2018, the Delaware Supreme Court largely affirmed the September 2017 decision of the Delaware Chancery Court, including the $55.8 million awarded in judgment. In August of 2018, in a letter to the Company’s counsel, Wellstat Diagnostics Guarantors’ counsel confirmed that the Wellstat Diagnostics Guarantors are preserving the BTG Litigation judgment award proceeds consistent with the New York Court’s prior directions. On October 22, 2015, certain of the Wellstat Diagnostics Guarantors filed a separate complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect. This case has been joined for all purposes, including discovery and trial, and consolidated with the pending case filed by the Company. The Wellstat Diagnostic Guarantors filed a summary judgment motion with regard to this case, which was also heard by the court at the hearing on May 22, 2019. The court, in its September 11, 2019 decision, denied in its entirety the Wellstat Diagnostics Guarantors’ motion for summary judgment. Effective April 1, 2014, and as a result of the event of default, the Company determined the loan to be impaired and it ceased to accrue interest revenue. As of December 31, 2019, it was determined that an allowance on the carrying value of the note was not necessary, as the Company believed the value of the collateral securing Wellstat Diagnostics’ obligations is in-line with the carrying value of the asset and was sufficient to enable the Company to recover the carrying value at December 31, 2019 of $50.2 million. In August 2020, the Company entered into a settlement agreement (the “Settlement Agreement”) with related entities of Defined Diagnostics, LLC resolving litigation relating to loans made to Wellstat Diagnostics by the Company. Wellstat paid the company an amount of $7.5 million upon the signing of the Settlement Agreement and must pay either (1) $5.0 million by February 10, 2021 and $55.0 million by July 26, 2021; or (2) $67.5 million by July 26, 2021. Further under the terms of the Settlement Agreement, upon payment of either $5.0 million prior to April 21, 2021 or completion of the payment of $67.5 million by July 26, 2021, the Company will transfer to Wellstat Diagnostics on an "as is" and "where is" basis certain assets currently owned by the Company which were obtained through the Company's credit bid in 2017 for the assets of Wellstat Diagnostics. If the Wellstat Parties fail to make payment in full by July 26, 2021, the Company shall be authorized to record and confess judgment against the Wellstat Parties for an amount of $92.5 million or such lesser amount as may be owed under the Settlement Agreement. The $7.5 million initial signing payment was received by the Company in August 2020. The Company’s Settlement Agreement with Defined Diagnostics, LLC and related entities also settled its disputes with Hyperion (a Wellstat Diagnostics Guarantor). As of September 30, 2020 under the Liquidation Basis, the estimated realizable value of $51.4 million has been reflected as “Notes Receivable” on the Company’s Condensed Consolidated Statement of Net Assets. CareView Credit Agreement On June 26, 2015, the Company entered into a credit agreement with CareView, under which the Company made available to CareView up to $40.0 million in loans comprised of two tranches of $20.0 million each, subject to CareView’s attainment of specified milestones relating to the placement of CareView Systems. On October 7, 2015, the Company and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones and the Company funded the first tranche of $20.0 million, net of fees, based on CareView’s attainment of the first milestone, as amended. The second $20.0 million tranche was not funded due to CareView’s failure to achieve the related funding milestones and there is no additional funding obligation due from the Company. Outstanding borrowings under the credit agreement bear interest at the rate of 13.5% per annum and are payable quarterly in arrears. The CareView note receivable is secured by substantially all assets of, and equity interests in CareView’s subsidiaries. As part of the original credit agreement, the Company received a warrant to purchase approximately 4.4 million shares of common stock of CareView at an exercise price of $0.45 per share. The Company has accounted for the warrant as a derivative asset with an offsetting credit as debt discount. At each reporting period under the Going Concern Basis the warrant was marked to market for changes in fair value. In connection with the October 2015 amendment of the credit agreement, the Company and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant’s exercise price from $0.45 to $0.40 per share. In February 2018, the Company entered into a modification agreement with CareView (the “February 2018 Modification Agreement”) whereby the Company agreed, effective December 28, 2017, to modify the credit agreement before remedies could otherwise have become available to the Company under the credit agreement in relation to certain obligations of CareView that would potentially not be met, including the requirement to make principal payments. Under the February 2018 Modification Agreement, the Company agreed that (i) a lower liquidity covenant would be applicable and (ii) principal repayment would be delayed until December 31, 2018. In exchange for agreeing to these modifications, among other things, the exercise price of the Company’s warrants to purchase 4.4 million shares of common stock of CareView was repriced from $0.40 to $0.03 per share and, subject to the occurrence of certain events, CareView agreed to grant the Company additional equity interests. As a result of the February 2018 Modification Agreement, the Company determined the loan to be impaired and it ceased to accrue interest revenue effective October 1, 2017. In September 2018, the Company entered into an amendment to the February 2018 Modification Agreement with CareView whereby the Company agreed, effective as of September 28, 2018, that a lower liquidity covenant would be applicable. In December 2018, the Company further modified the loan by agreeing that (i) a lower liquidity covenant would be applicable, (ii) the first principal payment would be deferred until January 31, 2019, and (iii) the scheduled interest payment due December 31, 2018 would be deferred until January 31, 2019. In December 2018, and in consideration of the further modification to the credit agreement, the Company completed an impairment analysis and determined that the note was impaired and recorded an impairment loss of $8.2 million. As of March 31, 2019, the principal repayment and interest payments were deferred until April 30, 2019. The principal repayment and interest payment were subsequently deferred until May 15, 2019 under additional amendments. In May 2019, and in consideration of additional capital raised by CareView, the Company further modified the loan by agreeing that (i) the first principal and interest payments would be deferred until September 30, 2019 and (ii) the remaining liquidity covenant would be removed. In September 2019, the Company further modified the loan by agreeing that the first principal and interest payments would be deferred, and (iii) the interest rate would be increased to 15.5%. Pursuant to further amendments to the February 2018 Modification Agreement in September 2019, December 2019, January 2020, April 2020, and September 2020, the Company agreed to defer principal and interest payments until November 30, 2020. For additional information see Note 7, Fair Value Measurements . In December 2019, and in consideration of the further modification to the credit agreement and February 2018 Modification Agreement, the Company updated its impairment analysis and determined that an additional impairment was necessary and recorded an impairment loss of $10.8 million. At September 30, 2020, the Company estimated the value of the warrant to be $0.1 million.

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	Leases Lessor arrangements The Company has operating leases for medical device equipment generated from its medical devices segment. The components of Lease revenue are as follows: Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) Classification 2020 2019 2020 2019 Operating lease income Lease revenue $ 703 $ 1,322 $ 2,139 $ 3,854 Lessee arrangements The Company has operating leases for corporate offices and certain equipment. On August 20, 2020, LENSAR amended its lease for corporate offices pursuant to which the term of the lease was extended through November 30, 2027 commencing on September 1, 2020. The lease amendment constitutes a modification as it extends the original lease term, which requires evaluation of the remeasurement of the lease liability and corresponding right-of-use-asset. The reassessment resulted in continuing to classify the lease as an operating lease and remeasurement of the lease liability on the basis of the extended lease term and the incremental borrowing rate at the effective date of modification of 10%. The remeasurement for the modification resulted in an increase to the lease liability and the right-of-use-asset of $3.3 million. Following the change, the Company's future minimum lease payments under non-cancellable leases as of September 30, 2020 were as follows (in thousands): Fiscal Year Amount Remainder of 2020 $ 88 2021 704 2022 613 2023 552 2024 and thereafter 2,309 Total operating lease payments 4,266 Less: imputed interest (121) Total operating lease liabilities $ 4,145
Leases	Leases Lessor arrangements The Company has operating leases for medical device equipment generated from its medical devices segment. The components of Lease revenue are as follows: Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) Classification 2020 2019 2020 2019 Operating lease income Lease revenue $ 703 $ 1,322 $ 2,139 $ 3,854 Lessee arrangements The Company has operating leases for corporate offices and certain equipment. On August 20, 2020, LENSAR amended its lease for corporate offices pursuant to which the term of the lease was extended through November 30, 2027 commencing on September 1, 2020. The lease amendment constitutes a modification as it extends the original lease term, which requires evaluation of the remeasurement of the lease liability and corresponding right-of-use-asset. The reassessment resulted in continuing to classify the lease as an operating lease and remeasurement of the lease liability on the basis of the extended lease term and the incremental borrowing rate at the effective date of modification of 10%. The remeasurement for the modification resulted in an increase to the lease liability and the right-of-use-asset of $3.3 million. Following the change, the Company's future minimum lease payments under non-cancellable leases as of September 30, 2020 were as follows (in thousands): Fiscal Year Amount Remainder of 2020 $ 88 2021 704 2022 613 2023 552 2024 and thereafter 2,309 Total operating lease payments 4,266 Less: imputed interest (121) Total operating lease liabilities $ 4,145

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets The Company acquired certain intangible assets (customer relationships, acquired technology and acquired trademarks) as part of its acquisition of LENSAR in May 2017. They were being amortized on a straight-line basis over a weighted-average period of 15 years. The intangible assets for customer relationships were being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. Subsequent to the May 2017 acquisition, LENSAR further acquired certain intangible assets for customer relationships from a domestic distributor in an asset acquisition, which were being amortized on a straight-line basis over a period of 10 years. LENSAR also acquired certain intangible assets from a medical technology company in an assets acquisition, which were being amortized on a straight-line basis over a period of 15 years. The components of intangible assets as of December 31, 2019 were as follows: December 31, 2019 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Finite-lived intangible assets: Customer relationships $ 4,045 $ (884) $ 3,161 Acquired technology 11,500 (1,741) 9,759 Acquired trademarks 570 (304) 266 Total $ 16,115 $ (2,929) $ 13,186 Intangible assets of $42.1 million at September 30, 2020 reflect the estimated value of LENSAR under the liquidation basis of accounting. These assets, which relate in their entirety to LENSAR, represent customer relationships, acquired technology and acquired trademarks, as well as previously expensed research and development costs incurred to develop the current LENSAR Laser system and the next-generation ALLY system. These research and development costs were previously required to be expensed as incurred under the going concern basis of accounting. LENSAR was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information. For the two and eight months ended August 31, 2020, amortization expense was $0.2 million and $0.8 million, respectively, and for the three and nine months ended September 30, 2019, amortization expense was $0.3 million and $1.0 million, respectively.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accrued Liabilities	. Accrued Liabilities Accrued liabilities under Going Concern Basis consisted of the following: (in thousands) December 31, Compensation $ 6,823 Deferred revenue 959 Interest 70 Legal 921 Accrued rebates, chargebacks and other revenue reserves 5 Other 3,145 Total (1) (2) $ 11,923 ________________ (1) The amounts above exclude $16.4 million of accrued liabilities at Noden classified as held for sale as of December 31, 2019. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. (2) The table above includes amounts held by LENSAR which was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information. Upon adoption of the Liquidation Basis of accounting, the Company accrued for all future estimated expenses and liabilities. For additional information, see Note 2, Net Assets in Liquidation.

Convertible Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Convertible Senior Notes	. Convertible Senior Notes Principal Balance Outstanding Carrying Value September 30, September 30, December 31, Description Maturity Date 2020 2020 2019 (in thousands) (Liquidation Basis) (Going Concern Basis) Convertible Senior Notes December 2021 Notes December 1, 2021 $ 13,805 $ 14,238 $ 16,950 December 2024 Notes December 1, 2024 1,000 1,000 10,300 Total $ 14,805 $ 15,238 $ 27,250 December 2021 Notes On November 22, 2016, the Company issued $150.0 million in aggregate principal amount, at par, of 2.75% Convertible Senior Notes due December 1, 2021 (the “December 2021 Notes”) in an underwritten public offering, for net proceeds of $145.7 million. The December 2021 Notes are due December 1, 2021, and the Company pays interest at 2.75% on the December 2021 Notes semiannually in arrears on June 1 and December 1 of each year, beginning June 1, 2017. In September 2019, the Company entered into privately negotiated exchange agreements with certain holders of approximately $86.1 million aggregate principal amount of outstanding December 2021 Notes. The Company exchanged $86.1 million aggregate principal of December 2021 Notes for an identical principal amount of 2.75% Convertible Senior Notes due December 1, 2024 (the “December 2024 Notes”), plus a cash payment of $70.00 for each $1,000 principal amount tendered (“September 2019 Exchange Transaction”). See “December 2024 Notes” below. The terms of the remaining December 2021 Notes remained unchanged. The September 2019 Exchange Transaction qualified as a debt extinguishment and the Company recognized a loss on exchange of the convertible notes of $3.9 million in the third quarter of 2019. Upon the occurrence of a fundamental change, as defined in the indenture, entered into in connection with the December 2021 Notes (the “December 2021 Notes Indenture”), holders have the option to require the Company to repurchase their December 2021 Notes at a purchase price equal to 100% of the principal, plus accrued interest. A fundamental change was triggered as a result of the stockholders’ approval of the dissolution of the Company on August 19, 2020 pursuant to the Plan of Dissolution. This fundamental change also constituted a make-whole fundamental change as defined in the December 2021 Notes Indenture. Upon the occurrence of a fundamental change, as discussed above, the Company is required to repurchase for cash, at the bondholder’s option, all of the bondholder’s December 2021 Notes, or any portion of the principal amount thereof equal to $1,000 or an integral multiple of $1,000 at a price equal to 100% of the principal amount, plus accrued and unpaid interest thereon. The fundamental change repurchase right ended on September 29, 2020. No December 2021 Notes were tendered for repurchase under this offer. As a result of the fundamental change and the make-whole fundamental change, and notwithstanding the fundamental change repurchase right, the December 2021 Notes were convertible, at the option of the bondholder, at any time up to and including September 28, 2020 (the “September 2020 Conversion Period”). During the September 2020 Conversion Period, the Company received notification that bondholders exercised their right to convert a total of $11.2 million par value of the December 2021 Notes (the “September 2020 Conversion”). The Company intends to settle all notes submitted for conversion entirely in cash. The cash settlement price for each conversion notice received is equal to the sum of the daily conversion values, as defined in the December 2021 Notes Indenture, over a 60-trading day observation period (the “Observation Period”). The daily conversion value is calculated as the product of the daily volume-weighted stock price and the conversion rate in effect on each trading day. The carrying amount as of September 30, 2020 includes the estimated conversion settlement in excess of par value. The December 2021 Notes are convertible under any of the following circumstances at any time prior to the close of business on the business day immediately preceding June 1, 2021 (or at any time beginning on June 1, 2021 until the close of business on the second scheduled trading day immediately preceding the stated maturity): • During any fiscal quarter (and only during such fiscal quarter) commencing after the fiscal quarter ended June 30, 2017, if the last reported sale price of Company common stock for at least 20 trading days (whether or not consecutive), in the period of 30 consecutive trading days, ending on, and including, the last trading day of the immediately preceding fiscal quarter, exceeds 130% of the conversion price for the notes on each applicable trading day; • During the five business-day period immediately after any five consecutive trading-day period, which the Company refers to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of Company common stock and the conversion rate for the notes for each such trading day; or • Upon the occurrence of specified corporate events as described in the December 2021 Notes Indenture. The initial conversion rate for the December 2021 Notes was 262.2951 shares of the Company’s common stock per $1,000 principal amount of December 2021 Notes, equivalent to an initial conversion price of approximately $3.81 per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the December 2021 Notes Indenture. After the distribution by the Company of its stock in Evofem to the PDL stockholders in May 2020, the conversion rate for the December 2021 Notes increased to 316.5801 shares of the Company’s common stock per $1,000 principal amount of December 2021 Notes equating to a conversion price of $3.16 per share of common stock. After the stockholders’ approval of the dissolution of the Company on August 19, 2020, a fundamental make-whole change was triggered and the conversion rate for the December 2021 Notes was increased to 343.1098. In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the December 2021 Notes between the fair value of the debt component with the remainder of the consideration being allocated to the equity component. Using an assumed borrowing rate of 9.5%, which represented the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a debt discount of $4.3 million, allocated $23.8 million to Additional paid-in capital for the conversion feature and allocated $12.8 million to deferred tax liability. Under Going Concern Basis, the debt discount, including the conversion feature and issuance costs allocated to debt, which remained after amortization and the effect of the September 2019 Exchange Transaction, was being amortized to interest expense over the term of the December 2021 Notes and increased interest expense during the term of the December 2021 Notes from the 2.75% cash coupon interest rate to an effective interest rate of 9.7%. On December 17, 2019, the Company repurchased $44.8 million in aggregate principal amount of its December 2021 Notes for $39.9 million in cash and 3.5 million shares of its common stock in privately negotiated transactions (the “December 2019 Exchange Transaction”). It was determined that the repurchase of the principal amount should be accounted for as a partial extinguishment of the December 2021 Notes. As a result, a loss on extinguishment of $2.5 million was recorded at closing of the transaction. During the eight months ended August 31, 2020, the Company repurchased $5.4 million in aggregate principal amount of its December 2021 notes for $6.0 million in cash. It was determined that the repurchase of the principal amount should be accounted for as a partial extinguishment of the December 2021 Notes. As a result, a loss on extinguishment of $0.1 million was recorded at closing of the transaction. The carrying value of the December 2021 Notes as of September 30, 2020 and December 31, 2019 were as follows: (in thousands) September 30, 2020 December 31, 2019 (Liquidation Basis) (Going Concern Basis) Principal amount of the December 2021 Notes $ 13,805 $ 19,170 Estimated conversion settlement above par value 433 — Unamortized discount of liability component — (2,220) Carrying value of the December 2021 Notes $ 14,238 $ 16,950 Interest expense for the December 2021 Notes included in the Company’s Condensed Consolidated Statements of Operations under the Going Concern Basis was as follows: Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Contractual coupon interest $ 63 $ 939 $ 281 $ 3,002 Amortization of debt issuance costs 1 17 5 57 Amortization of debt discount 9 130 39 406 Amortization of conversion feature 125 1,692 544 5,252 Total $ 198 $ 2,778 $ 869 $ 8,717 As of September 30, 2020, the December 2021 Notes are not convertible. Capped Call Transaction In connection with the offering of the December 2021 Notes, the Company entered into a privately-negotiated capped call transaction with an affiliate of the underwriter of such issuance. The aggregate cost of the capped call transaction was $14.4 million. The capped call transaction is generally expected to reduce the potential dilution upon conversion of the December 2021 Notes and/or partially offset any cash payments the Company is required to make in excess of the principal amount of converted December 2021 Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction. This initially corresponded to the approximate $3.81 per share conversion price of the December 2021 Notes and was subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the December 2021 Notes. The cap price of the capped call transaction was initially $4.88 per share subject to certain adjustments under the terms of the capped call transaction. Upon the distribution by the Company of its stock in Evofem to the PDL stockholders in May 2020, the conversion price of the December 2021 Notes was adjusted to $3.16 per share and the cap price was adjusted to $4.04 per share. The Company will not be required to make any cash payments to the option counterparty upon the exercise of the options that are a part of the capped call transaction, but the Company will be entitled to receive from it an aggregate amount of cash and/or number of shares of the Company’s common stock, based on the settlement method election chosen for the related convertible senior notes, with a value equal to the amount by which the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction during the relevant valuation period under the capped call transaction, with such number of shares of the Company’s common stock and/or amount of cash subject to the cap price. The Company evaluated the capped call transaction under authoritative accounting guidance and determined that it should be accounted for as separate transaction and classified as a net reduction to Additional paid-in capital within stockholders’ equity with no recurring fair value measurement recorded. In connection with the September 2019 Exchange Transaction, the Company unwound a portion of the capped call entered into when the December 2021 Notes were issued, as they were no longer scheduled to mature in 2021. In connection with the December 2019 Exchange Transaction, the Company unwound a corresponding portion of the capped call related to the notes and repurchased 1.6 million shares of its common stock from the counterparty. In connection with the repurchases of the December 2021 Notes in the eight months ended August 31, 2020, the Company unwound a corresponding portion of the capped call related to the notes. As the individual Observation Period for the above-described September 2020 Note Conversion will not elapse until December 2020, the unwinding of a corresponding portion of the capped call will not occur until such time. December 2024 Notes On September 17, 2019, in connection with the September 2019 Exchange Transaction, the Company exchanged $86.1 million aggregate principal of December 2021 Notes for an identical aggregate original principal amount of December 2024 Notes, plus a cash payment of $70.00 for each $1,000 principal amount exchanged, totaling approximately $6.0 million. The December 2024 Notes are due December 1, 2024, and the Company pays interest at 2.75% on the December 2024 Notes semiannually in arrears on June 1 and December 1 of each year, beginning December 1, 2019. The original principal of the December 2024 Notes will accrete at a rate of 2.375% per year (“Accretion Interest”) commencing September 17, 2019 through the maturity of the December 2024 Notes. The accreted principal amount of the December 2024 Notes is payable in cash upon maturity and is included in Other accrued liquidation costs on the Company’s Condensed Consolidated Statement of Net Assets. Upon the occurrence of a fundamental change, as defined in the indenture entered into in connection with the December 2024 Notes (the “December 2024 Notes Indenture”), holders have the option to require the Company to repurchase all of the their December 2024 Notes, or any portion of the principal amount thereof equal to $1,000 or an integral multiple of $1,000 at a purchase price equal to 100% of the accreted principal amount of such December 2024 Notes, plus accrued interest on the original principal amount thereon. A fundamental change, which constituted a make-whole fundamental change as defined in the December 2024 Notes Indenture, was triggered as a result of the stockholders’ approval of the dissolution of the Company on August 19, 2020 pursuant to the Plan of Dissolution. The fundamental change repurchase right ended on September 29, 2020. No December 2024 Notes were tendered for repurchase under this offer. As a result of the fundamental change and the make-whole fundamental change, and notwithstanding the fundamental change repurchase right, the December 2024 Notes were convertible, at the option of the bondholder, at any time up to and including September 28, 2020 (the “September 2020 Conversion Period”). No conversion notices were received for the December 2024 Notes during the September 2020 Conversion Period. The December 2024 Notes are convertible under any of the following circumstances at any time prior to the close of business on the business day immediately preceding June 1, 2024 (or at any time beginning on June 1, 2024 until the close of business on the second scheduled trading day immediately preceding the stated maturity): • During any fiscal quarter (and only during such fiscal quarter) commencing after the fiscal quarter ended December 31, 2019, if the last reported sale price of Company common stock for at least 20 trading days (whether or not consecutive), in the period of 30 consecutive trading days, ending on, and including, the last trading day of the immediately preceding fiscal quarter, exceeds 130% of the conversion price for the notes on each applicable trading day; • During the five business-day period immediately after any five consecutive trading-day period, which the Company refers to as the measurement period, in which the trading price per $1,000 original principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of Company common stock and the conversion rate for the notes for each such trading day; • Upon the occurrence of specified corporate events or upon a redemption of the notes, in each case as described in the December 2024 Notes Indenture; or • On or after June 1, 2024, at the option of the holder prior to the second scheduled trading day preceding December 1, 2024. In accordance with the terms of the December 2024 Notes Indenture, the Company has the right, but not the obligation, to redeem all or any portion of the December 2024 Notes that is equal to $1,000 original principal amount or an integral multiple of $1,000 prior to their scheduled maturity on a redemption date beginning on or after December 1, 2021 and on or before the 60th scheduled trading day before December 1, 2024, for a cash purchase price equal to the redemption price, but only if the last reported sale price of Company common stock exceeds 128% of the conversion price for the December 2024 Notes on (i) each of at least 20 trading Days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the redemption notice date for such redemption; and (ii) the trading day immediately before such redemption notice date. The redemption price for the December 2024 Notes called for redemption is equal to the then accreted principal amount of such December 2024 Notes plus accrued but unpaid interest on the original principal amount thereon. The calling of any December 2024 Notes for redemption will constitute a make-whole fundamental change with respect to such notes, entitling the holders who convert such December 2024 Notes called for redemption prior to the applicable redemption date to receive an increase in the applicable conversion rate, as described in the December 2024 Notes Indenture. The initial conversion rate for the December 2024 Notes was 262.2951 shares of the Company’s common stock per $1,000 original principal amount of December 2024 Notes, equivalent to an initial conversion price of approximately $3.81 per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the December 2024 Notes Indenture. After the distribution by the Company of its stock in Evofem to the PDL stockholders, the conversion rate for the December 2024 Notes was 316.5801 shares of the Company’s common stock per $1,000 principal amount of December 2024 Notes equating to a conversion price of $3.16 per share of common stock. After the stockholders’ approval of the dissolution of the Company on August 19, 2020, a fundamental make-whole change was triggered and the conversion rate for the December 2024 Notes was increased to 378.8004. In accordance with the accounting guidance for an extinguishment of convertible debt instruments with a cash conversion feature, the Company was required to allocate the fair value of the consideration transferred between the liability component and the equity component. To calculate the fair value of the debt immediately prior to derecognition, the carrying value was recalculated in a manner that reflected the estimated market interest rate for a similar nonconvertible instrument at the date of issuance. Using an assumed borrowing rate of 7.05% the Company calculated the fair value of the debt representing the amount allocated to the liability component of the December 2024 Notes with the remainder of the consideration allocated to the equity conversion feature, to reflect the reacquisition of the embedded conversion option. The conversion feature together with the fees allocated to the debt are accounted for as a debt discount. As a result of the September Exchange Transaction, the Company recorded a total debt discount of $9.4 million, which included the cash conversion feature of $8.1 million and the debt issuance fees of $1.3 million, charged $5.5 million to Additional paid-in capital ($13.5 million charge to Additional paid-in capital representing the reduction to the 2021 equity component, partially offset by the $8.1 million allocated to equity for the 2024 notes) and recorded $1.2 million to deferred tax liability. The net amount charged to Additional paid-in capital represents the difference between the consideration paid for the September Exchange Transaction and the fair value of the convertible debt prior to the extinguishment. Under Going Concern Basis, the Accretion Interest and debt discount, including the conversion feature and issuance costs allocated to debt, were being amortized to interest expense over the term of the December 2024 Notes which increases interest expense during the term of the December 2024 Notes from the 2.75% cash coupon interest rate to an effective interest rate of 7.5%. On December 17, 2019, in connection with the December Exchange Transaction, the Company repurchased $74.6 million in aggregate principal amount of its December 2024 Notes for $58.0 million in cash and 9.9 million shares of its common stock in privately negotiated transactions, resulting in a loss on extinguishment of $2.1 million. During the eight months ended August 31, 2020 the Company repurchased $10.5 million in aggregate principal amount of its December 2024 notes for $12.9 million in cash, resulting in a loss on extinguishment of $0.5 million. The carrying value, accretion and unamortized discount of the December 2024 Notes as of September 30, 2020 and December 31, 2019 were as follows: (in thousands) September 30, 2020 December 31, 2019 (Liquidation Basis) (Going Concern Basis) Principal amount of the December 2024 Notes $ 1,000 $ 11,500 Unamortized discount of liability component — (1,200) Carrying value of the December 2024 Notes $ 1,000 $ 10,300 Interest expense for the December 2024 Notes included in the Company’s Condensed Consolidated Statements of Operations under the Going Concern Basis was as follows: Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Contractual coupon interest $ 5 $ 92 $ 49 $ 92 Accretion interest on outstanding principal 4 79 42 79 Amortization of debt issuance costs 1 8 6 8 Amortization of conversion feature 2 54 29 54 Total $ 12 $ 233 $ 126 $ 233 Capped Call Transaction In connection with the issuance of the December 2024 Notes in the September Exchange Transaction, the Company entered into a privately-negotiated capped call transaction with an affiliate of the underwriter of such issuance. The aggregate cost of the capped call transaction was $4.5 million. The capped call transaction is generally expected to reduce the potential dilution upon conversion of the December 2024 Notes and/or partially offset any cash payments the Company is required to make in excess of the principal amount of converted December 2024 Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction. This initially corresponded to the approximate $3.81 per share conversion price of the December 2024 Notes subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the December 2024 Notes. The cap price of the capped call transaction was initially $4.88 per share subject to certain adjustments under the terms of the capped call transaction. Upon the distribution by the Company of its stock in Evofem to the PDL stockholders in May 2020, the conversion price of the December 2024 Notes was adjusted to $3.16 per share and the cap price was adjusted to $4.04 per share. The Company will not be required to make any cash payments to the option counterparty upon the exercise of the options that are a part of the capped call transaction, but the Company will be entitled to receive from it an aggregate amount of cash and/or number of shares of the Company’s common stock, based on the settlement method election chosen for the related convertible senior notes, with a value equal to the amount by which the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction during the relevant valuation period under the capped call transaction, with such number of shares of the Company’s common stock and/or amount of cash subject to the cap price. The Company evaluated the capped call transaction under authoritative accounting guidance and determined that it should be accounted for as a separate transaction and classified as a net reduction to Additional paid-in capital within stockholders’ equity with no recurring fair value measurement recorded. In connection with the December Exchange Transaction, the Company

Other Long-Term Liabilities

Other Long-Term Liabilities	9 Months Ended
	Sep. 30, 2020
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	Other Long-Term Liabilities Other long-term liabilities under Going Concern Basis consisted of the following: December 31, (in thousands) 2019 Uncertain tax positions $ 37,574 Deferred tax liabilities 1,571 Accrued lease guarantee 10,700 Other 1,020 Total (1) (2) $ 50,865 ________________ (1) The amounts above exclude $0.1 million of Other long-term liabilities at Noden classified as held for sale as of December 31, 2019. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. (2) The table above includes amounts held by LENSAR which was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Lease Guarantee In connection with the spin-off by the Company of Facet Biotech Corporation (“Facet”), the Company entered into amendments to the leases for the Company’s former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify the Company for all matters related to the leases attributable to the period after the spin-off date. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie Biotherapeutics, Inc. (“AbbVie”). If AbbVie were to default under its lease obligations, the Company could be held liable by the landlord as a co-tenant and, thus, the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of September 30, 2020, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $14.1 million. The Company prepared a discounted, probability weighted cash flow analysis to calculate the estimated fair value of the lease guarantee as of the spin-off. The Company was required to make assumptions regarding the probability of Facet’s default on the lease payment, the likelihood of a sublease being executed and the times at which these events could occur. These assumptions are based on information that the Company received from real estate brokers and the then-current economic conditions, as well as expectations of future economic conditions. The fair value of this lease guarantee was charged to Additional paid-in capital upon the spin-off. In future periods, the Company may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable. The Company has recorded a liability of $10.7 million on its Condensed Consolidated Statement of Net Assets and Condensed Consolidated Balance Sheet as of September 30, 2020 and December 31, 2019, respectively, related to this guarantee.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders’ Equity	15. Stockholders’ Equity Stock Repurchase Program On September 24, 2018, the Company announced that the Board authorized the repurchase of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $100.0 million pursuant to a share repurchase program. The repurchases under the share repurchase program were made from time to time in the open market or in privately negotiated transactions and were funded from the Company’s working capital. All shares of common stock repurchased under this share repurchase program were retired and restored to authorized but unissued shares of common stock. The Company repurchased 31.0 million shares of its common stock under the share repurchase program for an aggregate purchase price of $100.0 million, or an average cost of $3.22 per share, including trading commissions. This program was completed in July 2019 .

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	16. Stock-Based Compensation The Company grants restricted stock awards and stock options pursuant to the stockholder approved Equity Plan. On February 7, 2020, the Board approved the Plan of Liquidation, which accelerated the vesting of a significant portion of the Company’s outstanding equity awards pursuant to provisions in the Wind Down Retention Plan. The Wind Down Retention Plan further provides for equitable adjustments to outstanding stock options held by participants to ensure such participants realize the same benefits provided to shareholders in the event one or more cash dividends or other distributions become payable to shareholders. Consistent with the existing terms of the Equity Plan, in the event one or more cash dividends or other distributions are paid to shareholders, the exercise price of outstanding stock options will be reduced on a dollar-for-dollar basis to reflect the per share value of such dividends or distribution; provided that such exercise price will not be reduced below the par value of the shares subject to the option. Furthermore, in the event that the Company declares a cash dividend or other distribution that exceeds the difference between the exercise price of an outstanding stock option and the par value of the underlying shares, the holder of such stock option will be entitled to receive from the Company, in lieu of such equitable adjustment, a cash payment in an amount equal to the number of shares subject to such stock option multiplied by the per share amount of the cash dividend that exceeds the difference between exercise price of the outstanding option and the par value of the underlying shares (a “true-up payment”). In May 2020, in accordance with this provision and in conjunction with the Evofem distribution, the exercise prices of the outstanding option awards was decreased by $0.58 per share. The following table summarizes the Company’s stock option and restricted stock award activity during the nine months ended September 30, 2020: Stock Options Restricted Stock Awards (in thousands, except per share amounts) Number of Shares Outstanding Weighted Average Exercise Price Number of Shares Outstanding Weighted Average Grant-date Fair Value Per Share Balance at December 31, 2019 12,613 $ 2.55 1,013 $ 3.53 Granted 630 $ 3.56 3,045 $ 3.10 Exercised / vested (600) $ 2.46 (2,746) $ 3.12 Forfeited / canceled (728) $ 3.08 (1,089) $ 3.39 Balance at September 30, 2020 11,915 $ 2.62 223 $ 3.43

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	17. Revenue from Contracts with Customers Revenue Nature of Goods and Services The following is a description of principal activities - separated by reportable segments - from which the Company generated its revenue. As noted in Note 3, Discontinued Operations Classified as Assets and Liabilities Held for Sale under Going Concern Basis, the Company sold its Pharmaceutical segment in September 2020. On October 1, 2020, the Company spun off its Medical device segment. See Note 21, Subsequent Events , for additional information. For more detailed information about reportable segments, see Note 18, Segment Information . Medical Devices Product and Service Revenue Recognition Product and Service revenue are recognized from our Medical Device segment. Revenue is recognized from the sale of products and services when the company transfers control of such promised products and services. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products and services. A five-step model is utilized to achieve the core principle and includes the following steps: (1) identify the customer contract; (2) identify the contract’s performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when the distinct performance obligations are satisfied. LENSAR principally derives its revenue from the sale and lease of the LENSAR Laser System and the sale of other related products and services, including PIDs, procedure licenses, and extended warranty service agreements. A procedure license represents a one-time right to utilize the LENSAR Laser System surgical application in connection with a surgery procedure. Without separately procuring procedure licenses granted by LENSAR, either together with the purchase of the LENSAR Laser System or under separate subsequent contracts, the customer does not have the right to use the surgical software application to perform surgical procedures. Typically, returns are not allowed. LENSAR’s contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Judgement is required to determine the level of interdependency between the LENSAR Laser System and the sale of other related products and services. LENSAR evaluates each product or service promised in a contract to determine whether it represents a distinct performance obligation. A performance obligation is distinct if (1) the customer can benefit from the product or service on its own or with other resources that are readily available to the customer and (2) the products or service is separately identifiable from other promises in the contract. For contracts involving the sale or lease of the LENSAR Laser System, LENSAR’s performance obligations generally include the LENSAR Laser System, PID, procedure license, and extended warranty service agreements. In addition, customer contracts contain provisions for installation and training services, which are not assessed as performance obligations as they are determined to be immaterial promises in the context of the contract and are required for a customer to use the LENSAR Laser System. LENSAR has determined that the LENSAR Laser System, PID and procedure license are each capable of being distinct because they are each sold separately and the customer can benefit from these products with the other readily available resources that are sold by the Company. In addition, LENSAR has determined each are separately identifiable because the LENSAR Laser System, PID and procedure license (1) are not highly interdependent or interrelated; (2) do not modify or customize one another; and (3) LENSAR does not provide a significant service of integrating the promised goods into a bundled output. This is because LENSAR is able to fulfill each promise in the contract independently of the others. That is, LENSAR would be able to fulfill its promise to transfer the LENSAR Laser System even if the customer did not purchase a PID or procedure license and LENSAR would be able to fulfill its promise to provide the PID or the procedure license even if the customer acquired the LENSAR Laser System separately. The extended warranty, unlike LENSAR’s standard product warranty, is a performance obligation because it provides an incremental service that is beyond ensuring the product delivered will be consistent with stated contractual specifications. When a contract contains multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. LENSAR recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer as described below. LENSAR records a contract liability, or deferred revenue, when it has an obligation to provide a product or service to the customer and payment is received or due in advance of LENSAR’s performance. Product revenue . LENSAR recognizes revenue for the sale of the products at a point in time when control is transferred to customers. Equipment . LENSAR Laser System sales are recognized as Product revenue when LENSAR transfers control of the system. This usually occurs after the customer signs a contract, LENSAR installs the system, and LENSAR performs the requisite training for use of the system for direct customers. LENSAR Laser System sales to distributors are recognized as revenue upon shipment. PID and procedure licenses. The LENSAR Laser System requires both a PID and a procedure license to perform each procedure. We recognize Product revenue for PIDs when the company transfers control of the PID. LENSAR recognizes Product revenue for procedure licenses, which represents a one-time right to utilize the LENSAR Laser System surgical software application, at the point in time when control of the procedure is transferred to the customer. Control transfers at the time a customer receives the license key. For the sale of PIDs and procedure licenses, LENSAR may offer volume discounts to certain customers. To determine the amount of revenue that should be recognized at the time control over these products transfers to the customer, LENSAR estimates the average per unit price, net of discounts. Service revenue. LENSAR offers an extended warranty that provides additional maintenance services beyond the standard limited warranty and recognizes Service revenue from the sale of extended warranties over the warranty period on a ratable basis. Customers have the option of renewing the warranty period, which is considered a new and separate contract. Lease Revenue Lease revenue is recognized from our Medical Device segment. For LENSAR Laser System operating leases, LENSAR recognizes Lease revenue over the length of the lease. For additional information regarding accounting for leases, see Note 1, Summary of Significant Accounting Policies—Revenue Recognition and Note 9, Leases to our financial statements included herein. LENSAR leases equipment to customers under operating lease arrangements. At contract inception LENSAR performs an evaluation to determine if a lease arrangement conveys the right to control the use of an identified asset. To the extent such rights of control are conveyed, LENSAR further makes an assessment as to the applicable lease classification. The identification of specified assets and determination of appropriate lease classification may require the use of management judgement. Some of LENSAR’s operating leases include a purchase option for the customer to purchase the leased asset at the end of the lease arrangement, subject to a new contract. LENSAR does not believe the purchase price qualifies as a bargain purchase option. For lease arrangements with lease and non-lease components where LENSAR is the lessor, it allocates the contract’s transaction price (including discounts) to the lease and non-lease components on a relative standalone selling price which requires judgments. For those leases with variable lease payments, the variable lease payment is typically based upon use of the leased equipment or the purchase of procedure licenses and PIDs used with the leased equipment. For operating leases, rental income is recognized on a straight-line basis over the lease term as lease revenue. Depreciation expense associated with the leased equipment under operating lease arrangements is reflected in cost of lease in the statements of operations. Pharmaceutical The Company’s Pharmaceutical segment consisted of revenue derived from the Noden Products. Noden’s revenue is included in Income (loss) from discontinued operations. The Pharmaceutical segment principally generated revenue from products sold to wholesalers and distributors. Customer orders were generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations were usually limited to transfer of the product to the customer. The transfer occurred either upon shipment or upon receipt of the product in certain countries outside the United States after considering when the customer obtained control of the product. In addition, in some countries outside of the United States, the Company sold product on a consignment basis where control was not transferred until the customer resold the product to an end user. At these points, customers were able to direct the use of and obtain substantially all of the remaining benefits of the product. Sales to customers were initially invoiced at contractual list prices. Payment terms were typically 30 to 90 days based on customary practice in each country. Revenue was reduced from the list price at the time of recognition for expected chargebacks, discounts, rebates, sales allowances and product returns, which were collectively referred to as gross-to-net adjustments. These reductions were attributed to various commercial agreements, managed healthcare organizations and government programs such as Medicare, Medicaid, and the 340B Drug Pricing Program containing various pricing implications such as mandatory discounts, pricing protection below wholesaler list price and other discounts when Medicare Part D beneficiaries were in the coverage gap. These various reductions in the transaction price were estimated using either a most likely amount, in the case of prompt pay discounts, or expected value method for all other variable consideration and were reflected as liabilities and was settled through cash payments, typically within time periods ranging from a few months to one year. Significant judgment is required in estimating gross-to-net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel. For licenses that were bundled with other promises, the Company utilized judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation was satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front license fees. The Company evaluated the measure of progress each reporting period and, if necessary, adjusted the measure of performance and related revenue recognition. Disaggregation of Revenue The Company disaggregates its revenue from contracts with customers by segment and geographic location as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following tables, revenue is disaggregated by segment and primary geographical market for the two and eight months ended August 31, 2020 and three and nine months ended September 30, 2019 under the Going Concern Basis: Two Months Ended Three Months Ended August 31, 2020 September 30, 2019 (in thousands) Medical Devices Pharmaceutical (1) Medical Devices Pharmaceutical (1) Primary geographical markets: North America $ 2,172 $ 1,709 $ 2,779 $ 6,119 Europe 522 3,144 699 5,496 Asia 618 1,428 3,178 654 Other 63 — 68 — Total revenue from contracts with customers (2) $ 3,375 $ 6,281 $ 6,724 $ 12,269 Eight Months Ended Nine Months Ended August 31, 2020 September 30, 2019 (in thousands) Medical Devices Pharmaceutical (1) Medical Devices Pharmaceutical (1) Primary geographical markets: North America $ 6,656 $ 10,093 $ 7,066 $ 21,295 Europe 2,078 13,008 2,421 16,532 Asia 4,137 6,378 8,540 4,817 Other 200 — 253 — Total revenue from contracts with customers (2) $ 13,071 $ 29,479 $ 18,280 $ 42,644 ________________ (1) The revenue from the Company’s Pharmaceutical segment for the two and eight months ended August 31, 2020 and the three and nine months ended September 30, 2019 is included in Income (loss) from discontinued operations. For additional information, see Note 3, Discontinued Operations Classified as Assets held for sale under Going Concern Basis. (2) The tables above do not include lease revenue from the Company’s Medical Devices segment for the two months ended August 31, 2020 and three months ended September 30, 2019, of $0.7 million and $1.4 million, respectively, , for the eight month period ended August 31, 2020 and nine month period ended September 30, 2019, of $2.1 million and $3.9 million, respectively. For additional information, see Note 9, Leases. Contract Balances The following table provides information about receivables, contract assets and contract liabilities from contracts with customers: (in thousands) December 31, 2019 Receivables, net $ 10,377 Contract assets $ 3,512 Contract liabilities $ 4,024 ________________ The table above includes LENSAR which was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information. Receivables, Net —Receivables, net include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value based on the timing of when the Company expects to receive payment. The Company maintains an allowance for credit losses to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables, collateral to the extent applicable and reflects the possible impact of current conditions and reasonable forecasts not already reflected in historical loss information. The Company classifies Receivables, net as current or noncurrent on the Company’s Condensed Consolidated Balance Sheet as of December 31, 2019. Receivables, net for the Company’s Pharmaceutical segment are classified as a current asset and included in Assets held for sale as of December 31, 2019. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. Contract Assets —The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company’s contract assets are only attributable to the Pharmaceutical segment, and, as such, are classified as current in Assets held for sale in the Company’s Condensed Consolidated Balance Sheet as of December 31, 2019. (in thousands) Medical Devices Pharmaceutical Total Contract assets at December 31, 2019 $ — $ 3,512 $ 3,512 Contract assets recognized — (6,730) (6,730) Payments received — 8,562 8,562 Contract assets sold with the Noden subsidiaries — (5,344) (5,344) Contract assets at September 30, 2020 $ — $ — $ — Contract Liabilities —The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies Medical Devices deferred revenue as a liability and is included in Other liabilities on the Company’s Condensed Consolidated Statement of Net Assets as of September 30, 2020. The Company classified Medical Devices deferred revenue as current or noncurrent based on the timing of when it expected to recognize revenue. The current portion of deferred revenue is included in Accrued liabilities and the noncurrent portion of deferred revenue is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheet as of December 31, 2019. The Pharmaceutical deferred revenue is classified as a current liability and included in Liabilities held for sale on the Company’s Condensed Consolidated Balance Sheet as of December 31, 2019. (in thousands) Medical Devices Pharmaceutical Total Contract liabilities at December 31, 2019 $ 1,075 $ 2,949 $ 4,024 Contract liabilities recognized 658 1,659 2,317 Amounts recognized into revenue (851) (888) (1,739) Contract liabilities sold with the Noden subsidiaries — (3,720) (3,720) Contract liabilities at September 30, 2020 $ 882 $ — $ 882

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Information	Segment Information Information regarding the Company’s segments for the two and eight months ended August 31, 2020 and three and nine months ended September 30, 2019 is as follows: Revenues by segment Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Medical Devices $ 4,078 $ 8,076 $ 15,211 $ 22,224 Strategic Positions — — — — Pharmaceutical — — — — Income Generating Assets 37 (45) 110 (39) Total revenues $ 4,115 $ 8,031 $ 15,321 $ 22,185 ________________ The table above excludes revenues related to discontinued operations. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. Income (loss) by segment Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Medical Devices $ 216 $ (3,323) $ (4,454) $ (6,216) Strategic Positions (1) — (4,738) (15,723) 14,306 Pharmaceutical (1) 687 (2,123) (15,855) 3,177 Income Generating Assets (1) 2,201 (7,600) (37,217) (26,790) Total 3,104 (17,784) (73,249) (15,523) Change in fair value of warrants not allocated to segments (2) 1,294 — (4,047) — Net income (loss) attributable to PDL’s shareholders $ 4,398 $ (17,784) $ (77,296) $ (15,523) ________________ (1) The Income (loss) by segment presented above includes amounts related to both continuing and discontinued operations. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. (2) The change in fair value of warrants not allocated to segments presented above includes the amounts related to the change in fair value of the Evofem warrants after the distribution of the Evofem common stock to PDL stockholders on May 21, 2020. The Strategic Positions segment ceased to be a reporting segment as of this date. Information regarding the Company’s segments as of December 31, 2019 is as follows: Long-lived assets by segment (in thousands) December 31, Medical Devices $ 2,435 Strategic Positions — Pharmaceutical (1) 2,960 Income Generating Assets 125 Total long-lived assets (1) $ 5,520 ________________ (1) The amounts above include Property and Equipment in the Pharmaceutical segment classified as Assets held for sale. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. The operations for the Medical Devices segment are primarily located in the United States and the operations for the Pharmaceutical segment were primarily located in Italy, Ireland and the United States.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes On March 27, 2020 the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other provisions, permits Net Operating Loss (“NOL”) carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company was a significant taxpayer in the earlier eligible carryback years and expects that the NOL carryback provision of the CARES Act will result in a material cash benefit as a result of the 2020 ordinary tax losses being generated and, to a lesser degree, for the 2019 tax year. Historically, we calculated our provision for income taxes during interim reporting periods by applying the estimated annual effective tax rate for the full fiscal year to pre-tax income or loss. Upon the Company’s adoption of the liquidation basis of accounting, we employ the discrete method of determining our tax provision based on the pre-tax results for the eight month period ending August 31, 2020 and the one month period ending September 30, 2020. Income tax benefit from continuing operations for the two months ended August 31, 2020 and three months ended September 30, 2019, was $3.6 million and $3.1 million, respectively, and for the eight months ended August 31, 2020 and nine months ended September 30, 2019, was $17.8 million and $6.6 million, respectively, which in the current period resulted primarily from anticipated use of NOL carrybacks as allowed by the CARES Act. The Company’s effective tax rate for the current year periods differs from the U.S. federal statutory rate of 21% due primarily to the effect of state income taxes, non-deductible executive compensation and the tax provisions of the CARES Act. The CARES Act receivable included in Income tax receivable on the Condensed, Consolidated Statement of Net Assets as of September 30, 2020 is $80.5 million and includes, in addition to the losses from operations, the ordinary losses incurred on the Noden transaction and the sale of the royalty assets. See Note 21, Subsequent Events , for additional information on the LENSAR spin-off. The Income tax receivable as of September 30, 2020 also includes a refund of $7.9 million for a prior year overpayment that was requested after the 2016 Internal Revenue Service (the “IRS”) audit was settled. The uncertain tax positions decreased by $4.4 million in September 2020 upon settlement of the IRS audit for the tax year 2016. The Company recorded $1.0 million and $1.1 million of interest related to uncertain tax positions during the eight months ended August 31, 2020 and the nine months ended September 30, 2019, respectively. The Company’s income tax returns are subject to examination by U.S. federal, foreign, state and local tax authorities for tax years 2000 forward. In September 2020, the Company settled the IRS audit for the tax year 2016. The Company is currently under audit by the California Franchise Tax Board (the “CFTB”) for the tax years 2009 through 2015. The timing of the resolutions to the CFTB audit and the amount to be ultimately paid, if any, is uncertain. Final resolution of this complex matter could have a material impact on our Condensed Consolidated Financial Statements. The Company believes its accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law and judgments; however, the outcome of these audits could result in the payment of tax amounts that substantially differ from the amounts the Company has reserved resulting in incremental expense or a reversal of the Company’s reserves in a future period. At this time, the Company does not anticipate a material change in the unrecognized tax benefits related to the CFTB audit that would affect the effective tax rate or deferred tax assets over the next 12 months. See Note 21, Subsequent Events , for additional information on the CFTB.

Net (Loss) Income per Share

Net (Loss) Income per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net (Loss) Income per Share	20. Net Income (loss) per Share Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, Net Income (loss) per Basic and Diluted Share 2020 2019 2020 2019 (in thousands, except per share amounts) Numerator Net loss from continuing operations $ (10,852) $ (11,811) $ (43,040) $ (28,277) Income (loss) from discontinued operations $ 15,236 $ (6,155) $ (34,915) $ 12,414 Less: Net loss attributable to noncontrolling interests $ (14) $ (182) $ (659) $ (340) Net income (loss) attributable to PDL’s stockholders used to compute net income (loss) per basic and diluted share $ 4,398 $ (17,784) $ (77,296) $ (15,523) Denominator Total weighted-average shares used to compute net income (loss) attributable to PDL’s stockholders, per basic share 113,889 112,986 118,001 119,966 Shares used to compute net income (loss) attributable to PDL’s stockholders, per diluted share 113,889 112,986 118,001 119,966 Net income (loss) per share - basic: Continuing operations $ (0.10) $ (0.10) $ (0.36) $ (0.23) Discontinued operations 0.14 (0.06) (0.30) 0.10 Net income (loss) attributable to PDL’s stockholders per basic share $ 0.04 $ (0.16) $ (0.66) $ (0.13) Net income (loss) per share - diluted: Continuing operations $ (0.10) $ (0.10) $ (0.36) $ (0.23) Discontinued operations 0.14 (0.06) (0.30) 0.10 Net income (loss) attributable to PDL’s stockholders per diluted share $ 0.04 $ (0.16) $ (0.66) $ (0.13) The Company computes net income (loss) per diluted share using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of net income (loss) per diluted share include shares that may be issued pursuant to outstanding stock options and restricted stock awards in each case, on a weighted-average basis for the period they were outstanding, including, if applicable, the underlying shares using the treasury stock method. The December 2021 Notes and the December 2024 Notes allow for the settlement entirely or partially in cash, and are accounted for under the treasury stock method. Under the treasury stock method, the shares issuable upon conversion of the notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of the notes exceeds their principal amount. The effect of which, for diluted earnings per share purposes, is that only the number of shares of common stock that would be necessary to settle such excess, if the Company elected to settle such excess in shares, are included in the computation. December 2021 Notes and December 2024 Notes Capped Call Potential Dilution In November 2016, the Company issued $150.0 million in aggregate principal of the December 2021 Notes. The Company entered into an Exchange Transaction in September 2019 through which it exchanged a portion of the December 2021 Notes for the December 2024 Notes with a later maturity of December 2024. Both the notes that mature in December 2021 and those that mature in December 2024 provide in certain situations for the conversion of the outstanding principal amount into shares of the Company’s common stock at a predefined conversion rate. In conjunction with the issuance of the December 2021 Notes and the issuance of the December 2024 Notes pursuant to the Exchange Transaction, the Company entered into capped call transactions with a hedge counterparty. The capped call transactions are expected generally to reduce the potential dilution, and/or offset, to an extent, the cash payments the Company may choose to make in excess of the principal amount, upon conversion of the December 2021 Notes or the December 2024 Notes. The Company has excluded the capped call transaction from the net income (loss) per diluted share computation as such securities would have an anti-dilutive effect and those securities should be considered separately rather than in the aggregate in determining whether their effect on net income (loss) per diluted share would be dilutive or anti-dilutive. For additional information regarding the conversion rates and the capped call transaction related to the Company’s December 2021 Notes and December 2024 Notes, see Note 12, Convertible Senior Notes . Anti-Dilutive Effect of Restricted Stock Awards and Stock Options For the two months ended August 31, 2020 and three months ended September 30, 2019, the Company excluded approximately 0.2 million and 1.0 million shares underlying restricted stock awards, respectively, and for the eight and nine months ended August 31, 2020 and 2019, the Company excluded approximately 0.2 million and 0.8 million shares underlying restricted stock awards, respectively, in each case calculated on a weighted-average basis, from its net income (loss) per diluted share calculations because their effect was anti-dilutive. For the two months ended August 31, 2020 and three months ended September 30, 2019, the Company excluded approximately 11.9 million and 12.6 million shares underlying outstanding stock options, respectively, and for the eight and nine months ended August 31, 2020 and 2019, the Company excluded approximately 11.9 million and 10.7 million shares underlying outstanding stock options, respectively, in each case calculated on a weighted-average basis, from its net income (loss) per diluted share calculations because their effect was anti-dilutive.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Spin-off of LENSAR and unaudited proforma information On October 1, 2020, the Company completed the previously announced spin-off of LENSAR into a new, independent publicly traded company, through a distribution in the form of a dividend of all outstanding shares of LENSAR common stock owned by the Company to holders of the Company’s common stock on a pro rata basis (the “Distribution”). The Distribution was made to the Company’s stockholders of record as of the close of business on September 22, 2020 (the “Record Date”) and such stockholders received 0.075879 shares of LENSAR common stock for every one share of the Company’s common stock held as of close of business on the Record Date. Prior to the Distribution, the Company owned approximately 81.5% of LENSAR common stock. The Liquidation Basis net assets of LENSAR presented below have been adjusted to reflect the Company’s ownership percentage. Following the completion of the distribution, PDL does not own any equity interest in LENSAR. LENSAR became an independent public company whose stock is listed and trading under the symbol “LNSR” on the Nasdaq Stock Market. The September 30, 2020 Condensed Consolidated Statement of Net Assets includes the following assets and liabilities related to LENSAR: September 30, (in thousands) 2020 Assets Cash and cash equivalents $ 42,701 Accounts receivable 2,429 Notes receivable 989 Inventory 13,685 Property and equipment 783 Equipment under lease 3,033 Intangible assets 42,113 Other assets 4,863 Total assets $ 110,596 Liabilities Accounts payable $ 2,349 Other liabilities 7,678 Total liabilities $ 10,027 Net assets attributable to LENSAR $ 100,569 As a result of the spin-off of LENSAR, the Company expects to realize an estimated tax gain on disposal of $11.8 million . This is expected to result in a decrease to the Company’s Income tax receivable and is not an asset transferred in the spin-off of LENSAR. The accompanying pro forma Condensed Consolidated Statement of Net Assets as of September 30, 2020 has been prepared to give effect to spin-off of LENSAR and the related tax impact to PDL as if the spin-off was completed as of September 30, 2020. The pro forma financial information is presented for informational purposes only and is not intended to present actual results that would have been attained had the transaction been completed as of September 30, 2020 or to project potential results as of any future date or for any future periods. Board approval for filing for dissolution At its November 5, 2020 meeting, the Board approved the filing of a certificate of dissolution with the state of Delaware on January 4, 2021. In connection with the Board approving the filing of a certificate of dissolution with the Secretary of State of Delaware on January 4, 2021, all of the outstanding and unvested stock options and restricted stock granted to the Board accelerated and vested. Notice of California Franchise Tax Board planned audit The Company recently received notice, dated November 3, 2020, that the CFTB plans to examine the Company’s tax returns for 2016 through 2018.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation, Policy	Basis of Presentation Throughout its history, the mission of PDL BioPharma, Inc. and its subsidiaries (collectively, the “Company” or “PDL”) has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies. PDL was founded in 1986 as Protein Design Labs, Inc. when it pioneered the humanization of monoclonal antibodies, enabling the discovery of a new generation of targeted treatments that have had a profound impact on patients living with different cancers as well as a variety of other debilitating diseases. In 2006, the Company changed its name to PDL BioPharma, Inc. Historically, the Company generated a substantial portion of its revenues through license agreements related to patents covering the humanization of antibodies, which it refers to as the Queen et al. patents. In 2012, the Company began providing alternative sources of capital through royalty monetizations and debt facilities, and, in 2016, the Company began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products first with its acquisition of branded prescription pharmaceutical drugs from Novartis AG, Novartis Pharma AG and Speedel Holding AG (collectively, “Novartis”) in 2016 and, in 2017, with the acquisition of LENSAR, Inc. (“LENSAR”), a medical device ophthalmology equipment manufacturing company. In 2019, it entered into a securities purchase agreement with Evofem Biosciences, Inc. (“Evofem”), pursuant to which it invested $60.0 million in a private placement of securities structured in two tranches. Evofem is a publicly-traded commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. Evofem is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-R™) platform for PhexxiTM (L-lactic acid, citric acid and potassium bitartrate) for hormone-free birth control. Based on the composition of its investment portfolio, the Company historically structured its operations in four segments designated as Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets. Following is a summary of the Company’s segments including those that have been classified as discontinued operations: • The Company’s Medical Devices segment consists of revenue derived from the LENSAR ® Laser System sales made by the Company’s subsidiary, LENSAR which may include equipment, Patient Interface Devices (“PIDs” or “consumables”), procedure licenses, training, installation, warranty and maintenance agreements. • The Company’s Strategic Positions segment consisted of an investment in Evofem, which included shares of common stock and warrants to purchase shares of common stock. • The Company’s Pharmaceutical segment consisted of revenue derived from branded prescription medicine products sold under the name Tekturna ® and Tekturna HCT ® in the United States and Rasilez ® and Rasilez HCT ® in the rest of the world and an authorized generic form of Tekturna sold in the United States (collectively, the “Noden Products”). The branded prescription Noden Products were acquired from Novartis in July 2016 (the “Noden Transaction”) by the Company’s wholly-owned subsidiary, Noden Pharma DAC (“Noden DAC”). • The Company’s Income Generating Assets segment consists of revenue derived from (i) notes and other long-term receivables, (ii) equity investments and (iii) royalties from issued patents in the United States and elsewhere covering the humanization of antibodies (“Queen et al. patents”). In September 2019, the Company engaged financial and legal advisors and initiated a review of its strategy. This review was completed in December 2019 at which time the Company announced that it decided to halt the execution of its growth strategy, cease additional strategic transactions and investments and instead pursue a formal process to unlock value by monetizing its assets and returning net proceeds to stockholders (the “monetization strategy”). Pursuant to the Company’s monetization strategy, the Company does not expect to enter into any additional strategic investments. The Company further announced in December 2019 that it would explore a variety of potential transactions in connection with the monetization strategy, including a whole Company sale, divestiture of assets, spin-offs of operating entities, merger opportunities or a combination thereof. Over the subsequent months, the Company’s Board of Directors (the “Board”) and management analyzed, together with outside financial and legal advisors, how to best capture value pursuant to the monetization strategy and best return the value of the assets in its portfolio to its stockholders. During the first quarter of 2020, the Board approved a plan of complete liquidation (the “Plan of Liquidation”) and passed a resolution to seek stockholder approval to dissolve the Company as permitted by the General Corporation Law of the State of Delaware (the “DGCL”). The proposal was approved by stockholders on August 19, 2020 at the Company’s 2020 Annual Meeting of Stockholders. On November 5, 2020, our Board approved filing a Certificate of Dissolution with the Secretary of State of Delaware on January 4, 2021 (the “Final Record Date”) and proceeding to complete the dissolution process for the Company in accordance with the Delaware General Corporate Law. The liquidation and dissolution process will take a minimum of three years. However, the timing may be extended due to circumstances such as pending litigation or other factors that may affect the ability of the Company to wind down its business. Upon filing the Certificate of Dissolution on January 4, 2021 (the Final Record Date), we will close our stock transfer books. After such time, we will not record any further transfers of our common stock, except pursuant to the provisions of a deceased stockholder’s will, intestate succession, or by operation of law and we will not issue any new stock certificates, other than replacement certificates. In addition, after the Final Record Date, we will not issue any shares of our common stock upon exercise of outstanding stock options. As a result of the closing of our transfer books, it is anticipated that distributions, if any, made in connection with the dissolution will be made pro rata to the same stockholders of record as the stockholders of record as of the Final Record Date, and it is anticipated that no further trading of our common stock will occur after the Final Record Date. In accordance with our dissolution plan, we intend to begin the voluntary delisting process from the Nasdaq Stock Market exchange so that such delisting will occur at market close on December 31, 2020 and we do not anticipate transferring into OTC trading. Pursuant to the Company’s monetization strategy, the Company explored a variety of potential transactions, including a whole Company sale, divestiture of assets, spin-offs of operating entities, merger opportunities or a combination. During the quarter ended March 31, 2020, the Company’s Pharmaceutical segment and the royalty right assets within the Income Generating Assets segment met the criteria to be classified as held for sale. Those investments are reported as discontinued operations on the Condensed Consolidated Statements of Operations for the two and eight months ended August 31, 2020 and for the three and nine months ended September 30, 2019, and as Assets and Liabilities held for sale on the Condensed Consolidated Balance Sheet as of December 31, 2019. During the quarter ended June 30, 2020, the Evofem common stock held within the Strategic Positions segment was distributed to the Company’s stockholders and, as a result, the Strategic Positions segment and all investments included in the segment met the criteria to be classified as discontinued operations. Therefore, the Strategic Positions segment is also presented as discontinued operations on the Condensed Consolidated Statements of Operations. The Company continues to hold warrants to purchase shares of Evofem’s common stock. In September 2020, the Company sold the Noden business, including its Noden Pharma USA, Inc. subsidiary (“Noden USA” and, together with Noden DAC, “Noden”) to a third party. Separately, the Company also sold three royalty right assets in August 2020 to a third party. As a result of the approval of the Company’s stockholders to pursue dissolution of the Company pursuant to a plan of dissolution, the Company’s basis of accounting transitioned, effective September 1, 2020, from the going concern basis of accounting (“Going Concern Basis”) to the liquidation basis of accounting (“Liquidation Basis”) in accordance with Generally Accepted Accounting Principles (“GAAP”) of the United States. Under the Liquidation Basis, all assets are valued at the estimated amount of cash or other consideration that the Company expects to collect. Liabilities with specified, contractual amounts are measured in accordance with applicable GAAP and all other liabilities are stated at their estimated settlement amounts over the remaining estimated liquidation period. The assets and liabilities of LENSAR included in the Statement of Net Assets reflect the expected distribution value. LENSAR was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information. The accompanying unaudited Condensed Consolidated Financial Statements of PDL have been prepared in accordance with GAAP for interim financial information. The financial statements include all adjustments that management of the Company believes are necessary for a fair statement of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year. The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited Consolidated Financial Statements and the related notes thereto for the fiscal year ended December 31, 2019, included in its Current Report on Form 8-K, filed with the Securities and Exchange Commission (“SEC”) on June 29, 2020, which re-casts certain historical financial information from our 2019 Annual Report on Form 10-K to present the Pharmaceutical segment and the royalty right assets within the Income Generating Assets segment as discontinued operations for all periods presented. The Condensed Consolidated Balance Sheet at December 31, 2019, included herein, has been derived from the audited Consolidated Financial Statements at that date, as adjusted to conform with the financial statement presentation as of and for the two and eight months ended August 31, 2020 as discussed in Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , but does not include all disclosures required by GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying Notes to the Condensed Consolidated Financial Statements. The accounting estimates that require management’s most significant, difficult and subjective judgments include the estimated sales proceeds of our assets in liquidation and estimated settlement amounts of our liabilities as well as the estimated revenue and operating expenses during dissolution that are projected under the Liquidation Basis. Significant estimates include, the valuation of royalty rights, product revenue recognition and allowances for customer rebates, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, the recognition and measurement of current and deferred income tax assets and liabilities, including amounts recoverable under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, and the valuation of warrants to acquire shares of common stock. Furthermore, the impact on accounting estimates and judgments on the Company’s financial condition and results of operations due to COVID-19 has introduced additional uncertainties. Actual results may differ materially from those estimates. The Condensed Consolidated Financial Statements included herein include the accounts of the Company and its wholly-owned subsidiaries (up to the date of sale) and majority-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have, and, as a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict. If the financial markets or the overall economy are impacted for an extended period, the Company’s liquidity, revenues and assets may be adversely affected. Significant Accounting Policies Liquidation Basis of Accounting Under the Liquidation Basis, the values of the Company's assets and liabilities include management's estimate of income to be generated from the remaining assets until the anticipated date of sale, estimated sales proceeds, estimates for operating expenses and expected amounts required to settle liabilities. The estimated liquidation values for assets derived from future revenue streams and asset sales and the settlement of estimated liabilities are reflected on the Condensed Consolidated Statement of Net Assets in Liquidation. The actual amounts realized could differ materially from the estimated amounts. Assets Held for Sale Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale. The assets and liabilities held for sale as of December 31, 2019 are recorded on the Company’s Condensed Consolidated Balance Sheet as Assets held for sale and Liabilities held for sale, respectively. Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period, represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes and represent a strategic shift that has or will have a major effect on the Company’s operations and financial results. The profits and losses are presented on the Condensed Consolidated Statements of Operations as discontinued operations. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. Severance and retention After the Company announced its monetization strategy, it recognized that its ability to execute on its plan and optimize returns to its stockholders depended to a large extent on its ability to retain the necessary expertise to effectively transact with respect to its assets. On December 21, 2019, the Compensation Committee of the Board adopted a Wind Down Retention Plan in which the Company’s executive officers and other employees who are participants in the Company’s Severance Plan are eligible to participate. Under the Wind Down Retention Plan, participants are eligible to earn a retention benefit in consideration for their continued employment with the Company. The Wind Down Retention benefits are equivalent to previously disclosed compensation payments contemplated in connection with a change in control under the Company’s existing Severance Plan. Under the Wind Down Retention Plan, the Company is currently obligated to pay a retention benefit to each participant upon termination of the participant’s employment with the Company either by the Company without cause or by the participant for good reason. The retention benefit, if paid, would be in lieu of (and not in addition to) any other severance compensation that could become payable to the participant under the Company’s Severance Plan. In connection with the adoption of the Wind Down Retention Plan, a severance liability was being recorded over the remaining service period for the participating employees under the Going Concern Basis. Upon the adoption of the Liquidation Basis on September 1, 2020, all remaining estimated severance and retention costs were accrued. As of September 30, 2020, the Company has recorded a severance liability of $10.9 million, which is reported as Compensation and benefit costs on the Company’s Condensed Consolidated Statement of Net Assets. Expenses associated with severance payments and accruals are reflected in Severance and retention on the Company’s Condensed Consolidated Statements of Operations for the two and eight months ended August 31, 2020. The Wind Down Retention Plan also provides that, consistent with the existing terms of the Company’s Amended and Restated 2005 Equity Incentive Plan (the “Equity Plan”), the vesting of all outstanding equity awards held by participants as of the date the Wind Down Retention Plan was adopted will be accelerated upon the earlier of: (i) a termination of the participant’s employment with the Company either by the Company without cause or by the participant for good reason or (ii) the consummation of a change in control (as defined in the Equity Plan) of the Company. In addition, the post-termination exercise period for all outstanding stock options will be extended until their expiration date. In connection with the Board adopting the Plan of Liquidation in the first quarter of 2020, all of the outstanding and unvested stock options and restricted stock granted to the Company’s employees and executive officers, with the exception of certain outstanding awards under the 2016/20 Long-Term Incentive Plan, accelerated and vested under the change in control definition in the Equity Plan. The expense associated with the accelerated vesting, totaling $15.7 million is reported as Severance and retention on the Company’s Condensed Consolidated Statements of Operations for the two and eight months ended August 31, 2020. For a discussion of other accounting policies, refer to the Company’s Current Report on Form 8-K for the fiscal year ended December 31, 2019. Summarized below are the accounting pronouncements and policies adopted subsequent to December 31, 2019 in addition to those described above.
Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements	Adopted Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments . The guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. The Company adopted ASU No. 2016-13 on January 1, 2020 using a modified retrospective approach. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. As a consequence of adopting ASU 2016-13, the Company’s accounts receivable accounting policy has been updated, as follows: Accounts and Notes Receivable The Company makes estimates of the collectability of accounts receivable. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for credit losses. Amounts are charged off against the allowance for credit losses when the Company determines that recovery is unlikely and the Company ceases collection efforts. The Company applies the practical expedient for its collateral-dependent notes receivable. Estimated credit losses are based on the fair value of the collateral (less costs to sell, as applicable). In April 2020, the FASB issued a staff question-and-answer document, “Topic 842 and Topic 840: Accounting for Lease Concessions Related to the Effects of the COVID-19 Pandemic” (the “COVID-19 Q&A”), to address certain frequently-asked questions pertaining to lease concessions arising from the effects of the COVID-19 pandemic. Existing lease guidance requires entities to determine if a lease concession was a result of a new arrangement reached with the lessee (which would be addressed under the lease modification accounting framework) or if a lease concession was under the enforceable rights and obligations within the existing lease agreement (which would not fall under the lease modification framework). The COVID-19 Q&A clarifies that entities may elect to not evaluate whether lease-related relief granted in light of the effects of COVID-19 is a lease or obligations of the lease. This election is available for concessions that result in the total payments required by the modified contract being substantially the same or less than the total payments required by the original contract. As a result of the COVID-19 pandemic, LENSAR entered into agreements with 23 customers through which LENSAR agreed to waive monthly rental and minimum monthly license fees ranging from one In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement . The new guidance modifies disclosure requirements related to fair value measurement. The Company adopted ASU No. 2018-13 on January 1, 2020. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required. In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software . The new guidance reduces complexity for the accounting for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The Company adopted ASU No. 2018-15 on January 1, 2020 using the prospective transition option. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. For public companies, the amendments in ASU No. 2019-12 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its Consolidated Financial Statements.

Net Assets in Liquidation (Tabl

Net Assets in Liquidation (Tables)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Assets in Liquidation	Upon adoption of the Liquidation Basis on September 1, 2020, the Company has estimated the net assets in liquidation, which represents the expected future cash flows related to the remaining assets and estimated liabilities and operating costs through dissolution. The actual cash inflows and outflows may differ from the estimated amounts. (in thousands) Consolidated Net Equity, as of August 31, 2020 $ 425,214 Effect of adopting the liquidation basis of accounting: Change in the estimated value of royalty rights (1) 13,770 Change in the receivable from the sale of Noden (2) 9,056 Increase in intangible assets (3) 28,702 Change in the estimated value of other assets (4) (4,813) Estimated liquidation and future operating costs (5) (25,376) Total effect of adopting the liquidation basis of accounting 21,339 Net assets in liquidation, as of September 1, 2020 $ 446,553 (1) The royalty assets, consisting of Assertio and University of Michigan (“U-M”), are valued using undiscounted estimated cash receipts until the estimated date of sale plus a discounted value of the remaining estimated cash flows to determine the expected cash consideration from such sale. Previously, under the going concern basis of accounting, royalty assets were valued using discounted cash flow models, see Note 7, Fair Value Measurements . (in thousands) August 31, 2020 September 1, 2020 Change (Going Concern Basis) (Liquidation Basis) Assertio $ 200,463 $ 211,626 $ 11,163 U-M 17,450 20,057 2,607 Total $ 217,913 $ 231,683 $ 13,770 (2) Adjustments reflect Liquidation Basis which does not discount future estimated cash receipts. Previously, under the going concern basis of accounting we had estimated the fair value of Noden, as an asset held for sale, using a discounted cash flow model, see Note 7, Fair Value Measurements . (3) The increase in intangible assets represents the difference between the existing assets and liabilities of LENSAR upon adoption of liquidation basis of accounting and its enterprise value that will be distributed to PDL shareholders in the spin-off. The enterprise value was determined through an analysis of comparable public companies combined with cash flow forecasts. Also see Note 10, Intangible Assets and Note 21, Subsequent Events. (4) Adjustments to other assets include a liquidity discount for the Evofem warrants and the write-off of certain assets that will not be converted to cash such as prepaid expenses, fixed assets and right of use assets. (5) Represents estimated future expenses related to operating the business through dissolution and settlement of future liabilities including estimated costs to dispose of our assets. Some of the estimated costs to dispose of our assets had already been accrued under the Going Concern Basis and were presented net with our assets held for sale.

Discontinued Operations Class_2

Discontinued Operations Classified as Assets Held for Sale (Tables)	9 Months Ended
	Sep. 30, 2020
Discontinued Operations and Disposal Groups [Abstract]
Schedule of discontinued operations	Components of amounts reflected in Income (loss) from discontinued operations on the Company’s Condensed Consolidated Statement of Operations are as follows: Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Revenues Product revenue, net $ 6,281 $ 12,269 $ 29,479 $ 42,644 Royalty rights - change in fair value (1,893) 23,865 (8,804) (4,277) Total revenues 4,388 36,134 20,675 38,367 Operating expenses Cost of product revenue (excluding intangible asset amortization) 3,894 10,268 17,576 26,697 Amortization of intangible assets — 1,253 389 3,760 General and administrative 1,540 2,029 6,105 5,969 Sales and marketing 59 168 257 1,536 Research and development — — — (41) Total operating expenses 5,493 13,718 24,327 37,921 Operating (loss) income from discontinued operations (1,105) 22,416 (3,652) 446 Non-operating income (expense), net Equity affiliate - change in fair value 1,296 (27,378) (25,365) 18,109 Loss on classification as held for sale — — (28,904) — Total non-operating income (expense), net 1,296 (27,378) (54,269) 18,109 Income (loss) from discontinued operations before income taxes 191 (4,962) (57,921) 18,555 Income tax (benefit) expense from discontinued operations (15,045) 1,193 (23,006) 6,141 Income (loss) from discontinued operations $ 15,236 $ (6,155) $ (34,915) $ 12,414 The carrying amounts of the major classes of assets reported as “Assets held for sale” on the Company’s Condensed Consolidated Balance Sheet consisted of the following: (in thousands) December 31, 2019 Cash and cash equivalents (1) $ 24,469 Accounts receivable, net 6,993 Inventory 31,712 Prepaid and other current assets 7,192 Property and equipment, net 2,960 Royalty rights - at fair value 266,196 Investment in equity affiliate 82,267 Intangible assets, net 10,112 Other assets 15,956 Total assets held for sale $ 447,857 ________________ (1) Cash and cash equivalents represent balances maintained by Noden as of December 31, 2019, which were retained by the buyer upon the sale of the Noden business and used to settle the commitment with Novartis as further described in Note 14, Commitments and Contingencies . The carrying amounts of the major classes of liabilities reported as “Liabilities held for sale” on the Company’s Condensed Consolidated Balance Sheet consisted of the following: (in thousands) December 31, 2019 Accounts payable $ 14,695 Accrued liabilities 16,400 Other long-term liabilities 120 Total liabilities held for sale $ 31,215 The September 30, 2020 Condensed Consolidated Statement of Net Assets includes the following assets and liabilities related to LENSAR: September 30, (in thousands) 2020 Assets Cash and cash equivalents $ 42,701 Accounts receivable 2,429 Notes receivable 989 Inventory 13,685 Property and equipment 783 Equipment under lease 3,033 Intangible assets 42,113 Other assets 4,863 Total assets $ 110,596 Liabilities Accounts payable $ 2,349 Other liabilities 7,678 Total liabilities $ 10,027 Net assets attributable to LENSAR $ 100,569

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	9 Months Ended
	Sep. 30, 2020
Cash and Cash Equivalents [Abstract]
Summary of cash and available-for-sale securities	The following table summarizes the Company’s cash and cash equivalents by significant investment category reported as cash and cash equivalents on the Condensed Consolidated Statement of Net Assets and the Condensed Consolidated Balance Sheet as of September 30, 2020 and December 31, 2019, respectively: (in thousands) September 30, 2020 December 31, 2019 (Liquidation Basis) (Going Concern Basis) Cash (1) (2) $ 74,580 $ 37,718 Money market funds 51,156 131,264 Total $ 125,736 $ 168,982 ________________ (1) The December 31, 2019 cash amount excludes $24.5 million of cash at Noden classified as held for sale. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. (2) The table above includes amounts held by LENSAR which was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory [Abstract]
Schedule of Inventory	Inventories consisted of the following: (in thousands) September 30, 2020 December 31, 2019 (Liquidation Basis) (Going Concern Basis) Raw materials $ 3,840 $ 3,739 Work in process 2,039 1,170 Finished goods 7,806 3,152 Total inventory (1) (2) $ 13,685 $ 8,061 ____________ (1) The December 31, 2019 amounts presented above exclude $31.7 million of inventory in aggregate at Noden classified as held for sale. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of fair value of financial instruments measured on recurring basis	The following table presents the fair value of the Company’s financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy under the Going Concern Basis: December 31, 2019 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Money market funds $ 131,264 $ — $ — $ 131,264 Corporate securities (1) 82,267 — — 82,267 Warrants (2) — 14,152 — 14,152 Royalty rights - at fair value (3) — — 266,196 266,196 Total $ 213,531 $ 14,152 $ 266,196 $ 493,879 ___________________ (1) Corporate securities are classified as “Long-term assets held for sale” on the December 31, 2019 Condensed Consolidated Balance Sheet. (2) Warrants consist of Evofem warrants, which are classified as “Long-term assets held for sale” and CareView Communications, Inc. (“CareView”) warrants, classified as “Other assets” on the Condensed Consolidated Balance Sheet as of December 31, 2019. (3) Royalty rights are classified as “Long-term assets held for sale” on the Condensed Consolidated Balance Sheet as of December 31, 2019.
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tables summarize the changes in Level 3 Royalty Right Assets and the gains and losses included in earnings for the eight months ended August 31, 2020 under the Going Concern Basis: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Right Assets (in thousands) Royalty Rights - Fair value as of December 31, 2019 $ 266,196 Total net change in fair value for the period Change in fair value of royalty rights - at fair value (8,804) Cash received from royalty rights (35,129) Total net change in fair value for the period (43,933) Sale of royalty rights (4,350) Fair value as of August 31, 2020 $ 217,913 The table above does not include the aggregate remaining estimated cost to sell the royalty right assets of $4.6 million. Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Right Assets Fair Value as of Sale of Royalty Rights - Fair Value as of (in thousands) December 31, 2019 Royalty Rights (1) Change in Fair Value August 31, 2020 (2) Assertio $ 218,672 $ — $ (18,209) $ 200,463 VB 13,590 (4,182) (9,408) — U-M 20,398 — (2,948) 17,450 AcelRx 12,952 — (12,952) — KYBELLA 584 (168) (416) — $ 266,196 $ (4,350) $ (43,933) $ 217,913 ________________ (1) In August 2020 the Company sold the royalty rights to VB, AcelRx, and KYBELLA to a third party. (2) Excludes the aggregate remaining estimated costs to sell of $4.6 million.
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	The following table represents significant unobservable inputs used in determining the estimated fair value of the Wellstat Diagnostics note receivable investment under the Going Concern Basis: Asset Valuation Unobservable December 31, 2019 Wellstat Diagnostics Wellstat Guarantors intellectual property Income Approach Discount rate 12% Undiscounted royalty amount $21 million Settlement Amount Income Approach Discount rate 15% Undiscounted settlement amount $28 million Real Estate Property Market Approach Annual appreciation rate —% Estimated realtor fee 6% Undiscounted market value $16 million

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Components of lease	The components of Lease revenue are as follows: Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) Classification 2020 2019 2020 2019 Operating lease income Lease revenue $ 703 $ 1,322 $ 2,139 $ 3,854
Future minimum lease payments under non-cancellable leases	Following the change, the Company's future minimum lease payments under non-cancellable leases as of September 30, 2020 were as follows (in thousands): Fiscal Year Amount Remainder of 2020 $ 88 2021 704 2022 613 2023 552 2024 and thereafter 2,309 Total operating lease payments 4,266 Less: imputed interest (121) Total operating lease liabilities $ 4,145

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	The components of intangible assets as of December 31, 2019 were as follows: December 31, 2019 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Finite-lived intangible assets: Customer relationships $ 4,045 $ (884) $ 3,161 Acquired technology 11,500 (1,741) 9,759 Acquired trademarks 570 (304) 266 Total $ 16,115 $ (2,929) $ 13,186

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Sales Allowances and Accruals [Table Text Block]	Accrued liabilities under Going Concern Basis consisted of the following: (in thousands) December 31, Compensation $ 6,823 Deferred revenue 959 Interest 70 Legal 921 Accrued rebates, chargebacks and other revenue reserves 5 Other 3,145 Total (1) (2) $ 11,923 ________________ (1) The amounts above exclude $16.4 million of accrued liabilities at Noden classified as held for sale as of December 31, 2019. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. (2) The table above includes amounts held by LENSAR which was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information. Upon adoption of the Liquidation Basis of accounting, the Company accrued for all future estimated expenses and liabilities. For additional information, see Note 2, Net Assets in Liquidation.

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of convertible and non-recourse notes activity	Principal Balance Outstanding Carrying Value September 30, September 30, December 31, Description Maturity Date 2020 2020 2019 (in thousands) (Liquidation Basis) (Going Concern Basis) Convertible Senior Notes December 2021 Notes December 1, 2021 $ 13,805 $ 14,238 $ 16,950 December 2024 Notes December 1, 2024 1,000 1,000 10,300 Total $ 14,805 $ 15,238 $ 27,250
Schedule of carrying value and unamortized discount on December 2021 Notes [Table Text Block]	The carrying value of the December 2021 Notes as of September 30, 2020 and December 31, 2019 were as follows: (in thousands) September 30, 2020 December 31, 2019 (Liquidation Basis) (Going Concern Basis) Principal amount of the December 2021 Notes $ 13,805 $ 19,170 Estimated conversion settlement above par value 433 — Unamortized discount of liability component — (2,220) Carrying value of the December 2021 Notes $ 14,238 $ 16,950
Schedule of interest expense for December 2021 Notes [Table Text Block]	Interest expense for the December 2021 Notes included in the Company’s Condensed Consolidated Statements of Operations under the Going Concern Basis was as follows: Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Contractual coupon interest $ 63 $ 939 $ 281 $ 3,002 Amortization of debt issuance costs 1 17 5 57 Amortization of debt discount 9 130 39 406 Amortization of conversion feature 125 1,692 544 5,252 Total $ 198 $ 2,778 $ 869 $ 8,717
Schedule of carrying value and unamortized discount on December 2024	The carrying value, accretion and unamortized discount of the December 2024 Notes as of September 30, 2020 and December 31, 2019 were as follows: (in thousands) September 30, 2020 December 31, 2019 (Liquidation Basis) (Going Concern Basis) Principal amount of the December 2024 Notes $ 1,000 $ 11,500 Unamortized discount of liability component — (1,200) Carrying value of the December 2024 Notes $ 1,000 $ 10,300
Schedule of interest expense for December 2024 Notes	Interest expense for the December 2024 Notes included in the Company’s Condensed Consolidated Statements of Operations under the Going Concern Basis was as follows: Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Contractual coupon interest $ 5 $ 92 $ 49 $ 92 Accretion interest on outstanding principal 4 79 42 79 Amortization of debt issuance costs 1 8 6 8 Amortization of conversion feature 2 54 29 54 Total $ 12 $ 233 $ 126 $ 233

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Other Liabilities Disclosure [Abstract]
Schedule of other liabilities	Other long-term liabilities under Going Concern Basis consisted of the following: December 31, (in thousands) 2019 Uncertain tax positions $ 37,574 Deferred tax liabilities 1,571 Accrued lease guarantee 10,700 Other 1,020 Total (1) (2) $ 50,865 ________________ (1) The amounts above exclude $0.1 million of Other long-term liabilities at Noden classified as held for sale as of December 31, 2019. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. (2) The table above includes amounts held by LENSAR which was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award	The following table summarizes the Company’s stock option and restricted stock award activity during the nine months ended September 30, 2020: Stock Options Restricted Stock Awards (in thousands, except per share amounts) Number of Shares Outstanding Weighted Average Exercise Price Number of Shares Outstanding Weighted Average Grant-date Fair Value Per Share Balance at December 31, 2019 12,613 $ 2.55 1,013 $ 3.53 Granted 630 $ 3.56 3,045 $ 3.10 Exercised / vested (600) $ 2.46 (2,746) $ 3.12 Forfeited / canceled (728) $ 3.08 (1,089) $ 3.39 Balance at September 30, 2020 11,915 $ 2.62 223 $ 3.43

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	In the following tables, revenue is disaggregated by segment and primary geographical market for the two and eight months ended August 31, 2020 and three and nine months ended September 30, 2019 under the Going Concern Basis: Two Months Ended Three Months Ended August 31, 2020 September 30, 2019 (in thousands) Medical Devices Pharmaceutical (1) Medical Devices Pharmaceutical (1) Primary geographical markets: North America $ 2,172 $ 1,709 $ 2,779 $ 6,119 Europe 522 3,144 699 5,496 Asia 618 1,428 3,178 654 Other 63 — 68 — Total revenue from contracts with customers (2) $ 3,375 $ 6,281 $ 6,724 $ 12,269 Eight Months Ended Nine Months Ended August 31, 2020 September 30, 2019 (in thousands) Medical Devices Pharmaceutical (1) Medical Devices Pharmaceutical (1) Primary geographical markets: North America $ 6,656 $ 10,093 $ 7,066 $ 21,295 Europe 2,078 13,008 2,421 16,532 Asia 4,137 6,378 8,540 4,817 Other 200 — 253 — Total revenue from contracts with customers (2) $ 13,071 $ 29,479 $ 18,280 $ 42,644 ________________ (1) The revenue from the Company’s Pharmaceutical segment for the two and eight months ended August 31, 2020 and the three and nine months ended September 30, 2019 is included in Income (loss) from discontinued operations. For additional information, see Note 3, Discontinued Operations Classified as Assets held for sale under Going Concern Basis. (2) The tables above do not include lease revenue from the Company’s Medical Devices segment for the two months ended August 31, 2020 and three months ended September 30, 2019, of $0.7 million and $1.4 million, respectively, , for the eight month period ended August 31, 2020 and nine month period ended September 30, 2019, of $2.1 million and $3.9 million, respectively. For additional information, see Note 9, Leases.
Contract with Customer, Asset and Liability [Table Text Block]	The following table provides information about receivables, contract assets and contract liabilities from contracts with customers: (in thousands) December 31, 2019 Receivables, net $ 10,377 Contract assets $ 3,512 Contract liabilities $ 4,024 ________________ The table above includes LENSAR which was spun-off on October 1, 2020. See Note 21, Subsequent Events , for additional information. Receivables, Net —Receivables, net include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value based on the timing of when the Company expects to receive payment. The Company maintains an allowance for credit losses to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables, collateral to the extent applicable and reflects the possible impact of current conditions and reasonable forecasts not already reflected in historical loss information. The Company classifies Receivables, net as current or noncurrent on the Company’s Condensed Consolidated Balance Sheet as of December 31, 2019. Receivables, net for the Company’s Pharmaceutical segment are classified as a current asset and included in Assets held for sale as of December 31, 2019. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. Contract Assets —The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company’s contract assets are only attributable to the Pharmaceutical segment, and, as such, are classified as current in Assets held for sale in the Company’s Condensed Consolidated Balance Sheet as of December 31, 2019. (in thousands) Medical Devices Pharmaceutical Total Contract assets at December 31, 2019 $ — $ 3,512 $ 3,512 Contract assets recognized — (6,730) (6,730) Payments received — 8,562 8,562 Contract assets sold with the Noden subsidiaries — (5,344) (5,344) Contract assets at September 30, 2020 $ — $ — $ — Contract Liabilities —The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies Medical Devices deferred revenue as a liability and is included in Other liabilities on the Company’s Condensed Consolidated Statement of Net Assets as of September 30, 2020. The Company classified Medical Devices deferred revenue as current or noncurrent based on the timing of when it expected to recognize revenue. The current portion of deferred revenue is included in Accrued liabilities and the noncurrent portion of deferred revenue is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheet as of December 31, 2019. The Pharmaceutical deferred revenue is classified as a current liability and included in Liabilities held for sale on the Company’s Condensed Consolidated Balance Sheet as of December 31, 2019. (in thousands) Medical Devices Pharmaceutical Total Contract liabilities at December 31, 2019 $ 1,075 $ 2,949 $ 4,024 Contract liabilities recognized 658 1,659 2,317 Amounts recognized into revenue (851) (888) (1,739) Contract liabilities sold with the Noden subsidiaries — (3,720) (3,720) Contract liabilities at September 30, 2020 $ 882 $ — $ 882

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Information regarding the Company’s segments for the two and eight months ended August 31, 2020 and three and nine months ended September 30, 2019 is as follows: Revenues by segment Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Medical Devices $ 4,078 $ 8,076 $ 15,211 $ 22,224 Strategic Positions — — — — Pharmaceutical — — — — Income Generating Assets 37 (45) 110 (39) Total revenues $ 4,115 $ 8,031 $ 15,321 $ 22,185 ________________ The table above excludes revenues related to discontinued operations. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. Income (loss) by segment Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Medical Devices $ 216 $ (3,323) $ (4,454) $ (6,216) Strategic Positions (1) — (4,738) (15,723) 14,306 Pharmaceutical (1) 687 (2,123) (15,855) 3,177 Income Generating Assets (1) 2,201 (7,600) (37,217) (26,790) Total 3,104 (17,784) (73,249) (15,523) Change in fair value of warrants not allocated to segments (2) 1,294 — (4,047) — Net income (loss) attributable to PDL’s shareholders $ 4,398 $ (17,784) $ (77,296) $ (15,523) ________________ (1) The Income (loss) by segment presented above includes amounts related to both continuing and discontinued operations. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. (2) The change in fair value of warrants not allocated to segments presented above includes the amounts related to the change in fair value of the Evofem warrants after the distribution of the Evofem common stock to PDL stockholders on May 21, 2020. The Strategic Positions segment ceased to be a reporting segment as of this date. Information regarding the Company’s segments as of December 31, 2019 is as follows: Long-lived assets by segment (in thousands) December 31, Medical Devices $ 2,435 Strategic Positions — Pharmaceutical (1) 2,960 Income Generating Assets 125 Total long-lived assets (1) $ 5,520 ________________ (1) The amounts above include Property and Equipment in the Pharmaceutical segment classified as Assets held for sale. See Note 3, Discontinued Operations Classified as Assets Held for Sale under Going Concern Basis , for additional information. The operations for the Medical Devices segment are primarily located in the United States and the operations for the Pharmaceutical segment were primarily located in Italy, Ireland and the United States.

Net (Loss) Income per Share (Ta

Net (Loss) Income per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of calculation of numerator and denominator in earnings per share	Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, Net Income (loss) per Basic and Diluted Share 2020 2019 2020 2019 (in thousands, except per share amounts) Numerator Net loss from continuing operations $ (10,852) $ (11,811) $ (43,040) $ (28,277) Income (loss) from discontinued operations $ 15,236 $ (6,155) $ (34,915) $ 12,414 Less: Net loss attributable to noncontrolling interests $ (14) $ (182) $ (659) $ (340) Net income (loss) attributable to PDL’s stockholders used to compute net income (loss) per basic and diluted share $ 4,398 $ (17,784) $ (77,296) $ (15,523) Denominator Total weighted-average shares used to compute net income (loss) attributable to PDL’s stockholders, per basic share 113,889 112,986 118,001 119,966 Shares used to compute net income (loss) attributable to PDL’s stockholders, per diluted share 113,889 112,986 118,001 119,966 Net income (loss) per share - basic: Continuing operations $ (0.10) $ (0.10) $ (0.36) $ (0.23) Discontinued operations 0.14 (0.06) (0.30) 0.10 Net income (loss) attributable to PDL’s stockholders per basic share $ 0.04 $ (0.16) $ (0.66) $ (0.13) Net income (loss) per share - diluted: Continuing operations $ (0.10) $ (0.10) $ (0.36) $ (0.23) Discontinued operations 0.14 (0.06) (0.30) 0.10 Net income (loss) attributable to PDL’s stockholders per diluted share $ 0.04 $ (0.16) $ (0.66) $ (0.13)

Subsequent Events (Tables)

Subsequent Events (Tables)	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Schedule of discontinued operations	Components of amounts reflected in Income (loss) from discontinued operations on the Company’s Condensed Consolidated Statement of Operations are as follows: Two Months Ended Three Months Ended Eight Months Ended Nine Months Ended August 31, September 30, August 31, September 30, (in thousands) 2020 2019 2020 2019 Revenues Product revenue, net $ 6,281 $ 12,269 $ 29,479 $ 42,644 Royalty rights - change in fair value (1,893) 23,865 (8,804) (4,277) Total revenues 4,388 36,134 20,675 38,367 Operating expenses Cost of product revenue (excluding intangible asset amortization) 3,894 10,268 17,576 26,697 Amortization of intangible assets — 1,253 389 3,760 General and administrative 1,540 2,029 6,105 5,969 Sales and marketing 59 168 257 1,536 Research and development — — — (41) Total operating expenses 5,493 13,718 24,327 37,921 Operating (loss) income from discontinued operations (1,105) 22,416 (3,652) 446 Non-operating income (expense), net Equity affiliate - change in fair value 1,296 (27,378) (25,365) 18,109 Loss on classification as held for sale — — (28,904) — Total non-operating income (expense), net 1,296 (27,378) (54,269) 18,109 Income (loss) from discontinued operations before income taxes 191 (4,962) (57,921) 18,555 Income tax (benefit) expense from discontinued operations (15,045) 1,193 (23,006) 6,141 Income (loss) from discontinued operations $ 15,236 $ (6,155) $ (34,915) $ 12,414 The carrying amounts of the major classes of assets reported as “Assets held for sale” on the Company’s Condensed Consolidated Balance Sheet consisted of the following: (in thousands) December 31, 2019 Cash and cash equivalents (1) $ 24,469 Accounts receivable, net 6,993 Inventory 31,712 Prepaid and other current assets 7,192 Property and equipment, net 2,960 Royalty rights - at fair value 266,196 Investment in equity affiliate 82,267 Intangible assets, net 10,112 Other assets 15,956 Total assets held for sale $ 447,857 ________________ (1) Cash and cash equivalents represent balances maintained by Noden as of December 31, 2019, which were retained by the buyer upon the sale of the Noden business and used to settle the commitment with Novartis as further described in Note 14, Commitments and Contingencies . The carrying amounts of the major classes of liabilities reported as “Liabilities held for sale” on the Company’s Condensed Consolidated Balance Sheet consisted of the following: (in thousands) December 31, 2019 Accounts payable $ 14,695 Accrued liabilities 16,400 Other long-term liabilities 120 Total liabilities held for sale $ 31,215 The September 30, 2020 Condensed Consolidated Statement of Net Assets includes the following assets and liabilities related to LENSAR: September 30, (in thousands) 2020 Assets Cash and cash equivalents $ 42,701 Accounts receivable 2,429 Notes receivable 989 Inventory 13,685 Property and equipment 783 Equipment under lease 3,033 Intangible assets 42,113 Other assets 4,863 Total assets $ 110,596 Liabilities Accounts payable $ 2,349 Other liabilities 7,678 Total liabilities $ 10,027 Net assets attributable to LENSAR $ 100,569

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Narrative) (Detail) $ in Thousands	8 Months Ended	9 Months Ended
	Aug. 31, 2020USD ($)	Sep. 30, 2020USD ($)numberOfNotesRecivables	Dec. 31, 2019USD ($)
Number of Reportable Segments | numberOfNotesRecivables		4
Severance		$ 10,900
Expense associated with accelerating vesting of outstanding awards	$ 15,700
Number of customers | numberOfNotesRecivables		23
Revenues impacted	900
Maximum [Member]
Duration of agreement		4 months
Minimum [Member]
Duration of agreement		1 month
Evofem [Member]
Investment Owned, at Cost			$ 60,000
Product Revenue [Member]
Revenues impacted	500
Lease Revenue
Revenues impacted	300
Service
Revenues impacted	$ 100

Net Assets in Liquidation (Deta

Net Assets in Liquidation (Details) - USD ($) $ in Thousands	Sep. 01, 2020	Aug. 31, 2020
Liquidation Basis Of Accounting [Line Items]
Effect of adopting the liquidation basis of accounting	$ 21,339
Royalty Assets
Liquidation Basis Of Accounting [Line Items]
Royalty assets	231,683	$ 217,913
Change in royalty assets	13,770
Assertio
Liquidation Basis Of Accounting [Line Items]
Royalty assets	211,626	200,463
Change in royalty assets	11,163
U-M
Liquidation Basis Of Accounting [Line Items]
Royalty assets	20,057	$ 17,450
Change in royalty assets	2,607
Change in the estimated value of royalty rights
Liquidation Basis Of Accounting [Line Items]
Effect of adopting the liquidation basis of accounting	13,770
Change in the receivable from the sale of Noden
Liquidation Basis Of Accounting [Line Items]
Effect of adopting the liquidation basis of accounting	9,056
Estimated value of LENSAR
Liquidation Basis Of Accounting [Line Items]
Effect of adopting the liquidation basis of accounting	28,702
Change in the estimated value of other assets
Liquidation Basis Of Accounting [Line Items]
Effect of adopting the liquidation basis of accounting	4,813
Estimated liquidation and future operating costs
Liquidation Basis Of Accounting [Line Items]
Effect of adopting the liquidation basis of accounting	$ 25,376

Discontinued Operations Class_3

Discontinued Operations Classified as Assets Held for Sale - Narrative (Details) - Discontinued Operations, Disposed of by Sale $ in Thousands	Sep. 09, 2020USD ($)quarterly_installment	Aug. 31, 2020USD ($)
Noden Subsidiaries
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale	$ 12,200
Consideration to be received in quarterly installments	$ 33,000
Number of quarterly installments | quarterly_installment	12
Disposal Group, Including Discontinued Operations, Installment Payments	$ 3,900
Contingent consideration from sale	$ 2,500
Period after closing date for binding agreement contingency	1 year
License fee rate of contingent consideration (as a percent)	50.00%
Period of receipt of license fee from third party to receive contingent consideration	10 days
Entitlement in case of VAT	$ 500
Gain on disposal	200
Noden Subsidiaries | Maximum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale	$ 52,800
Kybella, Zalviso, and Coflex
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale		$ 4,350

Discontinued Operations Class_4

Discontinued Operations Classified as Assets Held for Sale - Summary (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues	$ 4,115	$ 8,031	$ 15,321	$ 22,185
Cost of Revenue	1,127	4,765	6,626	13,494
Amortization of intangible assets	204	321	841	983
General and administrative	7,224	10,062	29,695	27,067
Selling and Marketing Expense	835	1,545	3,322	4,980
Research and Development Expense	(1,053)	(4,310)	(4,374)	(6,106)
Operating Income (Loss)	(8,728)	(12,972)	(54,250)	(30,445)
Total non-operating expense, net	(5,760)	(1,975)	(6,570)	(4,390)
Total non-operating income (expense), net	191	(4,962)	(57,921)	18,555
Discontinued Operation, Tax Effect of Discontinued Operation	(15,045)	1,193	(23,006)	6,141
Less: (Loss) income from discontinued operations	15,236	(6,155)	(34,915)	12,414
Cash and cash equivalents (1)	25,060	16,982	25,060	16,982
Accounts receivable, net						$ 6,559
Inventory					$ 13,685	8,061
Prepaid and other current assets						7,344
Property and equipment, net						2,560
Intangible assets, net						13,186
Assets						717,206
Accounts payable						2,675
Accrued liabilities						11,923
Total liabilities						123,928
Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues	4,388	36,134	20,675	38,367
Cost of Revenue	3,894	10,268	17,576	26,697
Amortization of intangible assets	0	1,253	389	3,760
General and administrative	1,540	2,029	6,105	5,969
Selling and Marketing Expense	59	168	257	1,536
Research and Development Expense	0	0	0	(41)
Operating Expenses	5,493	13,718	24,327	37,921
Operating Income (Loss)	(1,105)	22,416	(3,652)	446
Equity affiliate - change in fair value	1,296	(27,378)	(25,365)	18,109
Loss on classification as held for sale	0	0	(28,904)	0
Total non-operating expense, net	1,296	(27,378)	(54,269)	18,109
Total non-operating income (expense), net	191	(4,962)	(57,921)	18,555
Discontinued Operation, Tax Effect of Discontinued Operation	(15,045)	1,193	(23,006)	6,141
Less: (Loss) income from discontinued operations	15,236	(6,155)	(34,915)	12,414
Cash and cash equivalents (1)						24,469
Accounts receivable, net						6,993
Inventory						31,712
Prepaid and other current assets						7,192
Property and equipment, net						2,960
Royalty rights						266,196
Investment in equity affiliate						82,267
Intangible assets, net						10,112
Other Assets						15,956
Assets						447,857
Accounts payable						14,695
Accrued liabilities						16,400
Other long-term liabilities						120
Total liabilities						$ 31,215
Product Revenue [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	2,831	5,856	10,946	15,860
Product Revenue [Member] | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	6,281	12,269	29,479	42,644
Acquired rights [Member] | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue from Contract with Customer, Including Assessed Tax	$ (1,893)	$ 23,865	$ (8,804)	$ (4,277)

Investment in Evofem Bioscien_2

Investment in Evofem Biosciences, Inc. (Details) - USD ($) $ / shares in Units, $ in Thousands	2 Months Ended	3 Months Ended			8 Months Ended	9 Months Ended
	Aug. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	May 21, 2020	Dec. 31, 2019	Jun. 10, 2019	Apr. 11, 2019
Debt and Equity Securities, FV-NI [Line Items]
Noncash liquidating distribution		$ 64,400			$ 64,400		$ 0
Gain (Loss) on Investments	$ (5,576)			$ 0	(5,576)		$ 0
Evofem [Member]
Debt and Equity Securities, FV-NI [Line Items]
Investment Owned, at Cost									$ 60,000
Tranche 1 of investment											$ 30,000
Investment Owned, Balance, Shares								13,333,334			6,666,667
Cost of tranche two investment option, per share										$ 4.50	$ 4.50
Warrants acquired										1,666,667	1,666,667
Warrants and Rights Outstanding, Term											7 years
Investment Warrants, Exercise Price						$ 6.38
Tranche 2 of investment										$ 30,000
Shares acquired										6,666,667
Noncash liquidating distribution			$ 64,400
Investment ownership percentage						26.70%
Number of warrants to hold purchase of common shares								3,333,334
Fair value of warrants						$ 2,500
Evofem [Member] | Common Stock
Debt and Equity Securities, FV-NI [Line Items]
Equity affiliate - change in fair value					17,900
Warrant [Member] | Evofem [Member]
Debt and Equity Securities, FV-NI [Line Items]
Gain (Loss) on Investments	$ 1,300				$ 7,500

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Schedule of Available-For-Sale Securities [Line Items]
Cash and cash equivalents	$ 125,736	$ 168,982
Discontinued Operations, Held-for-sale
Schedule of Available-For-Sale Securities [Line Items]
Cash and cash equivalents		24,500
Cash [Member]
Schedule of Available-For-Sale Securities [Line Items]
Cash and cash equivalents	74,580	37,718
Money Market Funds [Member]
Schedule of Available-For-Sale Securities [Line Items]
Cash and cash equivalents	$ 51,156	$ 131,264

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory [Line Items]
Raw materials	$ 3,840	$ 3,739
Work in process	2,039	1,170
Finished goods	7,806	3,152
Inventory, Net	$ 13,685	8,061
Discontinued Operations, Held-for-sale
Inventory [Line Items]
Inventory, Net		$ 31,712

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Detail) $ / shares in Units, shares in Millions	Aug. 02, 2018USD ($)	Jul. 08, 2016USD ($)	Aug. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Aug. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)numberOfNotesRecivables	Aug. 03, 2018USD ($)	Jul. 09, 2016USD ($)	Dec. 31, 2015$ / shares	Dec. 15, 2015shares	Sep. 18, 2015USD ($)	Nov. 06, 2014USD ($)	Jun. 26, 2014USD ($)	Oct. 18, 2013USD ($)
Financing Receivable, before Allowance for Credit Loss, Noncurrent											$ 52,100,000
Cash payment for purchase of royalty right																	$ 65,600,000
Purchase of royalty rights	$ 20,000,000
Proceeds from the sale of intangible assets							$ 0	$ 5,000,000
Gain on sale of intangible assets			$ 0		$ 3,476,000	$ 0		3,476,000
Reversionary interest period												$ 481,000,000
Number of notes receivable assets | numberOfNotesRecivables											2
Percentage of royalty acquired																	75.00%
Convertible Notes Payable, Carrying Value				$ 15,238,000			$ 15,238,000				$ 27,250,000
Notes Payable, Fair Value Disclosure											33,900,000
Depomed [Member]
Cash payment for purchase of royalty right																			$ 240,500,000
Purchase of royalty rights																			241,300,000
Royalty right purchase transaction costs																			$ 800,000
Cash flow model expected royalty sales term			8 years
Contractual cap on potential royalty asset multiple							2
VB [Member]
Purchase of royalty rights																		$ 15,500,000
Proceeds from the sale of intangible assets				4,200,000
Gain on sale of intangible assets				0
Contractual cap on potential royalty asset multiple							2.3
University of Michigan
Cash flow model expected royalty sales term			2 years
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate			12.80%			12.80%
AcelRx [Member]
Purchase of royalty rights																$ 65,000,000
Period to give notice to terminate license agreement							180 days
Proceeds from the sale of intangible assets				0
Gain on sale of intangible assets						$ 0
Percentage of royalty acquired																75.00%
Percentage of first four milestone payments acquired																80.00%
Number of potential milestone royalties																4
Contractual cap on potential royalty asset multiple							3
Kybella [Member]
Purchase of royalty rights													$ 9,500,000
Proceeds from the sale of intangible assets				200,000
Gain on sale of intangible assets				$ 0
Maximum amount of additional funds, upon attainment of milestones		$ 1,000,000
Alphaeon [Member]
Investment Owned, Balance, Shares | shares															1.7
Investment Owned, at Cost			$ 1,000,000			$ 1,000,000					6,600,000
Investment estimated fair value, per share | $ / shares														$ 3.84
Minimum [Member] | Depomed [Member]
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate			10.00%			10.00%
Maximum [Member] | Depomed [Member]
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate			24.00%			24.00%
Discontinued Operations, Held-for-sale
Loss on classification as held for sale			$ 0		$ 0	$ (28,904,000)		$ 0
Royalty rights											266,196,000
Discontinued Operations, Held-for-sale | Income generating assets [Member]
Loss on classification as held for sale			$ 4,600,000			$ 4,600,000
Discontinued Operations, Held-for-sale | Pharmaceutical [Member]
Estimated cost to sell										$ 1,800,000
Loss on classification as held for sale, fair value adjustment										4,900,000
Loss on classification as held for sale									$ 16,800,000	$ 6,700,000
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate									17.00%	19.00%
Fair Value Level 3 [Member]
Royalty rights											266,196,000
Notes Receivable, Fair Value Disclosure											$ 57,300,000

Fair Value Measurements (Financ

Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) - USD ($) $ in Thousands	8 Months Ended
	Aug. 31, 2020	Dec. 31, 2019
Financial assets:
Assets, Fair Value		$ 493,879
Warrants and Rights Outstanding		14,152
Equity Securities [Member]
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments in and Advances to Affiliates, at Fair Value		82,267
Money Market Funds [Member]
Financial assets:
Cash and Cash Equivalents, Fair Value		131,264
Fair Value Level 1 [Member]
Financial assets:
Assets, Fair Value		213,531
Fair Value Level 1 [Member] | Equity Securities [Member]
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments in and Advances to Affiliates, at Fair Value		82,267
Fair Value Level 1 [Member] | Money Market Funds [Member]
Financial assets:
Cash and Cash Equivalents, Fair Value		131,264
Fair Value Level 2 [Member]
Financial assets:
Assets, Fair Value		14,152
Warrants and Rights Outstanding		14,152
Fair Value Level 2 [Member] | Equity Securities [Member]
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments in and Advances to Affiliates, at Fair Value		0
Fair Value Level 2 [Member] | Money Market Funds [Member]
Financial assets:
Cash and Cash Equivalents, Fair Value		0
Fair Value Level 3 [Member]
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty rights		266,196
Financial assets:
Assets, Fair Value		$ 266,196
Royalty right [Member]
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	$ (43,933)
VB [Member] | Royalty right [Member]
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	$ (9,408)

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Assets
Notes receivable, Carrying Value	$ 52,100
Fair Value Level 3 [Member]
Assets
Notes receivable, Fair Value	$ 57,300
Real estate appreciation [Member] | Wellstat Diagnostics [Member]
Fair Value by Balance Sheet Grouping [Line Items]
Loans Held-for-sale, Measurement Input	0
Estimated realtor fee [Member] | Wellstat Diagnostics [Member]
Fair Value by Balance Sheet Grouping [Line Items]
Loans Held-for-sale, Measurement Input	0.06
Minimum [Member] | Measurement Input, Discount Rate [Member] | Wellstat Diagnostics [Member]
Fair Value by Balance Sheet Grouping [Line Items]
Loans Held-for-sale, Measurement Input	0.12
Maximum [Member] | Measurement Input, Discount Rate [Member] | Wellstat Diagnostics [Member]
Fair Value by Balance Sheet Grouping [Line Items]
Loans Held-for-sale, Measurement Input	0.15

Fair Value Measurements Level 3

Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) $ in Thousands	8 Months Ended
	Aug. 31, 2020USD ($)
Royalty right [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 266,196
Change in fair value of acquired royalty rights, Level 3 Rollforward	(8,804)
Ending balance	217,913
Payments for (Proceeds from) Productive Assets	(35,129)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	(43,933)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales	(4,350)
Depomed [Member] | Royalty right [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	218,672
Ending balance	200,463
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	(18,209)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales	0
VB [Member] | Royalty right [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	13,590
Ending balance	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	(9,408)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales	$ (4,182)
University of Michigan
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate	12.80%
University of Michigan | Royalty right [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 20,398
Ending balance	17,450
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	(2,948)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales	0
AcelRx [Member] | Royalty right [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	12,952
Ending balance	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	(12,952)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales	0
Kybella [Member] | Royalty right [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	584
Ending balance	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	(416)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales	(168)
Measurement Input, Discount Rate [Member] | Intellectual Property [Member] | Wellstat Diagnostics [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	21,000
Measurement Input, Discount Rate [Member] | Other [Member] | Wellstat Diagnostics [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	28,000
Measurement Input, Discount Rate [Member] | Real Estate [Member] | Wellstat Diagnostics [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 16,000

Notes Receivable and Other Lo_2

Notes Receivable and Other Long-term Receivables (Narrative) (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions

Jul. 26, 2021

Apr. 21, 2021

Feb. 10, 2021

Jun. 26, 2015

Aug. 15, 2013

Feb. 28, 2013

Aug. 30, 2020

Dec. 31, 2019

Jan. 31, 2013

Aug. 31, 2020

Sep. 30, 2019

Dec. 31, 2018

Aug. 31, 2020

Sep. 30, 2020

Sep. 30, 2019

Dec. 31, 2013

Feb. 02, 2018

Oct. 07, 2015

Mar. 31, 2015

Jun. 28, 2013

Nov. 02, 2012

Accounts Notes And Loans Receivable [Line Items]

Revenues

$ 4,115

$ 8,031

$ 15,321

$ 22,185

Commitments and Contingencies

Asset Impairment Charges

10,800

$ 8,200

Increase in interest rate percentage

15.50%

15.50%

Financial Instruments, Owned, Other, at Fair Value

$ 14,152

Litigation Settlement, Amount Awarded to Other Party

$ 7,500

Scenario, Plan [Member]

Accounts Notes And Loans Receivable [Line Items]

Litigation Settlement, Amount Awarded to Other Party

$ 67,500

Scenario, Plan [Member] | Subsequent Event

Accounts Notes And Loans Receivable [Line Items]

Litigation Settlement, Amount Awarded to Other Party

$ 55,000

$ 5,000

$ 5,000

Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing Receivable, before Allowance for Credit Loss

$ 53,900

Financing Receivable, after Allowance for Credit Loss

50,200

Interest rate of note receivable (in Percent)

5.00%

Litigation Settlement, Amount Awarded to Other Party

92,500

CareView [Member]

Accounts Notes And Loans Receivable [Line Items]

Interest rate of note receivable (in Percent)

13.50%

Amount company has agreed to advance under agreement

$ 40,000

Tranche 1 of note receivable

20,000

Tranche 2 of note receivable

$ 20,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

4.4

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.45

$ 0.03

$ 0.40

Financial Instruments, Owned, Other, at Fair Value

$ 100

Credit Agreement [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing Receivable, before Allowance for Credit Loss

$ 40,000

Credit agreement, stated interest rate (in Percent)

5.00%

Proceeds received under remedies available for borrower's breach of terms credit agreement

$ 8,100

Forbearance number of days under terms of credit agreement (in Duration)

120 days

Amount company has agreed to advance under agreement

$ 8,700

Financing Receivable, Troubled Debt Restructuring, Postmodification

$ 44,100

Initial Loan [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing Receivable, Troubled Debt Restructuring, Postmodification

33,700

Additional Loan [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing Receivable, before Allowance for Credit Loss

$ 1,300

Term loan and interest [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing Receivable, Troubled Debt Restructuring, Postmodification

1,300

Forbearance principal and interest [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing Receivable, Troubled Debt Restructuring, Postmodification

$ 9,100

License and other [Member]

Accounts Notes And Loans Receivable [Line Items]

Revenues

$ 37

$ (45)

$ 110

$ (48)

Leases - Components of Lease Re

Leases - Components of Lease Revenue (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2019
Leases [Abstract]
Operating Lease, Lease Income	$ 703	$ 1,322	$ 2,139	$ 3,854

Leases - Lessee arrangements (D

Leases - Lessee arrangements (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Sep. 01, 2020
Leases [Abstract]
Lessee, Operating Lease, Discount Rate	10.00%
Total operating lease liabilities	$ 4,145	$ 3,300
Operating Lease, Right-of-Use Asset		$ 3,300

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Sep. 01, 2020
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
Remainder of 2020	$ 88
2021	704
2022	613
2023	552
2024 and thereafter	2,309
Total operating lease payments	4,266
Less: imputed interest	(121)
Total operating lease liabilities	$ 4,145	$ 3,300

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Proceeds from the sale of intangible assets				$ 0	$ 5,000
Amortization of intangible assets	$ 204	$ 321	$ 841		983
Research and Development Expense	$ 1,053	$ 4,310	$ 4,374		$ 6,106
Finite-Lived Intangible Assets, Gross						$ 16,115
Finite-Lived Intangible Assets, Accumulated Amortization						(2,929)
Finite-Lived Intangible Assets, Net						13,186
Liquidation Basis of Accounting, Intangible Assets				$ 42,100
Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross						4,045
Finite-Lived Intangible Assets, Accumulated Amortization						(884)
Finite-Lived Intangible Assets, Net						3,161
Acquired Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross						11,500
Finite-Lived Intangible Assets, Accumulated Amortization						(1,741)
Finite-Lived Intangible Assets, Net						9,759
Acquired Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross						570
Finite-Lived Intangible Assets, Accumulated Amortization						(304)
Finite-Lived Intangible Assets, Net						$ 266
Original acquisition [Member] | LENSAR
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				15 years
Precision Eye Services [Member] | LENSAR
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				10 years
third-party [Member] | LENSAR
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				15 years

Accrued Liabilities (Narrative)

Accrued Liabilities (Narrative) (Detail) $ in Thousands	Dec. 31, 2019USD ($)
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Accrued liabilities	$ 11,923
Discontinued Operations, Held-for-sale
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Accrued liabilities	$ 16,400

Accrued Liabilities (Accrued Li

Accrued Liabilities (Accrued Liabilities) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Compensation		$ 6,823
Severance	$ 10,900
Deferred revenue		959
Interest		70
Legal		921
Accrued rebates, chargebacks and other revenue reserves		5
Other		3,145
Accrued liabilities		$ 11,923

Convertible Notes (Narrative) (

Convertible Notes (Narrative) (Detail) $ / shares in Units, shares in Millions	Aug. 19, 2020	Dec. 17, 2019USD ($)shares	Sep. 18, 2019USD ($)	Nov. 21, 2016USD ($)	Sep. 30, 2020USD ($)$ / shares	Sep. 29, 2020	May 31, 2020	Sep. 30, 2019USD ($)	Aug. 31, 2020USD ($)	Nov. 18, 2019USD ($)	Sep. 30, 2020USD ($)$ / shares	Mar. 31, 2020USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2020USD ($)shares	Aug. 31, 2020USD ($)	Sep. 30, 2020USD ($)$ / shares	Sep. 30, 2019USD ($)	Jun. 01, 2020$ / shares	Dec. 31, 2019USD ($)	Dec. 12, 2019shares	Sep. 17, 2019USD ($)$ / shares	Nov. 22, 2016USD ($)$ / shares	Nov. 20, 2015USD ($)
Debt Instrument [Line Items]
Exchange of debt								$ 86,100,000			$ 86,100,000		$ (8,013,000)
Cash paid per round lot to exchange debt																					$ 70
Cash paid to exchange convertible note																					6,000,000
Debt Instrument, Face Amount					$ 14,805,000						14,805,000					$ 14,805,000
Round lot of notes																					$ 1,000
Net receipts for capped call transactions															$ 801,000		$ (3,694,000)
Gain on conversion of convertible notes									$ 0			$ 3,900,000	$ 3,900,000		606,000		$ 3,900,000
Notes receivable					53,070,000						53,070,000					53,070,000
Wellstat Diagnostics [Member]
Debt Instrument [Line Items]
Gain Contingency, Unrecorded Amount					55,800,000						55,800,000					55,800,000
December 2021 Notes [Member]
Debt Instrument [Line Items]
Payment for Debt Extinguishment or Debt Prepayment Cost											6,000,000			$ 39,900,000
Stock Issued During Period, Shares, Other | shares														3.5
Convertible notes					14,238,000						14,238,000					14,238,000			$ 16,950,000			$ 150,000,000	$ 150,000,000
Debt Instrument, Interest Rate, Stated Percentage																						2.75%
Unamortized discount of liability component					0						$ 0					$ 0			(2,220,000)			$ (4,300,000)
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature			$ 13,500,000
Convertible notes, amount converted					$ 11,200,000
Observation period of convertible notes																60 days
Convertible note rate conversion trading days (in days)																$ 20
Convertible Notes rate conversion consecutive trading days (in days)																$ 30
Debt discount recorded to additional paid in capital																						23,800,000
Debt discount recorded to deferred tax liability																						$ 12,800,000
Minimum conversion price percent for note conversion (in Percent)																130.00%
Maximum percent of common stock closing price and conversion rate to convert note (in Percent)																98.00%
Debt Instrument, Interest Rate, Effective Percentage																						9.70%
Convertible notes, conversion price (in Dollars per Share) | $ / shares					$ 3.16						$ 3.16					$ 3.16		$ 3.16			$ 3.81	$ 3.81
Cap Price capped call | $ / shares																		4.04				$ 4.88
Capped call unwind shares repurchased | shares																				1.6
Estimated market interest rate for similar nonconvertible instrument																						9.50%
Extinguishment of Debt, Amount											$ 5,400,000	44,800,000		$ 44,800,000
Net proceeds from the issuance of convertible notes				$ 145,700,000
Debt Instrument, Face Amount					$ 13,805,000						13,805,000					$ 13,805,000			19,170,000
Conversion Rate per $1,000 Principal Amount (in Ratio)	343.1098			262.2951			316.5801
Net receipts for capped call transactions				$ 14,400,000
Gain on conversion of convertible notes											$ (100,000)			$ (2,500,000)
December 2024 Notes [Member]
Debt Instrument [Line Items]
Payment for Debt Extinguishment or Debt Prepayment Cost		$ 58,000,000													12,900,000
Stock Issued During Period, Shares, Other | shares		9.9
Debt Instrument, Interest Rate, Stated Percentage																					2.75%
Debt instrument, accretion rate											2.375%
Unamortized discount of liability component					$ 0						$ 0					0			(1,200,000)		$ (9,400,000)
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature			$ 8,100,000													8,100,000
Adjustments to Additional Paid in Capital, Other																$ 1,300,000
Debt discount recorded to additional paid in capital																					5,500,000
Debt discount recorded to deferred tax liability																					$ 1,200,000
Maximum percent of common stock closing price and conversion rate to convert note (in Percent)											98.00%
Debt Instrument, Interest Rate, Effective Percentage					7.50%						7.50%					7.50%
Convertible notes, conversion price (in Dollars per Share) | $ / shares					$ 3.16						$ 3.16					$ 3.16		3.16			$ 3.81
Cap Price capped call | $ / shares																		$ 4.04			$ 4.88
Capped call unwind shares repurchased | shares																				1.6
Estimated market interest rate for similar nonconvertible instrument																					7.05%
Extinguishment of Debt, Amount		$ 74,600,000										$ 74,600,000			10,500,000
Repurchase price upon fundamental change as described in 2021 Notes indenture						100.00%										100.00%
Debt Instrument, Face Amount					$ 1,000,000						$ 1,000,000					$ 1,000,000			$ 11,500,000
Conversion Rate per $1,000 Principal Amount (in Ratio)	378.8004
Debt Instrument, Redeemable, Threshold Percentage of Stock Price Minimum											128.00%
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger											130.00%
Debt Instrument, Convertible, Threshold Consecutive Trading Days											20
Debt Instrument, Convertible, Threshold Trading Days											30
Net receipts for capped call transactions										$ 4,500,000
Gain on conversion of convertible notes		$ (2,100,000)													$ (500,000)
Settlement Agreement [Member]
Debt Instrument [Line Items]
Notes receivable					$ 51,400,000						$ 51,400,000					$ 51,400,000

Convertible Notes (Summary of C

Convertible Notes (Summary of Convertible Notes) (Detail) $ / shares in Units, $ in Thousands	Aug. 19, 2020	Nov. 21, 2016	May 31, 2020	Sep. 30, 2020USD ($)$ / shares	Jun. 01, 2020$ / shares	Dec. 31, 2019USD ($)	Sep. 17, 2019$ / shares	Nov. 22, 2016$ / shares
Debt Instrument [Line Items]
Convertible Notes, Principal Balance Outstanding				$ 14,805
Convertible Notes Payable, Carrying Value				$ 15,238		$ 27,250
December 2021 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								2.75%
Debt Instrument, Convertible, Conversion Ratio	343.1098	262.2951	316.5801
Convertible notes, conversion price (in Dollars per Share) | $ / shares				$ 3.16	$ 3.16		$ 3.81	$ 3.81
Convertible Notes, Maturity Date (Date)				Dec. 1, 2021
Convertible Notes, Principal Balance Outstanding				$ 13,805		19,170
Convertible Notes Payable, Carrying Value				$ 14,238		16,950
December 2024 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							2.75%
Debt Instrument, Convertible, Conversion Ratio	378.8004
Convertible notes, conversion price (in Dollars per Share) | $ / shares				$ 3.16	$ 3.16		$ 3.81
Convertible Notes, Principal Balance Outstanding				$ 1,000		11,500
Convertible Notes Payable, Carrying Value				$ 1,000		$ 10,300

Convertible Notes (Summary of S

Convertible Notes (Summary of Series 2012 Notes) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes, Principal Balance Outstanding	$ 14,805
Convertible Notes Payable, Carrying Value	$ 15,238	$ 27,250

Convertible Notes (Summary of M

Convertible Notes (Summary of May 2015 Notes) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 14,805
Convertible Notes Payable, Carrying Value	$ 15,238	$ 27,250

Convertible Notes Convertible N

Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) $ in Thousands	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 14,805

Convertible Notes Convertible_2

Convertible Notes Convertible Notes (Summary of December 2021 Notes) (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Nov. 22, 2016	Nov. 20, 2015
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 14,805
Debt Instrument, Estimated Conversion Settlement Above Par Value	433
December 2021 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	13,805	$ 19,170
Debt Instrument, Unamortized Discount	0	(2,220)	$ (4,300)
Convertible notes	$ 14,238	$ 16,950	$ 150,000	$ 150,000

Convertible Notes Convertible_3

Convertible Notes Convertible Notes (Interest Expense for December 2021 Notes) (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 125	$ 1,692	$ 544	$ 5,252
December 2021 Notes [Member]
Debt Instrument [Line Items]
Contractual coupon interest	63	939	281	3,002
Amortization of debt issuance costs	1	17	5	57
Amortization of debt discount	9	130	39	406
Interest Expense, Debt	$ 198	$ 2,778	$ 869	$ 8,717

Convertible Notes Summary of De

Convertible Notes Summary of December 2024 Notes (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019	Sep. 17, 2019
Debt Instrument [Line Items]
Accreted interest on convertible note principal			$ 44	$ 79
Amortization of convertible notes conversion option and debt issuance costs			622	5,776
Debt Instrument, Face Amount					$ 14,805
Convertible notes payable						$ 27,250
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 125	$ 1,692	544	5,252
December 2024 Notes [Member]
Debt Instrument [Line Items]
Contractual coupon interest	5	92	49	92
Accreted interest on convertible note principal	4	79	42	79
Amortization of convertible notes conversion option and debt issuance costs	1	8	6	8
Debt Instrument, Face Amount					1,000	11,500
Debt Instrument, Unamortized Discount					0	(1,200)	$ (9,400)
Convertible notes payable					$ 1,000	$ 10,300
Debt Instrument, Convertible, Beneficial Conversion Feature	2	54	29	54
Interest Expense, Debt	$ 12	$ 233	$ 126	$ 233

Convertible Notes Interest Expe

Convertible Notes Interest Expense for December 2024 Notes (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 125	$ 1,692	$ 544	$ 5,252
Accreted interest on convertible note principal			44	79
Amortization of convertible notes conversion option and debt issuance costs			622	5,776
December 2024 Notes [Member]
Debt Instrument [Line Items]
Interest Expense, Debt	12	233	126	233
Debt Instrument, Convertible, Beneficial Conversion Feature	2	54	29	54
Contractual coupon interest	5	92	49	92
Accreted interest on convertible note principal	4	79	42	79
Amortization of convertible notes conversion option and debt issuance costs	$ 1	$ 8	$ 6	$ 8

Other Long-Term Liabilities (Na

Other Long-Term Liabilities (Narrative) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Schedule of Other Liabilities [Line Items]
Accrued lease guarantee	$ 10,700	$ 10,700
Discontinued Operations, Held-for-sale
Schedule of Other Liabilities [Line Items]
Other long-term liabilities		$ 120

Other Long-Term Liabilities (Ot

Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Other Liabilities Disclosure [Abstract]
Uncertain tax positions		$ 37,574
Deferred tax liabilities		1,571
Accrued lease guarantee	$ 10,700	10,700
Other		1,020
Other long-term liabilities		$ 50,865

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Guarantor Obligations [Line Items]
Total lease payments for the duration of the guarantee	$ 14,100
Accrued lease guarantee	10,700	$ 10,700
LENSAR
Guarantor Obligations [Line Items]
Purchase Obligation	$ 2,500

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Dec. 17, 2019	Sep. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Aug. 31, 2020	Sep. 30, 2019	Aug. 07, 2019	Dec. 16, 2019	Dec. 09, 2019	Sep. 21, 2018
Debt Instrument [Line Items]
Stock Repurchase Program, Authorized Amount								$ 75,000	$ 200,000	$ 100,000
Stock Repurchased During Period, Shares					12.3		31
Stock Repurchased During Period, Value					$ 39,400		$ 100,000
Treasury Stock Acquired, Average Cost Per Share					$ 3.20		$ 3.22
Cash payment for repurchase of convertible notes			$ 97,900		$ 18,845	$ 0
Stock Issued During Period, Shares, New Issues			13.4
December 2021 Notes [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount		$ 5,400	$ 44,800	$ 44,800
Cash payment for repurchase of convertible notes					5,400
December 2024 Notes [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount	$ 74,600		$ 74,600		$ 10,500

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	2,746
Share-based Payment Arrangement, Option [Member]
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	(728)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$ 3.08
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	11,915	12,613
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	630
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ (3.56)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(600)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 2.62	$ 2.55
Restricted Stock [Member]
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]
Restricted Stock Award, Number of Shares, Balance at beginning of period (in Shares)	1,013
Restricted Stock Awards, Number of Shares Granted (in Shares)	3,045
Restricted Stock Awards, Number of Shares, Balance at end of period (in Shares)	223
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at beginning of period (in Dollars per Share)	$ 3.53
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Granted (in Dollars per Share)	3.10
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at end of period (in Dollars per Share)	3.43
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	3.12
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 3.39
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations	(1,089)

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - $ / shares	1 Months Ended	9 Months Ended
	May 31, 2020	Sep. 30, 2020
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]
Exercise price of the outstanding employee option awards were decreased (in USD per share)		$ (2.46)
Share-based Payment Arrangement, Option [Member]
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]
Exercise price of the outstanding employee option awards were decreased (in USD per share)	$ 0.58

Revenue from Contracts with C_3

Revenue from Contracts with Customers (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 4,115	$ 8,031	$ 15,321		$ 22,185
Proceeds from the sale of intangible assets				$ 0	5,000
License and other [Member]
Disaggregation of Revenue [Line Items]
Revenues	37	(45)	110		(48)
Medical devices [Member]
Disaggregation of Revenue [Line Items]
Revenues	4,078	8,076	15,211		22,224
Revenue Not from Contract with Customer	700	1,400		$ 2,100	3,900
Revenue from Contract with Customer, Excluding Assessed Tax	3,375	6,724	13,071		18,280
Medical devices [Member] | North America [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	2,172	2,779	6,656		7,066
Medical devices [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	522	699	2,078		2,421
Medical devices [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	618	3,178	4,137		8,540
Medical devices [Member] | Non-US [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	63	68	200		253
Pharmaceutical [Member]
Disaggregation of Revenue [Line Items]
Revenues	0	0	0		0
Revenue from Contract with Customer, Excluding Assessed Tax	6,281	12,269	29,479		42,644
Pharmaceutical [Member] | North America [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,709	6,119	10,093		21,295
Pharmaceutical [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	3,144	5,496	13,008		16,532
Pharmaceutical [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,428	654	6,378		4,817
Pharmaceutical [Member] | Non-US [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0	$ 0		$ 0
Minimum [Member]
Disaggregation of Revenue [Line Items]
Term of receivable (in Duration)				30 days
Maximum [Member]
Disaggregation of Revenue [Line Items]
Term of receivable (in Duration)				90 days

Revenue from Contracts with C_4

Revenue from Contracts with Customers Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Accounts Receivable, after Allowance for Credit Loss		$ 10,377
Movement in Deferred Revenue [Roll Forward]
Contract assets at December 31, 2019	$ 3,512
Contract assets recognized	(6,730)
Payments received	8,562
Contract assets sold with the Noden subsidiaries	(5,344)
Contract assets at September 30, 2020	0
Contract liabilities at December 31, 2019	4,024
Contract liabilities recognized	2,317
Amounts recognized into revenue	(1,739)
Contract liabilities sold with the Noden subsidiaries	(3,720)
Contract liabilities at September 30, 2020	882
Medical devices [Member]
Movement in Deferred Revenue [Roll Forward]
Contract assets at December 31, 2019	0
Contract assets recognized	0
Payments received	0
Contract assets sold with the Noden subsidiaries	0
Contract assets at September 30, 2020	0
Contract liabilities at December 31, 2019	1,075
Contract liabilities recognized	658
Amounts recognized into revenue	(851)
Contract liabilities sold with the Noden subsidiaries	0
Contract liabilities at September 30, 2020	882
Pharmaceutical [Member]
Movement in Deferred Revenue [Roll Forward]
Contract assets at December 31, 2019	3,512
Contract assets recognized	(6,730)
Payments received	8,562
Contract assets sold with the Noden subsidiaries	(5,344)
Contract assets at September 30, 2020	0
Contract liabilities at December 31, 2019	2,949
Contract liabilities recognized	1,659
Amounts recognized into revenue	(888)
Contract liabilities sold with the Noden subsidiaries	(3,720)
Contract liabilities at September 30, 2020	$ 0

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2019	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenues	$ 4,115	$ 8,031	$ 15,321	$ 22,185
Net Income (Loss) Attributable to Parent	4,398	(17,784)	(77,296)	(15,523)
Operating segment net income	3,104	(17,784)	(73,249)	(15,523)
Net income (loss) not allocated to a segment	1,294	0	(4,047)	0
Long-Lived Assets					$ 5,520
Income generating assets [Member]
Segment Reporting Information [Line Items]
Revenues	37	(45)	110	(39)
Net Income (Loss) Attributable to Parent	2,201	(7,600)	(37,217)	(26,790)
Long-Lived Assets					125
Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Revenues	0	0	0	0
Net Income (Loss) Attributable to Parent	687	(2,123)	(15,855)	3,177
Long-Lived Assets					2,960
Medical devices [Member]
Segment Reporting Information [Line Items]
Revenues	4,078	8,076	15,211	22,224
Net Income (Loss) Attributable to Parent	216	(3,323)	(4,454)	(6,216)
Long-Lived Assets					2,435
Strategic positions [Member]
Segment Reporting Information [Line Items]
Revenues	0	0	0	0
Net Income (Loss) Attributable to Parent	0	(4,738)	$ (15,723)	$ 14,306
Long-Lived Assets					$ 0
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	$ 4,115	$ 8,031

Concentration of Credit Risk (P

Concentration of Credit Risk (Percentage of Total Revenue From Licenses Over 10% of Revenue) (Detail) - Royalty right [Member] $ in Thousands	8 Months Ended
	Aug. 31, 2020USD ($)
Revenue, Major Customer [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	$ (43,933)
AcelRx [Member]
Revenue, Major Customer [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings	$ (12,952)

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Detail) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Sep. 30, 2020	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2020	Sep. 30, 2019
Investments, Owned, Federal Income Tax Note [Line Items]
Change in Uncertain Tax Positions	$ 4,400,000	$ 0	$ 0
Income Tax Expense		$ (3,636,000)	$ (3,136,000)	$ (17,780,000)		$ (6,558,000)
Federal income tax rate					21.00%
Income Tax Receivable, CARES Act	80,500,000				$ 80,500,000
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	$ 7,900,000				$ 7,900,000
Interest expense on uncertain tax positions				$ 1,000,000		$ 1,100,000

Net (Loss) Income per Share (Ne

Net (Loss) Income per Share (Net Income Per Basic and Diluted Share) (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2019
Numerator
Net loss from continuing operations	$ (10,852)	$ (11,811)	$ (43,040)	$ (28,277)
Less: (Loss) income from discontinued operations	15,236	(6,155)	(34,915)	12,414
Net Income (Loss) Attributable to Parent	$ 4,398	$ (17,784)	$ (77,296)	$ (15,523)
Denominator
Total weighted-average shares used to compute net income per basic share (in Shares)	113,889	112,986	118,001	119,966
Diluted (in Shares)	113,889	112,986	118,001	119,966
Income (Loss) from Continuing Operations, Per Basic Share	$ (0.10)	$ (0.10)	$ (0.36)	$ (0.23)
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share	0.14	(0.06)	(0.30)	0.10
Basic (in Dollars per Share)	0.04	(0.16)	(0.66)	(0.13)
Income (Loss) from Continuing Operations, Per Diluted Share	(0.10)	(0.10)	(0.36)	(0.23)
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share	0.14	(0.06)	(0.30)	0.10
Net income per diluted share (in Dollars per Share)	$ 0.04	$ (0.16)	$ (0.66)	$ (0.13)

Net (Loss) Income per Share (Na

Net (Loss) Income per Share (Narrative) (Detail) - USD ($) $ in Thousands, shares in Millions	2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2019	Aug. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019	Nov. 22, 2016	Nov. 20, 2015
December 2021 Notes [Member]
Debt Instrument [Line Items]
Convertible notes					$ 14,238	$ 16,950	$ 150,000	$ 150,000
Restricted Stock [Member]
Debt Instrument [Line Items]
Antidilutive securities excluded from computation of earnings per share (in Shares)	0.2	1	0.2	0.8
Option on Securities [Member]
Debt Instrument [Line Items]
Antidilutive securities excluded from computation of earnings per share (in Shares)	11.9	12.6	11.9	10.7

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Detail) - LENSAR - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Sep. 22, 2020
Disposal Group, Disposed of by Sale, Not Discontinued Operations
Subsequent Event [Line Items]
Shares issued per common stock owned (shares)			0.075879
Ownership interest prior to disposal (as a percent)		81.50%
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Spinoff
Subsequent Event [Line Items]
Cash and cash equivalents		$ 42,701
Disposal Group, Including Discontinued Operations, Accounts Receivable		2,429
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net		989
Disposal Group, Including Discontinued Operation, Inventory		13,685
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment		783
Disposal Group, Including Discontinued Operations, Leased Equipment		3,033
Disposal Group, Including Discontinued Operation, Intangible Assets		42,113
Disposal Group, Including Discontinued Operation, Other Assets		4,863
Disposal Group, Including Discontinued Operation, Assets		110,596
Disposal Group, Including Discontinued Operation, Accounts Payable		2,349
Disposal Group, Including Discontinued Operation, Other Liabilities		7,678
Disposal Group, Including Discontinued Operation, Liabilities		10,027
Disposal Group, Including Discontinued Operations, Net Assets (Liabilities)		$ 100,569
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Spinoff | Forecast
Subsequent Event [Line Items]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	$ 11,800